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ABSTRACT 
 
Endocrine agents have become the primary adjuvant treatment for breast cancer. In 
addition to endocrine therapy, cytotoxic chemotherapeutic agents have also been 
frequently used in the neoadjuvant and adjuvant settings, to reduce tumour size prior 
to surgery or to reduce the chance of relapse or metastasis. However, patients can 
be resistant to endocrine and chemotherapeutic agents, or become resistant after 
long term treatment. In this study, I investigated the role and the regulation of FOXM1 
in the sensitivity and resistance to the endocrine agent, tamoxifen, and the cytotoxic 
chemotherapeutic agent, epirubicin. Firstly, I demonstrated that tamoxifen repressed 
FOXM1 expression in sensitive but not in tamoxifen resistant breast cancer cell lines. 
In MCF-7 cells, FOXM1 protein and mRNA expression levels were regulated by ER-
ligands, and depletion of ERα by RNA interference down-regulated FOXM1 
expression. Importantly, ectopic expression of FOXM1 abrogated the cell cycle arrest 
mediated by the anti-oestrogen tamoxifen, and conferred tamoxifen resistance to 
MCF-7 cells. In contrast, silencing of FOXM1 in tamoxifen resistant cells abolished 
oestrogen-induced MCF-7 cell proliferation and overcame acquired tamoxifen 
resistance. Secondly, FOXM1 expression analysis in epirubicin resistant MCF-7 cells 
showed a higher level compared with MCF-7 cells. In addition, epirubicin treatment 
down-regulated FOXM1 expression in MCF-7, but FOXM1 protein level remained 
constant in epirubicin resistant MCF-7 cells. I established that p53 repressed FOXM1 
expression in MCF-7 cells, while this protein is lost in the MCF-7 epirubicin resistant 
cells. I also found that ataxia-telangiectasia mutated (ATM) was overexpressed at 
protein and mRNA levels in epirubicin resistant MCF-7 compared with MCF-7 cells, 
and that ATM depletion strongly decreased FOXM1 expression. Epirubicin treatment 
increased DNA damage levels in MCF-7 cells while this remained constant in 
similarly treated epirubicin resistant MCF-7 cells, suggesting a higher level of DNA 
repair in these cells. Taken together, these results indicate that deregulation of 
FOXM1 may contribute to resistance to endocrine and cytotoxic agents through its 
involvement in cell proliferation and DNA repair.  
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1.1  BREAST CANCER 
 
The development of cancer or carcinogenesis is a process by which normal 
cells transform into cancer cells. It is characterised by a series of alterations 
occurring at genetic and cellular levels leading to uncontrolled cell division and 
consequently formation of a malignant mass. These alterations affect two types of 
genes: oncogenes and tumour suppressors. An oncogene is a gene involved in cell 
proliferation and differentiation signalling pathways, which has been modified by 
mutation or in a post-translational manner, and consequently has acquired potential 
to cause cancer. In contrast to oncogenes, tumour suppressors are anti-oncogenic 
and protect cells from deregulation by inhibiting cell growth and inducing cell death. 
Hanahan and Weinberg summarize all biological properties acquired by tumour cells 
as self-sufficiency in growth signals, loss of sensitivity to anti-growth signals, loss of 
apoptotic and senescence capacities, acquisition of sustained angiogenesis and 
invaded neighbouring tissues (Hanahan and Weinberg 2011). Cancer is now the 
leading cause of death in the UK (Cancer Research UK) and around 293,000 people 
are diagnosed every year in the UK. There are about 200 different types of cancer 
but four of them, breast, lung, colorectal and prostate, account for over half of all new 
cases. 
  
1.1.1 Epidemiology  
 
Breast cancer is the most common diagnosed cancer in the UK despite the fact 
that it is rare in men. In 2008, 48,034 new cases of breast cancer were diagnosed in 
the UK: over 99 % in women and less than 1 % in men. Moreover, in the last ten 
years female breast cancer incidence rates have increased by 6 % in the UK (Cancer 
Research UK. Breast Cancer. 2009). The UK breast cancer screening program was 
set up in 1988 and uses mammography to screen all woman aged between 50 and 
70 every 3 years (Cancer Research UK. Breast Cancer. 2009). However, the majority 
of breast cancers are self-detected. 
 
Survival rates for breast cancer vary greatly depending on the breast cancer 
stage. Overall, women’s survival rate after five-year is 82 %, 72 % at ten years and 
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64 % at twenty years. Despite improvement of the survival rate in the past years, 
12,116 deaths from breast cancer were reported in the UK in 2008 and breast cancer 
remains the most common cause of death in younger women aged 35-54 years (Fig. 
1.1) (Cancer Research UK. Breast Cancer. 2009). Breast cancer accounts for around 
16% of female deaths from cancer in the UK annually and causes of death from 
breast cancer vary greatly according to the age at diagnosis, node involvement, 
cardiovascular condition and osteoporosis. It was found that non-breast cancer-
related deaths were more common than breast cancer-related deaths in a study 
involving 50 % of patients younger than 70 years and 50 % of patient over 70 years 
old. Two factors have different correlations with the type of death (Chapman, Meng et 
al. 2008). Cardiovascular disease was associated with significant increased risk of 
death from other causes than breast cancer, and osteoporosis was associated with 
significant risk of death from other malignancies. Breast cancer-related death was 
associated with lymph node involvement and metastases to other organs (Chapman, 
Meng et al. 2008). Between 1989 and 2008 the breast cancer mortality rate fell in 
each age range. The reduction in breast cancer mortality rates is likely to be due to 
improvements in screenings, specialization of care and the widespread adoption of 
tamoxifen treatment since 1992. 
 
Figure 1.1 Number of deaths and ages-specific mortality rates of breast cancer, UK, 
2008. Cancer Research UK. 
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1.1.2 Breast cancer development  
 
Breast cancer development involves a progression through different mammary 
lesions and clinical stages starting from ductal hyperplasia, with subsequent evolution 
to atypical hyperplasia, in situ carcinomas progressing into invasive carcinomas (Fig. 
1.2) (Allred, Mohsin et al. 2001). Among invasive carcinomas, 80 to 90 % are formed 
in breast ducts (referred as ductal carcinoma in situ or DCIS), while 10-20 % occur in 
breast lobules (referred as lobular carcinoma in situ or LCIS) (Fig. 1.2).  
Mammography is the first examination undergone by women and is followed by 
a biopsy. These tests are used to define the breast cancer stage. Stage 1 is defined 
by a tumour no wider than 2 centimetres, but not spreading to the lymph nodes. In 
contrast, stage 2 refers to a tumour wider than 2 centimetres, which has no sign of 
spread to other organs. Stage 3 involves a tumour of 5 centimetres or less that has 
reached the lymph nodes, whereas stage 4 is a stage where the tumour is seen in 
lymph nodes and has spread to other parts of the body. 
 
1.2 BREAST CANCER CLINICAL MANAGEMENT 
 
For years, mastectomy has been the treatment of choice for all types of breast 
cancer. After surgery, radiation is the first therapy used to kill cells left over from 
surgery to reduce recurrence rates (Schoenfeld and Harris 2011). Chemotherapies 
were introduced in the 1940’s to reduce tumour size before surgery, prevent 
recurrence, and treat cancers that have metastasized (Smith and Chua 2006). The 
discovery of the anti-oestrogen tamoxifen in 1966 and the identification of distinctive 
oestrogen receptor alpha (ERα) and progesterone receptor (PR) status in mammary 
tumour cells determined the significance of the hormone receptor status for breast 
cancer clinical management. Two types of tumours were established based on ERα 
/PR status: those with ERα (generally PR positive) benefit from anti-oestrogen or 
endocrine therapy, while those without ERα (generally negative for PR) do not 
respond to endocrine therapy. A transmembrane protein, human epidermal growth 
factor receptor 2 (HER2), was later found overexpressed on the surface of human 
breast cancer cells. Based on the poor prognosis of those patients ERα-/PR-/HER2+ 
receptor status, a monoclonal antibody specifically targeting the HER2, trastuzumab, 
20 
 
was developed and approved for the treatment of breast cancer in 1998 (Hynes and 
Stern 1994).  
 
Current clinical management of breast cancer involves patients’ first undergoing 
surgery to totally or partially remove the tumour depending on the breast cancer 
stage, followed by adjuvant radiotherapy for partially removed tumours. Then, 
chemotherapy and hormonal therapy is administrated according to the patient 
receptors status. Chemotherapy alone is administrated to ERα/PR/HER2 negative 
receptors. ERα/PR positive patients are administrated endocrine therapy in addition 
to chemotherapy, while HER2 positive patients will receive HER2-targeted therapy 
with chemotherapy (Fig. 1.2) (Smith and Isaacs).  
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Figure 1.2 Two main types of breast cancer and therapies. After surgery, the 
hormone receptor status is determined. Patients ER/PR/HER2 negative receptors will 
be administrated chemotherapies, while ER/PR/HER2 positive receptors patients will 
be treated hormonal therapies in addition to chemotherapies. 
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1.2.1 Breast cancer chemotherapies 
 
1.2.1.1 DNA damage agents 
  
About 10 to 20 % of breast cancer patients are triple negative receptors for 
ER/PR/HER2. These patients have poorer prognosis than ERα positive breast 
cancer patients because they are only sensitive to chemotherapy agents. So far, no 
biomarker has been identified to allow for the development of targeted therapy for 
these patients. Chemotherapy agents for breast cancer can be divided into five 
categories according to their mechanisms of action: alkylating, anti-metabolite, 
topoisomerase inhibitor, anthracycline and anti-mitotic agents (Hortobagyi 1995, 
Rodler, Korde et al. 2010, Rodríguez-Lescure 2010).  
 
Alkylating agents are one of the earliest used chemotherapy agents for the 
treatment of cancer, which alkylate many nucleophile functional groups in 
cells. Cisplatin and carboplatin, as well as oxaliplatin, are alkylating agents and act 
directly on DNA, causing cross-linking of DNA strands, abnormal base pairing, or 
DNA strand breaks, preventing cells from dividing (Euhus 2011). Alkylating 
chemotherapy drugs are effective during all phases of the cell cycle.  
 
The structure of anti-metabolites is similar to those of vitamins, amino acids and 
precursors of DNA and RNA, and act by inhibiting cell division. Anti-
metabolites block and prevent purines and pyrimidines from incorporating into DNA 
during the synthesis phase (S phase) of the cell cycle, stopping normal development 
and division. These anti-metabolites also effectively block RNA synthesis. Examples 
of anti-metabolites include 5-fluorouracil (5-FU), methotrexate and gemcitabine.  
 
Anthracyclines are anti-tumour antibiotics that interfere with enzymes involved 
in DNA replication (Morris, Hudis et al. 2011). These antibiotics work in all phases of 
the cell cycle and are widely used for a variety of cancers. A major dose-limiting 
factor when giving anthracyclines is that they can permanently damage the heart if 
given in high doses. Examples of anthracyclines include daunorubicin, doxorubicin 
(Adriamycin®) and epirubicin.  
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Topoisomerase inhibitors interfere with two enzymes called topoisomerase I 
and II, which help separate the strands of DNA during transcription and cell division. 
Examples of topoisomerase I inhibitors include topotecan and irinotecan (CPT-11) 
while examples of topoisomerase II inhibitors include etoposide (VP-16) and 
teniposide.  
 
Mitotic inhibitors are often plant alkaloids and other compounds derived from 
natural products. They act to stop mitosis or inhibit enzymes from producing proteins 
needed for cell division. They are effective during the mitotic phase (M phase) of the 
cell cycle, but can damage cells in all phases. These drugs are known for their 
potential to cause peripheral nerve damage, which can be a dose-limiting side effect. 
Examples of mitotic inhibitors include taxanes (paclitaxel (Taxol®) and docetaxel 
(Taxotere®) (Fig. 1.3).  
 
Clinically, combinations of up to three chemotherapy drugs are administrated 
together to achieve maximum efficiency against tumour growth. Some of the most 
common combinations used for breast cancer are CMF (cyclophosphamide, 
methotrexate and fluorouracil), FEC (epirubicin, cyclophosphamide and fluorouracil), 
E-CMF (epirubicin, followed by CMF), AC (doxorubicin (adriamycin) and 
cyclophosphamide) (Fig. 1.2) (Chu and Kiel 1982, Sledge, Neuberg et al. 2003, 
Blohmer, Schmid et al. 2010, Seidman, Brufsky et al. 2011). The oncologist may offer 
a choice of chemotherapy combinations as different combinations have different side 
effects. 
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Figure 1.3 Targets for chemotherapies. Alkylating agents cross-link DNA strands and 
induce DNA strand breaks. Anti-metabolites prevent the incorporation of purines and 
pyrimidines into DNA in S phase. Anthracyclines inhibit multiple enzymes involved in DNA 
replication. Topoisomerase inhibitors inhibit topoisomerase enzymes that are required for 
DNA replication. Mitotic inhibitors inhibit enzymes required for mitotic execution.  
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1.2.1.2 DNA damage response pathways 
 
Taken together, each category of chemotherapies affects DNA directly via 
cross-linking, synthesis inhibition, or indirectly via inhibition of enzymes required for 
DNA replication. Chemotherapy agents damage DNA and can further induce multiple 
DNA damage responses including cell cycle checkpoints, transcriptional activation 
and DNA repair.  
 
Cell cycle checkpoints are regulatory pathways governing the order and timing 
of cell cycle transitions to ensure accurate completion of the cell cycle phases. The 
key regulators of the checkpoint pathways in the mammalian DNA damage response 
are ATM (ataxia telangiectasia, mutated) and ATR (ATM and Rad3-related) protein 
kinases. Both of these proteins belong to a structurally unique family of serine-
threonine kinases. Although ATM and ATR share similar cellular substrates, they 
generally respond to distinct types of DNA damage (Traven and Heierhorst 2005). 
ATM is the primary mediator to DNA double strand breaks (DSBs) that can arise by 
exposure to ionizing radiation (IR), whereas ATR plays mainly a role in response to 
ultraviolet (UV) damage and stalls in DNA replication (single DNA breaks) (Abraham 
2001). The key trigger in the G1 cell cycle checkpoint is the activation of p53, which 
is phosphorylated by checkpoint kinase 2 (CHK2), downstream target of ATM. 
Activated p53 upregulates a number of target genes involved in DNA damage 
response (MDM2, GADD45α) and G1 cell cycle arrest (p21Cip1) (Fig. 1.4) (Bartek and 
Lukas 2001). During the S phase checkpoint, ATM activates two parallel pathways. 
Firstly, ATM phosphorylates CHK2 to prevent cyclin-dependent-kinase 2 
(cdk2)/cyclins activation and completion of DNA synthesis. Secondly, ATM 
phosphorylates a series of downstream substrates involved in DNA repair including 
Nijmegen breakage syndrome (NBS1), breast cancer susceptibility gene 1 (BRCA1) 
and structural maintenance of chromosome protein 1 (SMC1). The blockage of entry 
into mitosis is essential for the G2 checkpoint activation. ATM and ATR modulate the 
phosphorylation status of the cyclin-dependent CDC2 to keep it in its inactive form 
and prevent the entry into mitosis (Fig. 1.4) (Zhou and Elledge 2000).  
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Figure 1.4 Cell cycle checkpoints following DNA damage. ATM/ATR activated by DNA 
damage trigger signalling cascades leading to cell cycle arrest and delay. ATM/ATR induce a 
series of phosphorylation affecting p53 and MDM2 leading to G1 arrest. ATM/ATR also 
phosphorylate and stabilize CHK1/2 and the complex NBS1/BRCA1/SMC1, which cause a 
delay in S phase. G2 arrest is induced by the phosphorylation of CDC25C, which prevent 
phosphorylation and activation of the CDC2/CYCLIN B1 complex (From R&D systems 
website). 
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Multiple DNA repair pathways can be activated following DNA alterations. 
Chemotherapy agents induce DSBs that are the worst form of DNA damage. The 
signal transduction activated by DSBs is strictly dependent on the ATM/ATR family of 
serine-threonine kinases that regulates two main DSB repair pathways: the 
homologous recombination (HR) and non-homologous end-joining (NHEJ). Emerging 
studies have demonstrated there is a cross-talk between the signal of ATM/ATR, and 
HR and NHEJ repair mechanisms (Kühne, Tjörnhammar et al. 2003). NHEJ involves 
the ligation of two DNA double strand break without sequence homology between the 
two DNA ends. Whereas in HR, the damaged DNA retrieves genetic information from 
an undamaged DNA that shares sequence homology (San Filippo, Sung et al. 2008). 
 
NHEJ is the dominant repair mechanism in cells undergoing G0, G1 and early S 
phases. The central event involves the KU70/80 heterodimer binding to the two ends 
of the DSB enabling the recruitment of DNA-dependent protein kinase (DNA-PK). 
DNA-PK binds to a single strand of the DSBs, which triggers its kinase activity. One 
DNA-PK substrates is X-ray repair cross-complementing protein 4 (XRCC4) that 
forms a complex with the DNA ligase IV and stimulates DNA end-ligation (Fig. 1.5). 
Prior to the DNA end-ligation, the complex MRE11/RAD50/NBS1 exerts its 
exonuclease activity to clean up the DNA ends (Jackson 2002). 
 
HR, particularly important during S and G2 phases, involves DNA ends 
resection by nucleases, homology DNA pairs allowing strand invasion, homologous 
recombination and DNA repair synthesis. This process can be divided into four steps: 
resection, strand invasion, branch migration and Holliday junction formation. The 
nucleolytic resection of the DNA in the 5’ to 3’ is an early event involving the complex 
MRE11/RAD50/NBS1 (Fig. 1.5). The resulting 3’ single strand DNA ends are then 
bound by RAD51, which is a process involving the binding replication protein A 
(RPA), RAD52, RAD54 and BRCA1, BRCA2. The RAD51 nucleoprotein filament then 
interacts with the homologous undamaged DNA and catalyses strand exchanges, in 
which the damaged DNA invades the undamaged DNA. The 3’ terminus of the 
damaged DNA is extended by a DNA polymerase, which copies genetic information 
from the undamaged DNA molecule. Finally, the ends are ligated using DNA ligase I 
and the DNA cross-overs, called Holliday junctions, are cleaved and ligated to two 
intact DNA molecules (Jackson 2002, Mao, Bozzella et al. 2008). 
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Figure 1.5 Double strand break repair. Homologous recombination process uses a 
homologous chromosome to repair DNA. When no homologue is present, breaks can be 
repaired with the non-homologous end-joining mechanism, in which two ends are ligated.  
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1.2.2 Breast cancer endocrine therapies 
 
1.2.2.1 Anti-oestrogen therapies 
 
About 70 to 80 % of breast cancer patients are ERα positive (in which more 
than half are also PR positive) and ERα positivity predicts for response to endocrine 
therapy (Kuukasjärvi, Kononen et al. 1996, Bauer, Brown et al. 2007). Therefore, 
anti-oestrogen therapies are usually given to patient diagnosed ERα positive when 
surgery and neoadjuvant chemotherapy were already administrated.  
 
Tamoxifen (OHT) has been the standard adjuvant anti-oestrogen therapy for 
pre- and post-menopausal women with ERα and/or PR positive breast cancer for 
years. It is a selective ERα modulator (SERM) that functions as ERα antagonist in 
breast and as ERα agonist in the heart and bones (Smith and Chua 2006). 
It blocks the binding of oestrogen and consequently its activity on ERα. 
Tamoxifen binding further prevents critical ERα conformational changes that are 
required for the association of co-factors and the transcriptional activity of ERα. 
However, the oestrogen-agonist effects of tamoxifen have been associated with 
serious life-threatening events including endometrial cancer, stroke and trombo-
embolism. Selective ERα down-regulators (SERD) such as fulvestrant (ICI182,780) 
are used as alternatives to tamoxifen (Krell, Januszewski et al. 2011). In contrast to 
tamoxifen, SERDs are pure antagonists that bind with 100 fold greater affinity, 
inhibiting receptor dimerization and abrogating oestrogen signalling. Clinical studies 
have also shown that fulvestrant decreases ERα expression levels (Dauvois et al. 
1992). Third-generation aromatase inhibitors (AIs) have also been introduced as an 
alternative to tamoxifen therapy for post-menopausal women which cancer has 
progressed following tamoxifen treatment. AIs prevent oestrogen synthesis by 
inhibiting the action of aromatase, an enzyme necessary for the conversion of 
androgens to oestrogens (Fig. 1.6A).  
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Figure 1.6 Effects of anti-oestrogens. A. ERs are free in the cytoplasm and can be bound 
by oestrogen to translocate to the nucleus, and recruit ER co-activators to activate ER-
responsive genes transcription. When the anti-oestrogen OHT is added, it binds to ER, 
translocate to the nucleus and recruit ER co-repressors which inhibit gene transcription. In 
contrast, ICI binds ER and guides it to the proteasome for degradation. B. The cell cycle is 
divided in 4 phases which are regulated by different cyclin/cdk complexes. When cells are 
treated anti-oestrogens, cells arrest in G1 or G2 phases through the downregulation (-, in 
pink) of cyclin D1 and E and the upregulation (+, in blue) of cdk inhibitors and 
hypophosphorylated Rb. Adapted from Dehay and Kennedy, 2004.  
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The effect of anti-oestrogen therapies has been studied since 1975 and shown 
to induce cell cycle arrest in G1 resulting in a lower proportion of cells in S phase. 
Studies in MCF-7 breast carcinoma cells revealed a decrease of CYCLIN D1 mRNA 
level and suggested that cyclins involved in G1 phase might be the target for anti-
oestrogens to block cells entry in S phase (Lykkesfeldt, Madsen et al. 1994). Further 
studies using the pure ERα antagonist, ICI182,780, demonstrated a decrease in S 
phase cells combined with increased of hypophosphorylated Retinoblastoma protein 
(RB), which inhibits the transcriptional activity of E2F restricting the transcription of 
cyclins and cdks. Additionally, treatment of MCF-7 cells with the pure ERα antagonist 
decreased CYCLIN D1 at mRNA and protein levels. Studies of cyclin-dependent 
kinases revealed no change in their expression pattern. Anti-oestrogens treatment of 
breast cancer cell lines also showed an upregulation of two members of the cdk 
inhibitors Cip1/Kip1 family, p27Kip1 and p21Cip1, which by consequent inhibit G1 and 
G2 cyclins (Fig. 1.6B). Tamoxifen can also induce apoptosis at a higher 
concentration of 5 µmol/L in MCF-7 cells. Protein kinase C, C-MYC and p53 were 
identified as potential targets in triggering tamoxifen-induced apoptosis but the exact 
mechanism still remains elusive (Doisneau-Sixou, Sergio et al. 2003).  
 
1.2.2.2 The oestrogen receptor pathway 
 
Oestrogens, 17ß-estradiol (E2), estrone and estriol, are the most important 
regulators of breast cancer growth. Oestrogens are steroid hormones produced 
primarily by the developing follicles in the ovaries and the placenta, and act through 
the oestrogen receptors, ERα and ERß, products of different genes.  
 
The oestrogen receptors belong to the nuclear receptor superfamily of 
transcription factors, which includes steroid hormones, thyroid hormones, vitamin D 
and retinoic acid. ERα and ERβ are composed of three functional domains: the N-
terminal, DNA binding domain (DBD), and the ligand-binding domain (LBD) (Fig. 1.7) 
(Ruff, Gangloff et al. 2000). The N-terminal domain of nuclear receptor encodes a 
ligand-independent activation function (AF-1) that is involved in protein-protein 
interactions, and transcriptional activation of target gene expression. The DNA 
binding domain contains a two zinc finger structure, which plays an important role in 
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receptor dimerization and in binding within the oestrogen response element (ERE). 
The LBD mediates ligand binding, receptor dimerization, nuclear translocation, and 
transactivation of target gene expression. The activation function 2 (AF-2) in the LDB 
is governed by the binding of ligands (Hall and McDonnell 2005). 
 
 
 
Figure 1.7 Direct interactions of oestrogen receptor with its cofactors.  Oestrogen (E2)-
bound oestrogen receptor (ER) directly interacts with co-activators SRC-1, GRIP1 or AIB-1 at 
the AF-1 or AF-2 domain (shown by green lines).  Tamoxifen (OHT)-bound ER recruits co-
repressors NCOR and SMRT to the AF-2 domain (shown by red line).  
 
 
 
 
Oestrogen receptors act as transcription factors, either by activating or inhibiting 
the expression of a wide array of genes. ERα and ERß share a high degree of 
homology, 97 % in the DBD and 60 % in the LBD, and therefore interacts with the 
same oestrogen ligand (Bai and Gust 2009). However, the expression and 
characteristics of these receptors differ. ERα is widely expressed and is predominant 
in the breast, uterus and bone, while ERß is mostly expressed in ovary, prostate, 
testis, lung, thymus, spleen and areas of the brain. Animal models have shown that 
ERß can function as an inhibitor of ERα, and is often downregulated in breast 
tumours. While ERα activity induces breast cancer cell proliferation and 
tumourigenesis in mice under estradiol, ERß is anti-proliferative and prevents the 
formation of tumours (Paruthiyil, Parmar et al. 2004).  
 
The ERs are sequestered in a multi-protein complex, including heat shock 
proteins, in the cytoplasm of cells until their activation by ligands (Fig. 1.7). The 
binding of the ligand on ER induces its conformational changes, promoting its 
dimerization, its binding to DNA and the recruitment of co-factors inducing 
transcription of target genes. Among ER co-factors, some ER modulators bind to the 
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AF-2, including ER-interacting proteins 140 and 160 (ERAP140 and ERAP160), 
receptor interacting proteins 140 and 160 (RIP140 and RIP160) and the p160 family 
(SRC-1, GRIP1, AIB1) (Halachmi, Marden et al. 1994, Oñate, Tsai et al. 1995). In 
addition to co-factors that modulate ER activity by binding to AF-2, AF-1 interacting 
co-factors have also been described, such as p68 RNA helicase, which enhances ER 
activity through AF-1 (Endoh, Maruyama et al. 1999). While co-activators enhance 
ER activity, co-repressors decrease the agonist effect of oestrogens. The first 
identified and most studied are the nuclear receptor co-repressor (NcoR) and 
silencing mediator for retinoid and thyroid hormone receptors (SMRT). Cloning of 
cDNAs stimulated by oestrogen resulted in the identification of numerous target 
genes including pS2 and CATHEPSIN D, CYCLIN D1, C-MYC and many others 
(Elangovan and Moulton 1980, Brown, Jeltsch et al. 1984, Dubik and Shiu 1988, 
Altucci, Addeo et al. 1996). Promoter region analysis of these genes led to the 
discovery of two distinct mechanisms of ER binding, the “classical” and “non-
classical” binding as genomic response (Fig. 1.7). The former involves the binding of 
ER within the ERE, while the latter involves the binding of DNA through a different 
motif including those for AP-1 and Sp-1 (Klinge 2001, Carroll, Meyer et al. 2006). 
Another mechanism, by which ER regulates transcription indirectly, referred to as the 
non-genomic response, identified about sixty years ago. Oestrogen binding sites 
were identified on the membrane of endothelial cells. Further studies showed that ER 
can mediate rapid signals originating from the membrane into the nucleus by the 
activation of growth factor receptors, tyrosine kinases, mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3 kinases  (PI3K) (Fig. 1.7) (Migliaccio, Di 
Domenico et al. 1996, Migliaccio, Piccolo et al. 1998, Simoncini, Hafezi-Moghadam 
et al. 2000, Song, McPherson et al. 2002). 
 
The success of targeted anti-oestrogen therapy motivated the search for 
genetic mutations occurring in breast cancer and the development of new targeted 
therapies.  
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1.3 GENETIC AND NEW THERAPIES 
 
1.3.1 Genetic predispositions and mutations  
 
Risk factors for breast cancer can be divided into environmental and genetic 
categories. A number of environmental risks related to reproductive events include 
age, menstruation age, age at first birth, menopause and exogenous uptake. In 
addition, a strong family history involving genetic alterations is recognized as the 
strongest risk factor.  
 
Genetic predisposition to cancer occurs in a minority of patients and is 
conferred by inherited mutations in high penetrance genes. The BRCA1 and BRCA2 
genes have been identified in the 1990’s as “high risk” breast cancer susceptibility 
genes. Women carrying deleterious mutation of these genes have 45-65 % risks of 
developing breast cancer (Ahmed, Lalloo et al. 2009). Women with very strong family 
history can be tested for faulty BRCA genes, but account for just 3 %. 
 
While some of these alterations might be inherited, most accumulate during a 
woman’s lifetime. Gene alterations accumulated with time are known as somatic 
mutations that are permanent and transmissible in genetic material. A wide variety of 
genes is commonly mutated or incorrectly regulated in breast cancer cells and have 
been implicated in the development and progression of the disease. These genes 
encompass growth factors receptors and their ligands, intracellular signalling 
molecules, cell cycle regulators, apoptosis regulators and adhesion molecules 
leading to cell proliferation, inhibition of apoptosis and invasion (Cordon-Cardo 1995, 
She, Chandarlapaty et al. 2008). Studies of these altered molecules are promising as 
new potential targets for breast cancer therapy. The best example of such a therapy 
is trastuzumab, which has been shown to be effective in breast cancers 
overexpressing the growth factor HER2 (Bartsch, Wenzel et al. 2007).  
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1.3.2 Targeted therapies  
 
The human epidermal growth factor receptor/HER family of transmembrane 
type I receptor tyrosine kinases are enzymes that are fundamental in cellular 
processes such as proliferation, differentiation and survival. The members of this 
family contain an extracellular ligand-binding domain, a single membrane-spanning 
region, a nuclear localization signal, and a cytoplasmic tyrosine kinase domain. 
HER1, HER3 and HER4 members interact with specific ligands, while no natural 
ligand has been identified for HER2. HER2 can be activated by hetero-dimerization 
with ligand-activated HER co-receptors, which modulate receptor internalization and 
prolong signal transduction (Prenzel, Fischer et al. 2001, Li and Hristova 2010). 
Conformational changes occurring of dimer receptors lead to auto-phosphorylation 
and initiation of several signal transduction cascades. These type I receptors transmit 
signals through the Ras/Raf/mitogen-activated protein kinase/extracellular signal-
regulated kinase (ERK) pathway stimulating cell division (Fig. 1.8). Cell lines studies 
suggest that these receptors modulate cell survival via the activation of AKT/PI3K 
pathway. In vitro and in vivo studies have established oncogenic properties (Hubalek, 
Brunner et al. 2010). Aberrant HER1 and HER2 signalling have been associated with 
cancer cell proliferation and survival. Activated HER2 was first identified by a point 
mutation in rat neuroblastomas (Perantoni, Rice et al. 1987). It was later found to be 
overexpressed in 25 % of some human breast cancers. The prognosis of those 
patients with HER2 expression on breast cancer cells surface is poor, which 
warranted the development of antibodies and small molecules specifically targeting 
this receptor.  
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Figure 1.8 HER2 signalling and pathway targeted therapy. Hetero-dimerization of HER2, 
induced by the ligands of HER members, activates the phosphoinositol 3-kinase pathway 
including AKT leading to cell survival and the mitogen-activated protein kinases promoting 
cell proliferation (Hubalek et al 2010). 
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In the 1980’s, the monoclonal antibody against HER2, trastuzumab, was 
developed and approved in 1998 for the treatment of metastatic breast cancer. In 
2005, five adjuvant trials evaluated trastuzumab as a potent agent for early breast 
cancer with higher benefit than adjuvant chemotherapy and similar to that seen with 
adjuvant endocrine therapy (Harries and Smith 2002). Although trastuzumab’s 
method of inhibiting HER2 activity is not fully understood, studies suggest that the 
drug promotes internalization and degradation of HER2, or disrupts the activation of 
the AKT/PI3K pathway. Trastuzumab administration leads to cell cycle arrest at the 
G1/S boundary, which often results from an increase of p27Kip1 level, and a 
subsequent decrease of CYCLIN D1 and cdk2 (Baselga, Albanell et al. 2001). 
Currently, trastuzumab is the only HER2-targeted therapy approved by the FDA for 
the treatment of early and metastatic breast cancer overexpressing HER2, therefore 
evaluating HER2 expression has become mandatory in early breast cancer (Fig. 1.8).  
 
1.4 BREAST CANCER RECURRENCE 
 
1.4.1 Recurrence of the disease 
 
The recurrence rate among patients who did not receive adjuvant endocrine 
therapy is nearly 50 % throughout the first 10 years after diagnosis. 
There are so many factors that account into the risk of recurrence. Some 
common indicators of recurrence include the involvements of lymph node and 
vasculature, the tumour size, the histological grade, the receptor status, proliferative 
capacity, oncogene expression and somatic mutation (Smith and Chua 2006). 
Recurrent breast cancer can be categorized in three types: local recurrence 
appearing at the tumour site which may be considered as a failure of initial treatment, 
regional recurrence showing that cancer has spread is very common and distant 
recurrence or metastasis which is the most serious type and is associated with 
decreased patient survival. In 65-75 % of distant recurrences the breast cancer then 
spreads from the lymph nodes to the bones. In rare cases, breast cancer may also 
metastasize to other sites including the lungs, liver, brain or other organs.  
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1.4.2 Chemotherapy resistance 
 
Resistance to chemotherapies is a major problem in the clinical management of 
breast cancer and most particularly for triple negative patients, who can only be 
administered chemotherapy drugs. Response rate for first line chemotherapies is 
between 30 and 70 %. However, these agents are efficient only for 6 to 10 months. 
Patients who initially respond become resistant to the initial agents and to multiple 
anti-cancer drugs, which have different structure and mechanism of action. This 
phenomenon is referred as multidrug resistance (MDR).  
 
Chemotherapy resistance can be mediated by various mechanisms such as an 
increased activity of exporters or decreased activity of importers resulting in reduced 
intracellular drug concentrations or reduction of cellular uptake, respectively. Drug 
transport  is mediated by the ATP-binding cassette transporters (ABC-transporters) 
(Coley 2008). An increased of the ABC-transporter P-glycoprotein (PGP) expression 
from 11 % to 30 % in patients, who had received doxorubicin and taxol, correlated 
with drug resistance (Leonessa and Clarke 2003). Furthermore, multidrug resistance-
associated protein 1 (MRP1) is frequently found to be overexpressed in primary 
breast cancer and associated with relapse of node-positive and –negative patients 
who received cyclophosphoamide, methotrexate and 5-fluorouracil (Riordan and Ling 
1985, Tsuruo 1988). Additionally, the activation of detoxifying systems also allows 
cells to escape to the effect of chemotherapies. Upregulation of the cytochrome 
P450, aldehyde dehydrogenase and glutathione S-transferases particularly affect the 
toxicity of cyclophosphamide. Resistance can also be the consequence of defective 
apoptotic pathways or a change in cell cycle checkpoint. P53 is lost in cells where the 
cytotoxic effect of doxorubicin is delayed or lost. Mutations in p53 have been linked to 
doxorubicin resistance and to early relapse in breast cancer patients. Comparisons 
between mouse fibroblast cells containing wild-type p53 and p53 knock-out showed 
that the absence of p53 reduces apoptotic cell death and induces doxorubicin 
resistance. Mutated p53 loss of function was also associated with the abolition of 
p21Cip1 transcriptional activation resulting in cell cycle arrest defect. Expression of the 
anti-apoptotic family of protein BCL-2 has been detected in 80 % of breast cancers 
from women with primary tumours and having either node positivity or negativity. In 
contrast, the expression of the pro-apoptotic factor BAX is lost in some breast 
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tumours (Krajewski, Krajewska et al. 1999). Reduced BAX levels correlate with 
shorter overall survival, fast tumour progression and failure to respond to therapy 
(Coley 2008). 
 
1.4.3 Anti-oestrogen therapy resistance 
 
Currently, tamoxifen remains the treatment of choice for most women with ERα 
positive invasive breast carcinomas. Approximately 30 % of ERα positive breast 
cancer patients become resistant to tamoxifen. While anti-oestrogens have been 
available since the early 1970’s, the mechanisms of action and development of 
resistance is still not fully understood. There are two forms of anti-oestrogen 
resistance: de novo resistance and acquired resistance. By definition, de novo 
resistance is present before drug exposure, while acquired resistance occurs after 
drug exposure. Additionally, endocrine resistance can be categorized into loss or 
mutation of ERs, specific resistance to anti-oestrogens, modified ERα interaction 
proteins and ligand independent ERα activation (Clarke, Liu et al. 2003).  
 
Since the effects of anti-oestrogens are mediated through ERs, the degree of 
ER expression is a strong predictor of response. Loss of ER expression is the 
primary mechanism of de novo resistance to tamoxifen with ER/PR negative. 
However, the lost of ER occurs only in 15 % of cases (Ring and Dowsett 2004). In 
addition to genetic modifications, epigenetic changes such as CpG island 
hypermethylation causes transcriptional  inactivation of ER gene (Issa, Ottaviano et 
al. 1994). In a study, the analysis of the methylation status of CpG dinucleotides in 
ER from patients with recurrent breast cancer following tamoxifen allowed the 
development of a predictive score that could be used to identify patients likely to 
respond to tamoxifen (Martens, Nimmrich et al. 2005).  Further studies are 
undertaken to confirm the validity of this approach. A second ER was cloned from a 
rat prostate cDNA library and was named ERß (Kuiper, Enmark et al. 1996).  ERß is 
highly homologous to ERα and binds to the same ligands but has different effects on 
gene transcription. There is divergent data concerning the expression of ERß, patient 
prognosis and anti-oestrogen responsiveness (Omoto, Inoue et al. 2001, Fuqua, 
Schiff et al. 2003, Iwase, Zhang et al. 2003). However, evidence suggest that ERß 
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protein expression is decreased in breast carcinoma compared to normal or benign 
lesions (Roger, Sahla et al. 2001). 
 
The majority of patients that initially respond to tamoxifen acquire resistance 
after long-term exposure without losing ERα expression. Therefore, most of the 
published information on potential mechanisms of resistance has been documented 
by studies in ERα positive breast cancer cells selected by sustained exposure to anti-
oestrogen.  
A mechanism of drug resistance common to chemotherapies and endocrine 
therapies is the emergence of increased drug efflux or reduced drug influx. Intra-
tumoural tamoxifen concentration was decreased in tamoxifen-resistant breast 
cancer compared to tamoxifen-responsive breast cancer. Although the mechanism 
responsible for altered tamoxifen accumulation is not understood, in vitro study 
shows that overexpression of MDR1 in MCF-7 cells reduces tamoxifen sensitivity 
(Clarke, Currier et al. 1992). In addition, lower concentration of tamoxifen active 
metabolite (4-hydroxy-N-desmethyltamoxifen) was found in patients carrying a 
variant of the CYP2D6 allele (Stearns, Johnson et al. 2003).  
ERα is activated by binding of estradiol that induces recruitment of co-factors, 
conformational changes, phosphorylation of ERα, and its dimerization before binding 
of the ERE within the promoter of ER-responsive genes. This is referred to as the 
classical mode of action. The overexpression of AIB1, an ER co-activator, is 
observed in 50 % of breast tumours (Anzick, Kononen et al. 1997). AIB1 is also 
highly expressed in MCF-7 breast cancer cell line and in a mouse xenograft (List, 
Lauritsen et al. 2001). The overexpression and phosphorylation of AIB1 led to 
constitutive transcriptional activity of ERα conferring resistance in vitro and in 
xenograft models (Musgrove and Sutherland 2009). In addition, AIB1 overexpression 
is associated with reduced responsiveness to treatment in breast cancer patients and 
a worse disease-free survival (Osborne, Bardou et al. 2003, Alkner, Bendahl et al. 
2010). In vitro studies suggest that overexpression of other co-activators such as 
SCR-1, may also be able to enhance ER activation by oestrogen and agonist activity 
of tamoxifen. However, no clinical data have verified SCR-1 role in tamoxifen 
resistant patients. While ER co-activators levels are found overexpressed in tumours 
that acquired tamoxifen resistance, NCoR levels, an ER co-repressors, are declined 
(Chan, Lykkesfeldt et al. 1999). 
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ER can also regulate gene expression by interacting with DNA directly via other 
transcription factors, such as FOS/JUN activating protein 1 (AP-1) and NF-κB (non 
classical mode) (Nilsson, Mäkelä et al. 2001). The increase in transcriptional activity 
elicits an increase in ERα activity, which is associated with tamoxifen resistance.  
Post-translational modifications, such as phosphorylation, acetylation and 
methylation, affecting ERα can also influence its interaction with factors and lead to 
anti-oestrogen insensitivity. Numerous studies showed cross-talk between ERα and 
growth factor receptor pathways, such as HER family and insulin-like growth factor 
(IGFR) family. ERα can be phosphorylated on several sites but the most reported is 
serine 118. ER can be phosphorylated at serine 118 by the MAPK ERK1/2, which is 
downstream of HER2 signalling pathway (Kato, Endoh et al. 1995). Phosphorylation 
enhances ERα ligand sensitivity and may lead to ligand-independent activation. 
Indeed, ERK1/2 expression and activity are increased in endocrine resistant breast 
cancer cell lines (Kronblad, Hedenfalk et al. 2005). Upstream RAS/MAPK pathway 
can be activated by IGF stimulation inducing phosphorylation of ERα serine 118 and 
resulting in enhanced activation (Kato, Endoh et al. 1995). A direct interaction 
between ERα and IGFR leads to activation of IGFR downstream  targets, thereby 
leading to an increase in cell survival (Ring and Dowsett 2004). In MCF-7 breast 
cancer cell line, phosphorylation of ERα on serine 118 and serine 167 by the receptor 
tyrosine kinase RET and mTOR pathway leads to ligand-independent activation of 
ER-responsive genes and tamoxifen resistance (Morandi, Plaza-Menacho et al. 
2011). The clinical relevance of serine 118 phosphorylation has not been yet 
established; some studies showed a bad prognosis correlated with phospho-serine 
118, while other studies positively correlated phospho-serine 118 with response to 
endocrine treatments (Sarwar, Kim et al. 2006, Riggins, Schrecengost et al. 2007, 
Yamashita, Nishio et al. 2008).  
 
1.4.4 Targeted therapy resistance 
 
The anti-tumour effects exerted by the anti-HER2 antibody, trastuzumab, 
require modulation of key signalling pathways and cell cycle/apoptosis regulatory 
proteins that are not directly regulated by trastuzumab itself. Therefore, alterations in 
these pathways and regulatory proteins limit the therapeutic efficacy of trastuzumab 
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leading to resistance. Studies have shown that high expression of other HER family 
members or other growth receptors lead to trastuzumab resistance. For example, 
IGFR overexpression activates the AKT/PI3K pathway and renders trastuzumab-
sensitive HER2-overexpressing SKBR3 cells resistant to treatment (Lu, Zi et al. 
2001). The expression level of a receptor tyrosine kinase MET was increased in 
HER2-overexpressing breast cancer tumour samples with resistance to several 
targeted therapies (Shattuck, Miller et al. 2008). Aberrant regulation of the 
downstream signalling pathway of HER family, such as phosphoinositol 3-kinase 
pathway, also leads to resistance (Campbell, Russell et al. 2004). Furthermore, 
trastuzumab can induce the release of HER ligands conferring resistance to its anti-
proliferative effect (Kong, Calleja et al. 2008). In addition to the high levels of ligands, 
the membrane-associated glycoprotein mucin-4 (MUC4), which is overexpressed in 
breast cancers, can mask HER2 interfering with trastuzumab binding (Nahta and 
Esteva 2006). Several studies also identified a truncated version of HER2 which 
lacks the extracellular domain (p95 HER2) and able to escape trastuzumab´s 
binding. In a survey, Molina et al. found HER2 truncation more highly expressed in 
surgically excised node-positive breast cancer samples than node-negative ones 
(Molina, Sáez et al. 2002). Consistently, the comparison between MCF-7 transfected 
with HER2 and p95HER2 showed that only MCF-7/HER2 cells are sensitive to 
trastuzumab (Scaltriti, Rojo et al. 2007). The recruitment of phosphoinositol 3-kinase 
by a tyrosine kinase receptor catalyses the conversion of membrane-associated 
phosphatidylinositol 4,5-biphosphoate (PIP2) to 3,4,5-triphosphate (PIP3). PTEN is 
the negative regulator of Class I PI3K converting PIP3 back to PIP2 and has been 
reported to be frequently lost (26 %) and mutated (6 %) in breast cancer. 
Furthermore, in vitro and in vivo studies demonstrated that knocking-down PTEN in 
HER2-overexpressing breast cancer cells induces trastuzumab resistance (Nahta 
and Esteva 2006). Additionally, somatic mutations in phosphoinositol 3-kinase 
catalytic unit (PIK3CA) were identified in 2004 in several malignancies including 
breast cancer (Campbell, Russell et al. 2004). In vitro studies showed that gain-of-
function mutation of the PIK3CA gene lead to increased resistance to trastuzumab in 
breast cancer cells than breast cancer cell without PIK3CA mutation. Finally, p27Kip1 
expression responsible for the G1/S blockage induced by trastuzumab is reduced in 
resistant cells derived from SKBR3 and sensitivity is restored by reintroduction of 
p27Kip1 (Chang 2007). 
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1.4.5 Potential strategies overcoming drug resistance 
 
In breast cancer and leukaemia, expression of multidrug pump is observed in 
several tissues prior to exposure to chemotherapy and subsequently dramatically 
increased once resistance develops. Targeting of the pumps by small-molecular 
compounds is an attractive strategy to overcome MDR in cancer. Several inhibitors 
of pumps have been developed and are currently under clinical phased studies in 
different cancers. To increase the selectivity of MDR inhibition, gene silencing 
strategies were developed. Antisense oligonucleotide targeting MDR1 mRNA 
partially resensitizes the human MDR xenograft in mice to doxorubicin (Yagüe, 
Higgins et al. 2004). Similarly, silencing of MDR1 by RNAi reverses the resistance 
of doxorubicin-resistant leukemia cells to doxorubicin and taxol (Wu, Hait et al. 
2003). The application of shRNA strategy showed a successful knock-down in vivo 
(Yagüe, Higgins et al. 2004).  
 
Since chemotherapy agents exert their anti-tumour effect through production 
of DNA damage, inhibition of DNA repair machinery can be used. Poly (ADP-
ribose) polymerase 1 (PARP1) belongs to a large family of nuclear enzyme that are 
activated by and recruited to the sites of DNA damages. PARP1 catalyses the 
transfer of NAD+ to acceptor proteins and induce the formation of poly (ADP-
ribose) polymers important for the recruitment of the base excision repair 
machinery to the sites and repair of DNA. Based on the fact that PARP1 has a role 
on DNA repair, inhibition of PARP1 and consequently DNA repair on tumour 
resistant to chemotherapies effects may represent a good strategy. Two 
therapeutic strategies employ PARP inhibitors in the treatment of cancer. The first 
is the use of PARP inhibitors as sensitizers to DNA damaging chemotherapy 
agents, while the second aims to exert anti-tumour effect through production of 
DNA damage. Indeed, PARP inhibitors enhance cytotoxicity of DNA methylating 
agents (Veuger, Curtin et al. 2004). In 2005, pivotal evidence showed that the use 
of PARP inhibitors in cells BRCA1 and BRCA2 genes deficient resulted in selective 
cytotoxicity compared to wild-type or heterozygous (Bryant, Schultz et al. 2005, 
Farmer, McCabe et al. 2005). Based on this, a number of PARP inhibitors are 
currently in development for the treatment of cancers including breast cancer. The 
BRCA1 and BRCA2 proteins are described for their role in homologous 
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recombination, but BRCA proteins are also implicated in nucleotide excision and 
base excision repairs (Hartman and Ford 2002, Alli, Sharma et al. 2009). If PARP 
is inhibited, repair-associated breaks result in replication fork-mediated double 
strand break, which required BRCA1 and BRCA2-associated recombination 
(Arnaudeau, Lundin et al. 2001). Following successes in phase I and II, many 
pharmaceutical companies are now examining the efficacy of their PARP inhibitors 
in patients BRCA mutation-associated and triple negative breast cancers.  
 
The use of signal transduction inhibitors represents a promising therapeutic 
approach as overactivated growth factor signalling pathways are involved in 
endocrine resistance of breast cancer. Drugs blocking the signalling pathways of 
HER1, IGFR1, MAPK and AKT/PI3K are advanced in clinical development 
(Baselga 2011). Results from pre-clinical studies suggest that these drugs can be 
effective in both tamoxifen sensitive and resistant breast cancer patients. Indeed, 
several reports showed that additive or synergistic effects are obtained in ERα 
positive breast cancer patients when treated with a combination of tamoxifen and 
signal transduction inhibitors such as tyrosine kinase and farnesyltransferase 
inhibitors (Johnston 2005, Baselga 2011). Similar results were obtained with the 
combination of mammalian target of rapamycin (mTOR) antagonists and an 
aromatase inhibitor letrozole in cell lines models (Baselga 2011). A synergistic 
effect has been observed when combining trastuzumab with tamoxifen in ERα 
positive and HER2 overexpressing BT-474 breast cancer cell lines (Chen, Wang et 
al. 2008). Moreover, treatment of MCF-7 cells with tamoxifen and gefitinib, a HER1 
tyrosine kinase inhibitor (TKI), showed greater effects than tamoxifen alone by 
inhibition of cell growth and promotion of apoptosis (Gee, Harper et al. 2003). This 
pre-clinical data led to the development of clinical trials examining the combination 
of tamoxifen and signal transduction inhibitors in ERα positive breast cancer 
patients.  
Because ERα co-activators are important in ERα function, their 
overexpression contributes to endocrine resistance. As mentioned, AIB1 is 
amplified in breast cancer and correlate with ERα and PR positive cells. Pre-clinical 
studies showed that overexpression of co-activator AIB1 increases tamoxifen 
agonist activity suggesting that histone acetyl transferase (HAT) activity is 
increased to allow gene transcription. Conversely, ERα co-repressor NCOR1 is 
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underexpressed in tamoxifen resistant mouse models (Lavinsky, Jepsen et al. 
1998, Chan, Lykkesfeldt et al. 1999). Therefore, the treatment of breast cancer 
cells with histone deacetylase (HDAC) has been developed. TSA and SAHA 
treatments, two HDAC inhibitors, reduced breast cancer cell growth. In MCF-7 
cells, TSA induces CYCLIN D1 and ERα proteins degradation and derepression of 
p21Cip1 resulting in G1 arrest (Butler, Zhou et al. 2002, Alao, Stavropoulou et al. 
2006, Kim, Bang et al. 2006, Munster, Thurn et al. 2011). 
 
Currently, trastuzumab is the only HER2-targeted therapy approved by the 
FDA for the treatment of metastatic breast cancer overexpressing HER2. However, 
the HER2 overexpressing patients who originally responded to trastuzumab 
develop resistance. Therefore, the combination of trastuzumab with novel agents 
may increase the magnitude and duration of the response. Among novel biological 
agents, pertuzumab is a HER2 monoclonal antibody that blocks dimerization of 
HER2 with HER1 and HER3, and their signalling pathways. The combination of 
trastuzumab and pertuzumab showed synergistic effect inducing apoptosis in 
HER2 overexpressing breast cancer cells, but had no effect on trastuzumab 
resistant breast cancer cells (Nahta, Hung et al. 2004, Tanner, Kapanen et al. 
2004). This result suggests a cross-resistance to HER2 antibodies that are not yet 
understood. An alternative is to produce antibody-toxin conjugates. However, the 
major limitation of this strategy is the activation of immune response.  
In addition to anti-HER2 antibody strategy, TKIs that directly inhibit the 
cytoplasmic tyrosine kinase of the growth factor receptor are in development. 
Currently clinical trials are being conducted and showed a reduction in HER1 and 
HER2 phosphorylation after treatment. Lapatinib, TKIs inhibiting both HER1 and 
HER2, is currently being tested in clinical trials (Moy and Goss 2006, Sridhar, Hotte 
et al. 2010). Lapatinib has shown remarkable activity in vitro and in vivo including 
inhibition of MAPK and AKT activation and growth arrest and apoptosis in HER1- and 
HER2-dependent tumours (Xia, Mullin et al. 2002).  
To date, much of the information on mechanisms of resistance has come from 
cell line studies and too few genes have been considered.  The rate, at which breast 
cancer relapses, calls for new approaches to provide new target for the development 
of treatment capable of reversing drug resistance. 
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1.5 FORKHEAD BOX TRANSCRIPTION FACTORS  
 
A forkhead box transcription factor was discovered in Drosophila in 1989 by 
Deftlef Weigel, who identified a novel structure and nuclear localization of a protein 
(Weigel, Jürgens et al. 1989, Weigel and Jäckle 1990). The structure described was 
three α-helical domains at the N-terminal region, three β-sheets and two large loop 
regions located at the C-terminal end, forming a structure which is similar to the 
wings of a butterfly, leading to the term winged-helix family. The comparison between 
the forkhead box factor and HNF-3A, a gene cloned from a rat hepatocyte, showed 
striking similarity (Lai, Prezioso et al. 1990). Fifty-five members grouped into 17 
subfamilies (A-Q) (Myatt and Lam 2007) were then identified and described in 
vertebrates which have been given a wide range of names until Kaestner et al unified 
the nomenclature and the proteins name became FOX (Kaestner, Knochel et al. 
2000). The FOX family is an extensive family in which members share greater than 
90 % in their winged-helix forkhead DNA-binding domain (DBD) sequences (Clark, 
Halay et al. 1993, Kaestner, Knochel et al. 2000). Outside the DBD, FOX proteins 
differ significantly leading to differential function and regulation in many processes 
including metabolism, proliferation, development and differentiation, aging, 
angiogenesis, DNA repair and apoptosis.  
 
1.6 FORKHEAD BOX M1 (FOXM1) 
 
1.6.1 Structure 
 
FOXM1 protein contains three regions: the N-terminal Repressor Domain 
(NRD) followed by a conserved DNA Binding Domain called Forkhead winged-helix 
domain (FKH). The C-terminal region harbours the transactivation domain (TAD) with 
several cyclin/cyclin-dependent-kinase-dependent phosphorylation sites (Fig. 1.9) 
(Yao, Sha et al. 1997). FOXM1 can transactivate target genes through two 
mechanisms. First, FOXM1 transactivates genes via the binding of its DBD to 
FOXM1 binding sites in the promoter of the gene (Wierstra and Alves 2006). Second, 
FOXM1 binds human promoters through the binding of FOXM1 DBD to TATA-boxes 
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and the binding of its central domain to TATA-binding protein (TBP) (Wierstra and 
Alves 2006). FOXM1 binds to the DNA binding sequence of genes it regulates and 
facilitates binding of RNA polymerase to transcribe genes. 
 
 
 
 
 
Figure 1.9 FOXM1 structure. FoxM1 protein contains 3 main regions: the N-terminal 
Repressor Domain (NRD). This region is followed by a conserved DNA Binding Domain 
called Forkhead winged-helix domain (FKH). The C-terminal region harbours the 
Transactivation Domain (TAD) with several activating Cyclin-Cdk-dependent phosphorylation 
sites. FoxM1 transcriptional activity also requires the presence of appropriate mitogenic 
signals involving the Raf/MEK/MAPK signalling pathway which phosphorylate FOXM1 in two 
sites. 
 
 
1.6.2 Regulation  
 
A partial fragment of FOXM1, named after WIN, was originally cloned from a rat 
insulinoma cell line and detected in human thymus, testis, lung and intestine (Yao et 
al. 1997). This fragment WIN was previously isolated in a screen for phospho-
proteins in the mitotic phase, suggesting its regulation by phosphorylation 
(Westendorf, Rao et al. 1994, Yao, Sha et al. 1997). Study of FOXM1 in mouse 
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identified that its expression correlated with cycling cells (Korver, Roose et al. 1997). 
It is the only forkhead transcription factor known to be associated with proliferation 
and that displays a proliferation specific expression pattern (Costa, Kalinichenko et 
al. 2003, Laoukili, Stahl et al. 2007). It is expressed in embryos and proliferating 
tissues as well as in response to injury in adults (Yao, Sha et al. 1997, Ye, Holterman 
et al. 1999, Leung, Lin et al. 2001, Wang, Krupczak-Hollis et al. 2002, Wang, Chen et 
al. 2005, Tan, Raychaudhuri et al. 2007) 
 
Detailed cell cycle analysis revealed that the expression of FOXM1 protein 
increases during G1 and S phases, reaching a maximal level in G2/M transition 
(Korver, Roose et al. 1997, Laoukili, Kooistra et al. 2005). Despite FOXM1 mRNA 
and protein being expressed throughout the cell cycle, its transcriptional activity is 
tightly regulated in a cell cycle-dependent manner. Several important proliferation 
and anti-proliferation signals regulate FOXM1 transcriptional activity involving post-
translational modifications and protein-protein interactions. The G1 phase regulator 
CYCLIN D1/CDK4 complex strongly and indirectly activates FOXM1 by releasing the 
TAD from RB repression and by the release of the TAD by the NRD repression. The 
complexes CYCLIN E/CDK2, CYCLIN A/CDK2 and CYCLIN A/CDK1 also 
phosphorylate and activate FOXM1 (Fig. 1.9), and the M phase associated CYCLIN 
B1/CDK1 complex may also phosphorylate and activate FOXM1. The Ras-Raf-MEK-
ERK signalling pathway has been reported to regulate FOXM1 at multiple levels 
including nuclear localization, protein expression, and transcriptional activity. 
Antagonistically to these proliferation signals, the tumour suppressor ARF 
(Alternative Reading Frame) interacts with FOXM1 to prevent its transactivation and 
the tumour suppressor RB directly binds to the NRD and represses indirectly its TAD. 
The cyclin dependent kinases inhibitors p16INK4a, p21Cip1 and p27Kip1 also repress 
FOXM1 through the inhibition of CYCLIN D1/CDK4, CYCLIN E/CDK2 and CYCLIN 
A/CDK2. Moreover, glycogen synthase kinase-3α targets the TAD of FOXM1 and 
abolishes its transactivation (Wierstra and Alves 2006).  
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Figure 1.10 Cell cycle-dependent phosphorylation of FOXM1. Cell cycle-dependent 
regulation of FoxM1. FoxM1 protein expression (legend on the left) increases in late-G1. 
Upon mitogenic stimulation, Cyclin D/Cdk4, 6 and Cyclin E/Cdk2 inactivate pRb and relieve 
FOXM1 inhibition from pRb allowing the cells to progress into S phase. Increased FoxM1 
transcriptional activity (legend on the right) in G2/M correlates with its hyperphosphorylation 
(Laoukili et al 2007). 
 
 
 
 
 
 
 
 
 
 
 
protein protein 
phosphorylation 
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1.6.3 FOXM1 function  
 
1.6.3.1 Cell cycle 
 
So far, the best described function of FOXM1 is its role in cell growth. It 
stimulates proliferation by promoting G1/S and G2/M transitions (Leung, Lin et al. 
2001, Wang, Hung et al. 2001, Laoukili, Kooistra et al. 2005, Wierstra and Alves 
2007). The use of MEF foxm1-/- and siRNA interference demonstrated that FOXM1 
is necessary for the expression of CDC25A, phosphatase required to activate CDK2 
kinase activity during G1 and S phases. FOXM1 also facilitates CDK2 activation by 
induction of SKP2 and CKS1 expression, which induces cdk inhibitors degradation by 
the proteasome. In addition, CDC25A and cdk inhibitors regulate RB phosphorylation 
and E2F release, which in turn stimulate transcription and cell cycle progression. For 
the progression from G2 to M phase, FOXM1 controls the expression of CDC25B 
and CYCLIN B1 and upregulates PLK, SURVIVIN and AURORA B during the mitotic 
phase (Wang, Chen et al. 2005). Due to its role in mitosis, depletion of FOXM1 has 
dramatic consequences such as aneuploidy and polyploidy, failure of the prophase 
stage, misalignment of chromosomes at metaphase or mitotic spindle defect 
(Laoukili, Kooistra et al. 2005, Wang, Chen et al. 2005, Wonsey and Follettie 2005).  
 
1.6.3.2 Regenerative cell proliferation 
  
In addition to its role in cell growth, FOXM1 is important for tissue repair. It was 
shown that transgenic mice, with tissue-specific FOXM1 expression, display 
accelerated cell proliferation following partial hepatectomy, liver or lung injury (Ye, 
Holterman et al. 1999, Wang, Hung et al. 2001, Costa, Kalinichenko et al. 2003, 
Kalinichenko, Gusarova et al. 2003). In contrast, regenerative cell proliferation is 
reduced in mice with hepatocyte-specific and endothelial cell-specific FOXM1 knock-
out (Wang, Kiyokawa et al. 2002, Zhao, Gao et al. 2006).  
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1.6.3.3 Senescence 
 
In agreement with FOXM1 importance in cell proliferation, MEF foxm1-/- and 
cells from mice with pancreas-specific knock-out display senescence (Wang, Chen et 
al. 2005, Zhang, Ackermann et al. 2006, Li, Smith et al. 2008, Park, Carr et al. 2009, 
Zeng, Wang et al. 2009). The role of FOXM1 in carcinogenesis has also been 
investigated and demonstrated that FOXM1 depletion sensitizes cells to oxidative 
stress and senescence (Park, Carr et al. 2009). Furthermore, it was recently reported 
that FOXM1 plays a role in senescence inhibition through transcriptional activation of 
Bmi1 and inhibition of p27Kip1 (Li, Smith et al. 2008, Zeng, Wang et al. 2009).  
 
1.6.3.4 Apoptosis  
 
FOXM1 has recently been demonstrated to regulate apoptosis. It was first 
reported that MEF FOXM1 knock-out and pancreas-specific FOXM1 depleted show 
an increase in apoptosis (Zhang, Ackermann et al. 2006, Tan, Raychaudhuri et al. 
2007, Bhat, Halasi et al. 2009). In addition, FOXM1 inhibition by thiazole antibiotic, 
thiostrepton, siomycin A or ARF peptide inhibitor induce apoptosis in human cancer 
cells and SV-40 transformed human lung fibroblasts (Kalinichenko, Major et al. 2004, 
Radhakrishnan, Bhat et al. 2006, Kwok, Myatt et al. 2008, Bhat, Halasi et al. 2009). 
Although studies have demonstrated a correlation between FOXM1 inhibition and 
apoptosis, molecular mechanisms are not yet completely clarified. 
 
1.6.3.5 DNA damage 
 
The observation of aneuploidy and polyploidy in FOXM1 deficient cells indicates 
a requirement of FOXM1 in chromosome stability and integrity. Consistent with this, 
the percentage of DNA breaks increased when FOXM1 was depleted by knock-out 
and siRNA interference (Tan, Raychaudhuri et al. 2007). FOXM1 is likely to have a 
role in DNA damage but it is still elusive. A study has shown FOXM1 accumulation 
promoted by CHK2 following IR, UV and etoposide, and a role in regulation of DNA 
repair genes, including XRCC1 and BRCA2 (Tan, Raychaudhuri et al. 2007). In 
52 
 
addition, exogenous FOXM1 promotes cisplatin resistance in breast cancer cells 
(Kwok, Peck et al. 2010). 
 
1.6.3.6 Angiogenesis 
 
Histological studies showed strong FOXM1 staining in gastric tumours and 
lymph node metastases. The manipulation of FOXM1, by overexpression or 
silencing, demonstrated that FOXM1 promotes cell growth and angiogenesis via the 
modulation of genes involved in the degradation of the extracellular matrix and 
angiogenesis such as uPA (urokinase-type kinase plasminogen activator), uPAR 
(urokinase-type kinase plasminogen activator receptor), MMP-2 (matrix 
metalloproteinase 2), MMP-9 (matrix metalloproteinase 9) and VEGF (vascular 
endothelial growth factor) (Wang, Banerjee et al. 2007, Li, Zhang et al. 2009). This 
finding was confirmed by the discovery of FOXM1 binding sites in VEGF and MMP2 
promoters (Dai, Kang et al. 2007, Zhang, Zhang et al. 2008).  
 
In summary, this tight antagonistic regulation of FOXM1 may require control to 
exclude aberrant regulation of FOXM1 downstream target genes and their functions 
that could result in tumourigenesis (Fig. 1.10).  
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Figure 1.11 FOXM1 functions. FOXM1 regulates a wide range of genes involved in key 
biological processes. FOXM1 regulates genes involved in G1/S and G2/M transitions as well 
as in genomic integrity leading to cell cycle progression and DNA repair. FOXM1 also 
regulates genes involved in apoptosis, metastasis and blood vessels formation. Deregulation 
of FOXM1 and its downstream targets enhance cell cycle progression, DNA repair, survival 
and angiogenesis and participate to the initiation and development of cancers. 
 
 
 
1.7 FOXM1 IN CANCER  
 
FOXM1 has been shown to be overexpressed in an extensive number of human 
cancers, including gastric, cervical, breast, epidermal keratinocyte, lung, prostate, 
colon and hepatocellular carcinomas (Kalinichenko, Major et al. 2004, Pilarsky, 
Wenzig et al. 2004, Chandran, Ma et al. 2007, Yoshida, Wang et al. 2007, 
Gialmanidis, Bravou et al. 2009, Zeng, Wang et al. 2009, Teh, Gemenetzidis et al. 
2010, Kretschmer, Sterner-Kock et al. 2011). Particularly, it has been reported that 
FOXM1 expression level increased with tumour grade and was inversely correlated 
with patient survival (Kalin, Wang et al. 2006, Liu, Dai et al. 2006). Furthermore, the 
chromosome band 12p13 where FOXM1 is located is frequently amplified in cervical, 
head and neck carcinomas (Willem and Mendelow 1997, Sato, Kobayashi et al. 
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2001). Mice models highlighted the functional role of FOXM1 in tumour initiation and 
progression. The knock-out of FOXM1 before liver cancer induction decreased liver 
tumour development, and the knock-out of FOXM1 before lung and colon cancers 
induction reduced the size and the number of adenocarcinomas (Kalinichenko, Major 
et al. 2004, Kim, Ackerson et al. 2006, Yoshida, Wang et al. 2007). Similarly, 
anchorage-independent growth on soft agar and tumour formation in nude mice were 
increased by FOXM1 overexpression indicating that FOXM1 enhances tumour 
development (Wang, Park et al. 2011). The overexpression of FOXM1 in mice model 
increased the invasion capacity of glioma cells indicating that FOXM1 has a critical 
role in metastasis (Dai, Kang et al. 2007, Raychaudhuri and Park 2011).   
 
1.7.1 FOXM1 in breast cancer 
 
A pioneer study in 2005 has revealed that FOXM1 mRNA expression level is 
significantly overexpressed in 194 infiltrating ductal carcinomas, but not in 
untransformed breast epithelial tissues. Furthermore, RT-qPCR data showed a 
positive correlation between FOXM1 transcript levels and the stage of breast cancer 
disease (Wonsey and Follettie 2005).  
FOXM1 was identified among genes associated with high histological grade in 
ERα positive breast cancers.  During a survey of a panel of 16 different breast cell 
lines, FOXM1 correlates with ERα at mRNA and protein levels (Madureira, Varshochi 
et al. 2006). FOXM1 silencing results in a significant decrease of ERα expression 
levels in ERα positive breast cancer cells. Conversely, ectopic expression of FOXM1 
led to an upregulation of ERα transcript and protein levels. Furthermore, chromatin 
immunoprecipitation assay identified FOXM1 binding site on ERα promoter region 
(Madureira, Varshochi et al. 2006). Taken together, these data indicate FOXM1 as a 
physiological regulator of ERα in breast carcinomas. Moreover, FOXM1 levels predict 
early metastatic relapse for endocrine dependent breast cancers (Yau, Wang et al. 
2011).  
In addition to ERα, FOXM1 is associated with HER2 receptor. FOXM1 and 
HER2 mRNA and protein levels expression correlate in breast cancer cell lines and 
patient samples. Consistently, investigations of mammary epithelium targeted HER2 
mouse tumours resulted in an increase of FOXM1 expression (Francis, Myatt et al. 
55 
 
2009). Data from breast cancer cell lines demonstrated that HER2 directly regulates 
FOXM1 in HER2 overexpressing breast cancers. 
While there is no biomarker identified for patients who are oestrogen and 
progesterone receptor negative and exhibit low HER2 expression breast cancer, 
these patients are treated with chemotherapy and have poorer prognostic than 
receptor positive cancer patients. However, a recent study has shown that FOXM1 is 
found elevated by DNA copy number alterations in triple negative breast cancer, 
suggesting that targeting FOXM1 would be beneficial regardless the receptor status 
(Han, Jung et al. 2008).   
Taken together, FOXM1 inhibition could be a new strategy to treat breast 
cancer patients of any types. 
 
1.7.2 Development of FOXM1 inhibitors  
 
FOXM1 is an attractive target for targeted therapy because it has a key role in 
many biological processes and is overexpressed in a majority of cancers (Wang, 
Ahmad et al. 2010). This notion is supported by studies using RNA interference to 
knock-down FOXM1 expression. Depletion of FOXM1 in breast cancer cells lead to 
inhibition of cell growth, clonogenicity, migration and invasion (Wonsey and Follettie 
2005). In addition, FOXM1 silencing reduced cell proliferation and anchorage 
dependent cell growth on soft agar in several prostate and lung cancer cell lines 
(Kalinichenko, Gusarova et al. 2003, Kalin, Wang et al. 2006).  
Consistent with this, a study in 2004 revealed that FOXM1 is essential for 
initiation of carcinogen-induced liver tumours since liver cells with FOXM1 conditional 
depletion fail to proliferate and are resistant to liver cancer development 
(Kalinichenko, Major et al. 2004). Further results reported that ARF26-44 peptide can 
bind and inhibit FOXM1 transcriptional activity resulting in inhibition of cell 
proliferation and induction of apoptosis (Gusarova, Wang et al. 2007). 
Within the last ten years, an emerging class of naturally occurring thiostrepton 
group of antibiotics has shown a range of antibacterial, anti-parasitic and anti-cancer 
properties. In 2008, evidence showed that thiostrepton antibiotic selectively reduced 
FOXM1 expression resulting in breast cancer cell death. Furthermore, a study using 
a cell-based screening assay system identified another member of the family of 
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antibiotics, siomycin A, as a potent inhibitor FOXM1 transcriptional activity. The 
efficacy of siomycin A and thiostrepton was studied in neuroblastoma, liver, leukemia, 
melanoma and breast cancer and results showed that the antibiotics induced 
apoptosis (Bhat, Zipfel et al. 2008, Kwok, Myatt et al. 2008, Bhat, Halasi et al. 2009). 
Siomycin A has been shown to specifically reduce FOXM1 transcriptional activity, 
while the mechanism of action of thiostrepton still needs to be clarified.  
Taken together, these data suggest that targeting FOXM1 is a promising 
strategy for treating breast cancer and many other cancers. Moreover, studies have 
shown FOXM1 involvement in resistance to targeted therapy and chemotherapy. It is 
possible that inhibiting FOXM1 in combination with anti-cancer therapies will improve 
the efficacy of currently available treatments.  
 
1.8 HYPOTHESES AND OBJECTIVES: FOXM1 as a 
therapeutic strategy to overcome drug resistance  
 
Several members of the forkhead family have been found to be involved in 
diverse mechanisms of drug resistance. Notably, FOXO and FOXM1 members were 
associated with targeted therapies and chemotherapies resistance.  
FOXO proteins play an important role in protection of cells against genotoxic 
and environmental stresses. Although FOXO3A activation by anti-cancer drugs 
induces cell cycle arrest and apoptosis, chronic activation by doxorubicin induces the 
transcriptional expression of MDR1 leading to increased drug efflux ability, which can 
render cancer cells resistant to drug therapy (Hui, Francis et al. 2008). Activated 
FOXO3A can also contribute to the development of resistance to HER2 targeted 
therapies by increasing AKT/PI3K activity through the induction of PIK3CA 
expression and promotion of cell survival (Chen, Gomes et al. 2010). Another FOXO 
member, FOXO1 protein serves as a protector against oxidative stress and its 
contribution to drug resistance was highlighted during human pregnancy, when the 
human endometrial stromal cells are exposed to high fluctuations in oxygen levels. 
Through the induction of the expression of manganese superoxide dismutase 
(MnSOD), FOXO1 confers resistance to oxidative stress-induced apoptosis (Kajihara, 
Jones et al. 2006). Furthermore, FOXO1 is highly expressed in paclitaxel-resistant 
ovarian cells and enhanced by paclitaxel exposure. FOXO1 overexpression was 
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frequently observed in tissue samples from paclitaxel-resistant patients compared to 
paclitaxel-sensitive patients. FOXO1 silencing rendered chemoresistant cells 
sensitive to paclitaxel-induced apoptosis (Goto, Takano et al. 2008). In addition to 
taxane resistance, FOXO1 has been involved in breast cancer resistance to 
anthracyclines. A reporter assay showed that FOXO1 stimulates the transcription of 
MDR1 gene expression in MCF-7 cells. MDR1 expression and doxorubicin resistance 
in MCF-7 resistant cells was reversed by FOXO1 silencing indicating that FOXO1 
expression is crucial for chemoresistance (Han, Cho et al. 2008).  
 
In vitro studies showed that ectopic expression of FOXM1 confers breast cancer 
cells resistance to trastuzumab and paclitaxel. Resistance to the growth inhibitory 
effect of trastuzumab has been accounted by its ability to maintain low level of 
p27Kip1, preventing its accumulation and cell cycle arrest. Moreover, FOXM1 
transcriptionally activates the expression of STATHMIN, which inhibits the 
polymerization of the microtubules in response to the taxane agent paclitaxel (Carr, 
Park et al. 2010). An additional study demonstrated an increased FOXM1 protein 
expression in cisplatin resistant breast cancer cells (Kwok, Peck et al. 2010). FOXM1 
contribution to cisplatin resistance is thought to be due to its role in DNA repair. 
However, the role and detailed mechanisms of FOXM1 involvement in DNA repair 
and resistance have not yet been elucidated. Moreover, it was recently reported that 
overexpression of FOXM1 partially protects osteocarcinoma cells from apoptosis 
induced by thiazole antibiotic (Bhat, Halasi et al. 2009). The emerging evidence from 
in vitro and in vivo studies demonstrate that FOXM1 plays an important role in 
initiation and progression of cancer by the regulation of many target genes and cross-
talking with multiple signalling pathways (Kalin, Ustiyan et al. 2011). Therefore, 
FOXM1 signalling pathway is a promising therapeutic target and the development of 
agents targeting FOXM1 is likely to have a great impact for the treatment of drug 
resistant breast cancer.   
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1.8.1 FOXM1 regulation and role in tamoxifen sensitivity 
and resistance 
 
Due to an increase of evidence in clinical resistance to a wide range of targeted 
therapeutic and chemotherapeutic agents, the development of novel drugs to 
overcome drug resistance is needed. Tamoxifen is the main endocrine treatment 
used for ERα positive breast cancer patients. However, 70 % of patients that initially 
respond to tamoxifen become resistant after long term treatment. ERα is a strong 
proliferative factor activating the expression of a wide range of genes encoding 
cytokines and factors associated with immune response, signal transduction, cell 
migration and cytoskeleton regulation. Data has showed that deregulation of ERα at 
transcriptional or posttranslational level can elicit anti-oestrogen resistance. Previous 
work in the laboratory reported that FOXM1 and ERα correlate at mRNA and protein 
levels in a panel of breast cancer cell lines. Further results showed that FOXM1 
activates ERα transcriptional expression directly through the binding of forkhead site 
within ERα promoter in breast cancer cell lines (Madureira, Varshochi et al. 2006). 
Previous data also showed that FOXM1 is often regulated through a positive 
feedback loop with genes involved in proliferation such as CYCLIN B1 and PLK 
(Leung, Lin et al. 2001, Laoukili, Kooistra et al. 2005, Fu, Malureanu et al. 2008). 
These co-regulations occur amongst genes involved in cell cycle, which could lead to 
uncontrolled proliferation and drug resistance of cancer cells. Therefore, it is 
important to investigate FOXM1 regulators. This thesis examines the regulation of 
FOXM1 by ERα, given that FOXM1 is frequently overexpressed in breast cancer, and 
ERα deregulation leads to the development of anti-oestrogen resistance. 
Furthermore, this thesis examines reversing anti-oestrogen resistance by 
downregulating FOXM1 as therapeutic approach.  
 
1.8.2 FOXM1 regulation and role in chemotherapy 
sensitivity and resistance 
 
Hormone receptor negative patients can only be administrated 
chemotherapeutic agents. Identification of potential biomarkers is urgently needed to 
elucidate novel therapies and improve the overall survival rate. FOXM1 has been 
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identified in a high resolution array to be amplified in hormone receptor negative 
breast cancer tissue patients suggesting that FOXM1 could be a potential biomarker 
in hormone receptor negative breast cancer (Han, Jung et al. 2008). FOXM1 target 
genes are involved in cell proliferation; oxidative stress and DNA repair processes. 
Recent data identified FOXM1 as a mediator of cisplatin resistance. FOXM1 
involvement in cisplatin resistance is thought to be due to an increase in DNA repair 
but the detailed molecular events have not been clarified yet (Kwok, Peck et al. 
2010). Further studies revealed that FOXM1 is stabilized by DNA damage agents 
through the phosphorylation by checkpoint kinase, CHK2, and leading to the 
regulation of genes involved in homologous recombination DNA repair mechanism 
(Tan, Raychaudhuri et al. 2007). Cisplatin is a strong alkylating agent given to treat a 
variety of cancers, but is limited by its toxicity profile. Nowadays, anthracyclines, 
doxorubicin or epirubicin, are the most widely prescribed chemotherapeutic agents. 
For nearly thirty years, the anthracyclines, doxorubicin and epirubicin, have been 
pivotal in the management of early stage breast cancer, particularly in hormone 
receptor negative cases (Boér 2010). As emerging evidence has shown that FOXM1 
is involved in drug resistance and may in fact be a potential biomarker, this thesis 
investigates the involvement and regulation of FOXM1 in epirubicin-sensitive and –
resistant breast cancer. 
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CHAPTER 2 MATERIAL AND METHODS 
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2.1 CELL CULTURE 
 
2.1.1 Cell lines 
 
The human breast carcinoma MCF-7, ZR-75-1, and MDA-MB-231, MDA-MB-453 
cell lines originated from the American Type Culture Collection, were obtained from 
the Cancer Research UK Cell Line lab (CRUK, Clare Hall, UK), in which they were 
tested and authenticated, and maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10 % Foetal Calf Serum (FCS), 2 mM glutamine, and 
100 units/ml penicillin/streptomycin at 37 °C in an atmosphere of 10 % CO2.  
 
The COS-1 cells were derived from kidney cells and grown in DMEM 
supplemented with 10 % Foetal Calf Serum (FCS), 2 mM glutamine, and 100 units/ml 
penicillin/streptomycin at 37 °C in an atmosphere of 10 % CO2. 
 
2.1.2 Stably transfected cell lines 
 
Previously in our laboratory, parental MCF-7 cells were stably transfected with 
the N-terminal deleted FOXM1 fragment (Park, Wang et al. 2008) and the full-length 
FOXM1 in pcDNA3 expression vector and the transfection was maintained by DMEM 
supplemented with 1 µg/ml puromycin selection marker (Invitrogen, Paisley, UK).  
 
2.1.3 Knock-out cells 
 
The mouse embryonic fibroblasts (MEF) were derived from wild-type, p53-/- and 
p21Cip1-/-. The MEF wild-type (wt) and foxm1-/- were kindly provided by Pr René H. 
Medema (Department of Medical Oncology, University Medical Center Utrecht, The 
Netherlands). All cells were grown in humidified atmosphere 10 % CO2 at 37 °C and 
in DMEM supplemented with 10 % FCS, 2 mM glutamine, and 100 units/ml 
penicillin/streptomycin.  
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The wild-type 48BR (human fibroblast) primary skin fibroblasts were a generous 
gift by Dr Penny Jeggo (University of Sussex, UK). The human fibroblasts deficient in 
NBS1 (NBS1‐LBI) were kindly given by Veronique Smiths (Unidad de investigacion, 
Hospital Universitario de Canarias, Spain). All cells were grown in humidified 
atmosphere 10 % CO2 at 37 °C and in DMEM supplemented with 10 % FCS, 2 mM 
glutamine, and 100 units/ml penicillin/streptomycin.  
 
2.1.4 Drug resistant cell lines 
 
The tamoxifen 4-OHT resistant MCF-7TAMR4 cells have been kindly given by 
Anne Lykkesfeldt (Institute of Cancer Biology, Denmark), and their growth conditions 
previously characterized and described [Lykkesfeldt, 1994 #229; Madsen, 1997 
#230]. Briefly, a clone of MCF-7TAMR cells were established by two series of one 
week treatment with 10-6 mol/L 4-OHT (OHT) and the resistant cells were 
continuously propagated with 10-6 mol/L OHT. The MCF-7 and derivatives cells were 
exposed to ER ligands: 10-8 mol/L estradiol (E2), 10-6 mol/L 4-OHT (OHT) or 10-7 
mol/L ICI182780 (ICI) (prepared in ethanol), or only ethanol (vehicle control) for the 
indicated times prior to harvesting. For steroid starvation, these cells were cultured in 
phenol-free DMEM/F-12 containing 5 % double charcoal-stripped FCS.  
 
The MCF-7EPIR cell line is an epirubicin resistant cell line derived from parental 
MCF-7 cells. Previously in our laboratory, MCF-7 cells were subjected to a gradual 
concentration of epirubicin until cells acquire resistance up to 10 µmol/L of epirubicin 
(Pfizer, UK). MCF-7EPIR cells were maintained in 1 µmol/L of epirubicin. Prior 
experiments, epirubicin was removed for 24 h and then cells were treated with 
epirubicin 1 µmol/L for the indicated times before harvesting. For RNA interference, 
the cells were treated with epirubicin 24 h after transfection. For ATM inhibition, cells 
were treated with Ku-55933 at 10 µmol/L for 24 h alone or in combination with 1 
µmol/L epirubicin.  
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2.1.5 Cell line maintenance 
 
Cells were grown and split at approximately 90 % twice a week. Media was 
aspirated and the cell monolayer was rinsed once with 1X PBS and then detached 
using 1X trypsin-EDTA mix. After centrifugation at 1200 rpm for 5 min, cells were 
resuspended in the appropriate media and seeded into an appropriate flask or dish.  
 
For long term maintenance, cells were detached from the flask or dish by the 
addition of 1X trypsin-EDTA, spun 1200 rpm for 5 min. The supernatant was 
discarded and the cell pellet was resuspended in FCS with 10 % dimethyl sulphoxide 
(DMSO) at 1 million cells/ml and 1 ml was transferred per cryotube and slowly frozen 
at -80 °C for 2 days before being transferred to storage in liquid nitrogen. For 
defrosting cells, cryotubes were placed for 1min in a waterbath at 37 °C and the 
defrosted solution was added to complete media and spun at 1200 rpm for 5 min. the 
DMSO containing supernatant was removed and cell pellets were resuspended in 
fresh supplemented medium in flask or dish. 
 
2.1.6 Chemicals  
 
Tamoxifen was maintained as a stock solution at 2 mM at -20 °C and diluted in 
fresh media prior to treatment (Pfizer, UK). ICI182780 and estradiol were dissolved 
in ethanol and stored -20 °C at a concentration of 10-2 M (SigmaAldrich, UK). 
Epirubicin (2 mg/ml in 0.9 % sodium chloride) was obtained from Pfizer UK and 
stored at 4 °C. Ku-55933 was dissolved in ethanol and stored at -20 °C at a 
concentration of 10 mmol/L (Tocris Bioscience, UK). 
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2.2 PROTEIN ANALYSIS 
 
2.2.1 Preparation of total protein lysates and determination 
of protein concentration 
 
Whole cell extracts was prepared by harvesting cells using 1X trypsin-EDTA and 
spinning at 1200 rpm for 5 min to obtained cell pellets. The supernatant was 
discarded and cell pellets were washed in 1X PBS (Phosphate Buffered Saline) and 
spun for an additional 5 min at 1200 rpm. The supernatant was discarded and cell 
pellets were frozen at -80 °C until lysis was performed. Frozen pellets were lysed in a 
lysis buffer containing 0.1 % Triton X100, 150 mM NaCl2, 50 mM Tris-HCl (pH 7.8), 1 
mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and protease 
inhibitors (“Complete protease inhibitor mixture, as instructed by the manufacturer, 
Roche Applied Sciences, UK) on ice for 30 min (Table 2.1). Supernatant were 
collected after microcentrifugation at 13000 rpm at 4 °C for 10 min and protein 
concentration was measured using Bio-Rad Dc protein assay (Bio-Rad Laboratories, 
CA, USA) as instructed by the manufacturer. 20 μl of reagent S was added to 1 ml of 
reagent A.  A standard curve was established by assaying 5 dilutions of a protein 
standard within the range of 0.2 mg/ml to 1.5 mg/ml protein.  25 μl of reagent A was 
added to 2 μl of each dilution and mixed with 200 μl of reagent B.  After 15 min, 
absorbance was read at 700 nm. The protein concentration of the samples was 
determined by multiplying the absorbance of the sample by the standard curve’s 
regression coefficient.  
2.2.2 Western blotting or sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein expressions were determined using SDS-PAGE gels made using a 37.5 
% (w/v) acrylamide/bis stock solution, Tris-HCl and, 25 % of ammonium persulphate 
and tetramethylethylenediamine (TEMED). SDS-PAGE gels consist of a lower 
resolving gel and an upper stacking gel. The percentage of resolving gel used 
depends on the size of the protein of interest. The protein extracts were diluted at 20 
μg in 2X SDS loading buffer (4 % (w/v) SDS, 62.5 mM Tris-HCL (pH 6.8), 1 % (v/v) 
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glycerol, 0.01 % (w/v) bromophenol blue, 10 % (v/v) β-mercaptoethanol) and boiled 
at 100 °C for 5 min. Samples were then run at a constant voltage of 100V in running 
buffer (Table 2.1). Proteins were separated alongside a Novex® Sharp Pre-Stained 
protein standard (Invitrogen, Paisley, UK) to identify the molecular weight of the 
separated proteins. Subsequently, proteins were transferred to nitrocellulose 
membranes (Whatman® Protran®) using a transfer buffer at 90 V for 1 h (Table 2.1). 
After the transfer, membranes were saturated with a 5 % blocking solution (Bovine 
Serum Albumin or Milk) diluted in TBST for 1 h at room temperature (RT) (Table 2.1). 
The primary antibody was diluted at 1:1000 in the blocking solution previously used 
and incubated overnight at 4 °C, the membranes were then washed three times with 
TBST (Table 2.1) for 15 min and incubated either with peroxidase-conjugated 
secondary antibody against mouse or rabbit IgG at 1:5000 dilution in TBST for 45 min 
at RT. After the TBST washing steps, membranes were incubated with Western 
Lightning® ECL (chemiluminescence peroxidase substrate) according to the 
manufacturer’s instructions (Perkin Elmer, UK) and a signal was detected using 
Hyperfilm ECL (GE healthcare) on SRX-101A x-ray developer. 
 
Reagent Recipe 
Western Blotting   
1X TG                             25 mM Tris, 192 mM Glycine, pH 8.3 
TBS 10X 
24.23 g Tris HCl, 80.06 g NaCl add up to 1 L with ddH20 and adjust pH to 7.6 with 
concentrated HCl 
TBST 100 ml of TBS 10x, 890 ml ddH20, 10 ml Tween 10 % (v/v) 
Lysis buffer 
50 mM Tris pH 7.5, 150 mM NaCl, 0.10 % Triton x100 , 10 mM NaF, 1 tablet 
protease inhibitors (Roche) 
Running buffer 1x TG, 0.1 % SDS 
Transfer buffer 100 ml TG 10x, 800 ml ddH20, 100 ml Ethanol 
Blocking solution 5 % (w/v) BSA, TBST, 0.02 % (w/v) sodium azide 
Chromatin 
Immunoprecipitation 
  
TSE I buffer 
0.1 % (w/v) SDS, 1 % (v/v) Triton X-100, 2mM EDTA, 20 mM Tris-HCl pH 8.1, 150 
mM NaCl 
Buffer I 0.25 % (v/v) Triton X-100, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES pH 6.5 
Buffer II 200 mM NaCl, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES pH 6.5 
Lysis buffer 1 % SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1, 1 tablet protease inhibitors 
Table 2.1 SDS-PAGE and ChIP buffers 
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Antibody Company Reference Specie kDa 
 
Transcription factors and 
coactivators 
   
  
FOXM1 (WB, ChIP) Santa Cruz sc-502 Rabbit 100 
FOXM1 (IF) Santa Cruz sc-500 Rabbit 100 
ERα Santa Cruz sc-543 Rabbit 66 
AIB-1 
BD transduction 
laboratories 
611105 Mouse 160 
P-p53 (Ser15) Cell Signaling 9284 Rabbit 53 
p53 Santa Cruz Pab1801 Mouse 53 
 
Histones and histones modificators 
 
    
HDACI Santa Cruz sc-6299 Goat 55 
HDACII  Abcam ab7029 Rabbit 60 
Acetyl-H3 (ChIP) Upstate 06-599 Rabbit 10 
Acetyl-H4 (ChIP) Upstate 06-866 Rabbit 17 
 
Cell cycle regulators 
     
Cyclin A Santa Cruz sc-239 Mouse 54 
Cyclin B1 Santa Cruz sc-752 Rabbit 60 
Cyclin D1 Santa Cruz sc-246 Mouse 37 
CDK2 Abcam ab2363 Mouse 34 
CDK4 Cell Signaling DCS156 Mouse 30 
p21 Santa Cruz sc-6246 Mouse  21 
Cdc25b Abcam ab2358 Mouse 90 
PLK Santa Cruz sc-17783 Mouse 66 
pS2 Santa Cruz sc-28925 Rabbit 7-12 
E2F1 (WB, ChIP) Santa Cruz sc-193 Rabbit 60 
P-pRB (Ser807/811) Cell Signaling 9308 Rabbit 110 
pRB (ChIP) BD Pharmigen 554136 Mouse 110 
 
DNA damage and checkpoint 
markers      
P-ATM (Ser1981) Upstate MAB3806 Mouse 370 
ATM Calbiochem Ab-3 Rabbit 370 
P-Chk1 (Ser345) Cell Signaling 133D3 Rabbit 59 
Chk1 Santa Cruz sc-8408 Mouse 56 
P-Chk2 (Thr68) Cell Signaling C13C1 Rabbit 62 
Chk2 Upstate clone 7 Mouse 67 
P-H2AX (Ser139) Upstate clone JBW301 Mouse 17 
H2AX Cell Signaling 2595 Rabbit 17 
NBS1 Cell Signalling 3002 Rabbit 95 
Cell death markers     
PARP Cell Signaling 9542 Rabbit 89,116 
 
Ubiquitous proteins      
Beta-Tubulin Santa Cruz (H-235)sc-9104 Rabbit 57 
Table 2.2 Antibodies for western blotting and ChIP 
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2.3 PULL-DOWN using biotin-labelled oligonucleotides 
 
Nuclear and cytoplasmic extracts were prepared using NE-PER® nuclear and 
cytoplasmic extraction kit (Thermo Scientific, Rockford, USA). Briefly, cells were 
collected using trypsin and centrifuged to obtain dry pellet. CER I buffer (cytoplasmic 
extraction reagent) was added to the pellet, incubated for 5 min and centrifuge at 
maximal speed. The supernatant (cytoplasmic fraction) was transferred to a new 
eppendorf and stored at -80 ºC until use. The insoluble pellet was then resuspended 
in NER buffer (nuclear extraction reagent) and incubated on ice for 40 min. After the 
same process of centrifugation, the nuclear fraction was transferred to a new 
eppendorf and store at -80 ºC until use. 
 
The biotinylated oligonucleotides, oestrogen response element (ERE) (ERE-wt 
5’-GCCGATTGGCGACGTTCCGTCACGTGACCTTAACGCTCCGCCGGCG-3’, 5’-
CGCCGGCGGAGCGTTAAGGTCACGTGACGGAACGTCGCCAATCGGC-3’), or 
(mERE3 5’-GCCGATTGGCGACGTTCCGTAACGTTACGTTAACGCTCCGCCGGC-
3’, 5’-CGCCGGCGGAGCGTTAACGTAACGTTACGGAACGTCGCCAATCGGC-3’), 
were firstly annealed and bound to streptavidin beads on a rotator for 2 h at RT. 50 
µg of protein extract were added with or without an excess of unlabelled competitor 
oligonucleotides and incubated for 1 h at 4 °C on the rotator. Beads were then 
washed with three times 1X PBS, loading buffer was added. Beads were boiled at 
100 °C for 5 min and analysed by western blotting the supernatant.  
 
2.4 IMMUNOPRECIPITATION AND IMMUNOBLOTTING  
 
Cells were harvested and lysed as described in the protein analysis section. 
While the cells pellets were being extracted, 20 µl of dynabeads per reaction 
(Invitrogen, Paisley, UK) were washed with 1X PBS and incubated for 1 h 4 ºC with 
the appropriate antibody. After centrifugation at 14 000 rpm, protein lysates were 
incubated with the complexes beads/antibodies for 2 h at 4 ºC. For immunoblot 
analysis, the immunoprecipitated samples were diluted in 2X SDS-loading buffer, 
boiled and run on SDS-PAGE gels. After the transfer, membranes were blocked, 
incubated with primary antibody overnight 4ºC and then with the relevant peroxidase-
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conjugated secondary antibody for 1 h RT and visualised using Western Lightning® 
ECL 
 
2.5 CHROMATIN IMMUNOPRECIPITATION (ChIP) 
 
2.5.1 Beads preparation 
 
The day before chromatin immunoprecipitation was performed, 20 µl of 
dynabeads per condition (Invitrogen, Paisley, UK) were washed with TSE I buffer 
(Table 2.1) three times using a magnetic rack to discard the supernatant and were 
resuspended in 20 µl of TSE I buffer. One microgram of antibody and control 
immunoglobulin were incubated with the beads overnight on the rotator at 4 °C 
(Table 2.2). 
 
2.5.2 Cells preparation 
 
The cells were seeded in 10 cm dish to obtain 90 % confluency prior 
experiments. About 10 million of cells were cross-linked by adding 270 µl of 37 % 
formaldehyde to the 10 ml of cell medium (1 % formaldehyde) and were incubated at 
37 °C for 10 min. Under the chemical hood, formaldehyde/medium mix was 
discarded and cells were gently washed twice with cold 1X PBS. One millilitre of the 
mix containing 100 mM Tris-HCl pH 9.4 and 10 mM DTT was added to each 10 cm 
dish to scrape the cells and transferred to an ice-cold sterile eppendorf.  Cells were 
then centrifuged at 5 000 rpm for 5 min. Pellets were sequentially washed with 1 ml 
of 1X PBS, ChIP buffer I and ChIP buffer II (Table 2.1) to obtain chromatin.  
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2.5.3 Sonication 
 
After these washing steps, cell pellets were resuspended in a ChIP lysis buffer 
(Table 2.1), incubated on ice for 10 min and sonicated for 12 min at 30 sec intervals. 
Optimisation of sonication times has been optimised with the different cell lines used. 
The sonication time was determined by running DNA (chromatin) on 1 % DNA gel 
electrophoresis and selecting time for which DNA size is between 100-500 bp.  
 
2.5.4 DNA/beads-antibody incubation 
 
After sequential washing steps, the lysates were microcentrifuged at 14000 rpm 
for 10 min at 4 °C.  The chromatin pellets obtained were resuspended in the TSE I 
buffer, transferred to the beads-antibody complexes and incubated on the rotator for 
2 h at 4 °C. Afterwards, the beads were washed with the TSE I buffer five times and 
the DNA was eluted with a mixture of 1 % (w/v) SDS and 0.1 M NaHCO3 twice for 1 h 
on the rotator.  
 
2.5.5 DNA elution, purification and Polymerase Chain 
Reaction (PCR) 
 
The samples were decrosslinked at 65 °C overnight and DNA was purified using 
the QIAquick PCR Purification kit (Qiagen, Paisley, UK), as described in the 
manufacturer’s instructions. After the purification, a Polymerase Chain Reaction 
(PCR) was set up with primers designed using the ABI Primer Express software 
(Table 2.3). 50 ng of total eluted DNA or 1% of eluted DNA (input) with 1 µM of a 
forward and reverse primer specifically designed for each target gene (at the DNA 
binding site tested and control site upstream), mixture of dNTP and mix reaction of 
the DNA polymerase kit containing 10X buffer, Q solution, MnCl2 and Taq 
polymerase as described by the manufacturer (Qiagen, Paisley, UK) were incubated 
in a thermocycler (GeneAmp PCR system 9700, Applied Biosystems).  
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The controls performed include:  
- primers for a region where the protein of interest is absent (negative control) 
that were tested for each experiment (shown in the results). 
- a non-template control that was included in each PCR reaction to spot 
contamination (not shown in the results). 
 
 
 
 
 
 
 
 
Figure 2.1 DSB detection and repair model. I-PpoI cuts DNA (1) inducing chromatin 
structural change that initiates ATM activation. Activated ATM is recruited to DSBs and 
phosphorylate MRN proteins (2). Repair proteins such as XRCC4 are recruited to the DSB 
(3) (from (Berkovich, Monnat et al. 2007). 
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2.5.6 DNA gel electrophoresis 
 
Agarose (SigmaAldrich, UK) was dissolved in the appropriate volume of 1X TAE 
(Table 2.4) at the concentration of 1 % (w/v) and the mixture heated until fully 
dissolved. Ethidium bromide was added once the mixture was allowed to cool. 
Samples diluted in DNA loading buffer (Table 2.4) and DNA ladder was resolved and 
DNA visualized under Ultra Violet light using UVIPro Platinum software.  
 
Buffer Recipe 
Tris Acetate EDTA (TAE 50X) 2 M Tris, 57.1 ml acetic acid, 0.2 M EDTA pH 
8.0, ddH2O added until total volume 1 L 
 
DNA Loading buffer 
 
2.3 M sucrose and 100 mg Orange G made to 50 
ml with ddH2O 
Table 2.3 DNA gel electrophoresis buffers 
 
 
2.6 RNA ANALYSIS 
 
2.6.1 Total RNA extraction 
 
Total RNA was isolated from cells using the RNeasy Mini kit (Qiagen, Crawley, 
UK). The protocol was performed in line with the manufacturer’s instructions.  
 
Frozen cell pellets were resuspended in 350 μl of RLT buffer (containing 10% β-
mercaptoethanol) and homogenised by pipetting. 350 μl of 70 % ethanol was added 
and the total mixture was transferred to the provided column, which was placed in a 2 
ml collection tube, and spun in a benchtop centrifuge at 10000 rpm for 30 secondes 
(sec). The flow through was discarded and 700 μl of buffer RW1 was added to the 
column and spun at 10000 rpm for 30 sec. Then, 500 μl of RPE buffer was added to 
the column and spun at 10000 rpm for 30 sec. the low through was discarded and 
the column was spun for an additional 10000 rpm for 30 sec to remove any waste of 
the column. Next, the column was transferred to a clean sterile eppendorf tube. The 
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extracted RNA was eluted by the addition of 30 μl of RNase-free water to the centre 
of the column and spinning for 1 min at 10000 rpm. The purity and concentration of 
the RNA was determined using Nanodrop, which measures the spectrometric 
absorption at 260 nm and 280 nm. RNA samples were then stored at -80 °C or 
immediately used to make cDNA using first strand cDNA synthesis.  
 
2.6.2 First strand cDNA synthesis 
 
1 μg of total RNA was reverse transcribed into first strand cDNA using the 
Superscript III first strand cDNA synthesis system (Invitrogen, Paisley, UK).  
One microliter of random primers and 1 μl of 10 mM dNTPs mix (containing four 
bases adenine, cytosine, guanine and thymine) were added to 1 μg of total RNA to 
make a total volume of 14 μl using sterile RNase free water. The sample was heated 
for 5 min at 65 °C and placed immediately on ice for 1 min. Four microliters of 5X first 
strand buffer, 1 μl of 0.1 M DTT, 1 μl of RNaseOUT and 1 μl of the reverse 
transcriptase Superscript III were then added to make a total volume of 20 μl. The 
mixture was placed in a thermocycler (GeneAmp PCR system 9700, Applied 
Biosystems) where they were incubated for 5 min at 25 °C for 5 min, then heated to 
50 °C for 50 min. the reaction was terminated by heating the mixture at 70 °C for 15 
min.  
 
2.6.3 Primers 
The following human and mouse gene-specific primer pairs were designed using 
the ABI Primer Express software:  
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Table 2.4 Human and mouse gene-specific primer pairs for RT-qPCR and ChIP 
 
 
 
 
 
  
Forward sequence Reverse sequence 
Temp 
(˚C) 
ChIP primers (human): 
FOXM1 (ERE) CCACTTCTTCCCCCACAAG CCGGAGCTTTCAGTTTGTTC 65 
FOXM1 (E2F) CCACTTCTTCCCCCACAAG CCGGAGCTTTCAGTTTGTTC 65 
FOXM1 (cont) CCACGCTTCCCCCACAAG CCGGAGCTTTCAGTTT 65 
NBS1 (FHK) AATTAAAAATTTTCCTTATGTTGCTTT GGGCGCTTGCCCGCCACCTGGTGGTTGG 60 
NBS1 (cont) GCTAGAGTGCAGTGGCATGA AAGATCAGCATGGGCAACAT 60 
DAB1 TGCTGCTTTTTCTTCTTCTCC CTTCTTTCCCACCAAGTCTTC 64 
Β-actin AACTCCATCATGAAGTGTGACG GATCCACATCTGCTGGAAGG 60 
Gene expression primers (human): 
FOXM1 TGCAGCTAGGGATGTGAATCTTC GGAGCCCAGTCCATCAGAACT 60 
ERα CAGATGGTCAGTGCCTTGTTGG CCAAGAGCAAGTTAGGAGCAAACAG 60 
E2F1 CTGAGACAACTTGAGGAAGAG TTTGAACCTGTACTAGCCAGTC 60 
ATM AATATCCATTCACCGCAGCC CACAATTTGCCGTAGGTAGTATC 60 
ATR AGTCCCAGCCAGTCTCTACTCA TGCCCATCCGGGACAA 60 
NBS1 TTTTCAACCAGTTTTCCGTTACTTC ACACTGCGCGTATAAGCCAAT 60 
MRE11 TGAGAACTGGCCTTCGATTCA GGAGCCCAGACAAGCATGAT 60 
RAD50 TCCAAATCTTGTGGAAGTGCAT CTGCAAGCAGCCAGAACTTG 60 
L19 TCTGGATGATGCTGTGCTACCT GGCCCACAGCTCAGACTGA 60 
  
 Forward sequence Reverse sequence 
Temp 
(˚C) 
Gene expression primers (mouse): 
Foxm1 TGCAGCTAGGGATGTGAATCTTC GGAGCCCAGTCCATCAGAACT 60 
Nbs1 TGACAACCCGATAGAGGAGCAT TCTTGGCTCTCTGTCTGTCCAG 60 
Mre11 TTCCCTCGGTGGGATTCAA                  ACACCCATCTGGCTGTCAGAA 60 
Rad50 TAGCACACCAACACGTCGTA CAGTGCCTTCCTCCTCTTGT 60 
Atm  GCGCCACGCCTTGT CAAACGTTGCCTGAAT 60 
L19 TACACCTTCCCACTTACTGA ATTCCTCCGACTCTTCCTTT 60    
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2.6.4 Real-time quantitative PCR (RT-qPCR) 
 
The specificity of each primer was determined using NCBI BLAST module. Real 
time PCR was performed with ABI PRISM 7700 Sequence Detection System using 
SYBR Green Mastermix (Applied Biosystems, Brackley, UK).   
 
Transcript levels were quantified using the standard curve method, where 1 µg of 
cDNA from each sample was mixed and diluted into serial dilutions (1/4, 1/16, 1/64, 
1/256). L19, a non-regulated housekeeping gene, was used as an internal control to 
normalise the input cDNA.  
 
The reaction mix contained 2 µl of sample and 23 µl of of SYBR Green master 
mix, primers and RNase-free water were added to a final volume of 25 µl. All 
experiments were performed in triplicates. 
 
2.7 DNA MANIPULATION 
2.7.1 Plasmid amplification and extraction 
The XL1-Blue competent cells were used to amplify plasmids. 50 µl of XL1-Blue 
(per vector) were thawed on ice and 2 µl of plasmid was added and incubated on ice 
for 30 min. The mixture competent cells and plasmid was heated at 42 ºC in a 
waterbath for 45 sec and chilled on ice for 2 min prior incubation with 500 µl of SOC 
medium for 1 h at 37 ºC. 100 µl was spread into warm LB-agar plates containing the 
selective antibiotic and incubated at 37 ºC overnight. 
Sixteen hours after incubation, individual colonies were grown overnight in 3 ml 
of LB-broth supplemented with the corresponding antibiotic. The following day, 1 ml 
of overnight culture was used for screening. Bacterial DNA was extracted using the 
miniprep protocol (Qiagen, Crawley, UK) following the manufacturer’s instructions 
and DNA was digested using restriction enzymes to verify the presence of the insert. 
Positive clones were then grown overnight in 250 ml of LB-broth supplemented with 
the antibiotic and plasmid was extracted with a maxiprep protocol from Qiagen.  
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Reagent  Recipe 
Luria-Bertani (LB) medium 1% (w/v) tryptone, 1% (w/v) yeast extract, 1% 
(w/v) NaCl 
LB-agar medium 1% (w/v) tryptone, 1% (w/v) yeast extract, 1% 
(w/v) NaCl 
SOC media 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 
0.5% (w/v) NaCl, 5 mM MgSO4, 10 mM MgCl2, 
0.4% (w/v) glucose 
Ampicillin 1 g Ampicillin in 10 ml ddH2O (final 
concentration 100 mg/ml) 
Ampicillin resistance selection media/agar Ampicillin added to LB medium/agar at final 
concentration 100 µg/ml 
 
Table 2.5 Bacterial culture reagents 
 
2.7.2 DNA mutation and sequencing 
Mutagenesis of plasmids were performed using the Stratagene Quickchange 
site-directed mutagenesis kit (Agilent Technology, Berkshire) as indicated by the 
manufacturer. Two complementary oligonucleotides containing the desired mutation 
and flanked by unmodified nucleotide sequence were designed prior mutagenesis. A 
PCR mix containing the DNA template, the forward and reverse primers, dNTP 
mixture, 10X reaction buffer and the PfuTurbo DNA polymerase was placed in a 
thermocycler for the amplification of mutated DNA. One microliter of Dpn I restriction 
enzyme was then added directly to the amplification reaction and incubated 1 h at 37 
ºC to digest the parental non mutated DNA. Next, the sample reaction was 
transformed into XL1-Blue competent cells, as described in the above section, and 
DNA was extracted using the miniprep kit to determine whether the DNA contains the 
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desired mutation. All plasmids DNA were sequenced at the Medical research Council 
DNA Core laboratory using an ABI 7500 PRISM automated sequencer. 
2.7.3 Plasmid DNA transfection 
Cells were seeded into 10 cm dish to reach confluency approximately 60%. 
Plasmids DNA (Table 2.6) were transfected using Fugene 6 (Roche Applied 
Sciences, UK). The ratio 3:1 (µl of Fugene 6: µg of DNA) was used as recommended 
by the manufacturer.  
For one 10 cm dish, 988 µl of DMEM (containing no supplement) was added to a 
sterile eppendorf tube and 12 µl of Fugene 6 was added carefully. The mixture was 
shaken and left at RT for 5 min. 3 µg of plasmid DNA (Table 2.6) was added, mixed 
and left at RT for 15 min. the mixture was then added gently to the dish containing 
cells and 10 ml medium. Overexpressions of desired proteins were confirmed 24 h 
after transfection after protein extraction and western blotting. 
 
 
 
Vector Selection From/reference 
pcDNA3-FOXM1 Ampicillin Our laboratory 
pcDNA3-ΔN-FOXM1 Ampicillin Our laboratory 
HEG0 (ERα) Ampicillin Tora et al, 1989, EMBO 
pcDNA3-Flag- ERβ Ampicillin J. Hartman 
pcDNA3-Flag-p53 Ampicillin N. Hadjji 
pCMV-E2F-1 Ampicillin Helin et al, 1993 
pFlag-Nbs1 Ampicillin Kou-Juey Wu (Wu et al, 2007) 
Table 2.6 Expression vectors  
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2.7.4 Luciferase assay 
For promoter analysis, cells were treated with indicated drugs for Firefly/Renilla 
luciferase assays using the Steadyliteplus reporter assay system (Perkin Elmer, 
Cambridgeshire, UK) according to manufacturer’s instructions. Briefly, the substrate 
(luciferin, ATP, magnesium and molecular oxygen) was added to the cells (seeded in 
96-well plate) and the luminescence was measured after 15 min using a microplate 
reader (BMG Labtech, Offenburg, Germany). Subsequently, the substrate 
(coelenterate luciferin and molecular oxygen) for the Renilla was added to the 
previous mix and the cells, and luminescence was measured after 15 min. The ratio 
of luminescence of luciferase Reporter/Renilla reporter was calculated. All 
experiments were performed in triplicate.  
Cells were transfected with the promoter constructs (Table 2.7) and 5 ng of 
Renilla (pRL-TK; Promega, Southampton, UK) as internal transfection control using 
Fugene-6 according to manufacturer’s instructions (Roche Diagnostics Ltd, Burgess 
Hill, UK). For some experiments, cells were transfected with human FOXM1 or NBS1 
promoters and 5 ng of Renilla alone, or in combination with 10 ng and 30 ng of 
expression vectors.  
 
Promoter constructs Length From 
FOXM1 promoter   
pGL3-Full length 2.4kb  René H. Medema 
pGL3-Hind III 1.4kb  René H. Medema 
pGL3-ApaI 296bp  René H. Medema 
pGL3-ApaI-E2Fmut1 296bp  Made in the laboratory 
pGL3-ApaI-E2Fmut2 296bp  Made in the laboratory 
pGL3-ApaI-E2Fmut1/2 296bp  Made in the laboratory 
NBS1 promoter   
pXP2-NBS1-FHK 1500bp Kou-Juey Wu 
pXP2-NBS1-FHKmut 1500bp Made by myself 
Table 2.7 Promoter constructs  
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2.7.5 Host cell reactivation assay (HCR) 
 
The HCR assay is an assay measuring the DNA repair of single strand damaged 
DNA introduced into cells. This assay was performed using a damaged luciferase 
reporter vector, in which a CMV promoter drives the transcription of the luciferase 
gene. The plasmid harbouring luciferase was damaged prior transfection by a nicking 
endonuclease Nb.Bts1 (New England Biolabs) and was repaired by the cellular DNA 
repair machinery and only fully repaired plasmid will transcribe correctly to generate 
active luciferase.  
 
Two micrograms of the cyclinB1 promoter luciferase reporter plasmid was 
damaged using 10,000 units/ml of a nicking endonuclease Nb.BtsI for 2 h at 37 ºC 
(R0707S, New England Biolabs Ldt, Herts, UK) and 40 ng of plasmids were 
transfected along with 5 ng of Renilla plasmid (pRL-TK; Promega, Southampton, 
UK). One unit is defined as the amount of enzyme required to convert 1 µg of 
supercoiled plasmid to open circular form in 1 hour at 37°C in a total reaction volume 
of 50 µl. Each digestion was run on 1% agarose gel to confirm that the plasmid was 
linearized. 
 
The endonuclease Nb.Bts1 cleaves DNA as a heterodimer of one large subunit 
(B subunit) and one small subunit (A subunit); and, in the absence of their small 
subunits, the large subunits behave as sequence-specific DNA nicking enzymes and 
only nick the bottom strand of the sequences at this position: 
 
 
After the indicated time points, luciferase activity was measured and normalised 
against the internal control Renilla. Because of the variation in the transfection 
efficiency between undamaged and damaged plasmids, the percentage of luciferase 
recovery was determined comparing to the first time point at 0 h.  
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Figure 2.2 Host Cell Reactivation. Damaged pGL3-cyclinB1 luciferase reporter plasmid is 
transfected transfected along with undamaged Renilla plasmid. Luciferase activity was 
measured and normalised against the internal control Renilla. 
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2.8 RNA INTERFERENCE  
 
Transient RNA interference was used to specifically repress the expression of 
chosen genes and performed using small-interfering RNA (siRNA). 
 
In this study, cells were transfected with the SMARTpool siRNAs purchased from 
Dharmacon (Lafayette, CO) using OligofectAMINE (Invitrogen, Paisley, UK) 
according to manufacturer’s instructions. Briefly, cells were seeded in a 6-well plate 
24 h prior transfection to reach a confluency of 50 % and the specific target gene was 
silenced using 50 nM of siRNA. For each well, 70µl of Optimem was mixed with 5 µl 
of oligofectAMINE (Invitrogen, Paisley, UK) and incubated at RT for 10 min. This 
solution was then combined with 250 µl Optimem and 7,5 µl siRNA oligos for each 
gene. After 25 min incubation, 160 µl Optimem was added to the mixture reaching a 
final volume of 500 µl, which was added to the cells previously washed with 1X PBS. 
The 6-well plates were incubated at 37 °C for 4 h and 2 ml of culture medium 
containing 10 % FCS was subsequently added to cells to prevent toxic effects. Cells 
were harvested 24 h after transfection for protein and RNA analysis. SMARTpool 
FOXM1 siRNA (M-009762-00), ERα siRNA (L-003401-00), p53 siRNA (L-003329-
00), p21Cip1 (L-003471-00), ATM (L-003201-00), NBS1 (L-009641-00), CHK1 (L-
003255-00), CHK2 (L-003256-000) and siCONTROL non-targeting siRNA were used. 
All experiments were performed with a control mock condition. As control mock 
conditions showed the same results as the non/targeting siRNA, control mock 
condition was not shown in the data. 
 
2.8 IMMUNOFLUORESCENCE MICROSCOPY 
 
10000 cells per well were seeded into 8-well culture slide chambers (BD 
Falcon™, Oxford, UK) for confocal microscopy and 5000 cells per well into 96-well 
plate, black-walled with clear bottom (BD Falcon™, Oxford, UK) for foci/staining 
quantification with Image Xpress (Molecular Devices, Berkshire, UK). After 24 h, cells 
were treated with epirubicin 1 µmol/L for indicated times and then fixed and 
permeabilized with 100 % methanol for 10 min at RT. Wells were washed three times 
with 1X PBS  and blocked with 5 % goat serum for 1 h at RT. Then, fixed cells were 
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incubated with a specific primary antibody for FOXM1 (Santa Cruz, sc-500) (1:250), 
P-ATM (Ser1981) (1:120) (Upstate, MAB3806), P-CHK2 (Thr68) (C13C1) or for P-
H2AX (Ser139) (Upstate, JBW301) (dilution 1:250) overnight at 4 ºC, followed by 
Alexa 488 (green)-conjugated anti-secondary antibody or Alexa 555 (red)-conjugated 
anti-secondary antibody (Invitrogen, Molecular Devices, UK) for 1 h at RT. Cells were 
counterstained with TO-PRO®-3 iodide or DAPI (Invitrogen, Molecular Devices, UK) 
to show the nuclei. Specific staining was visualised and images captured with Zeiss 
LSM 500 system confocal microscope. Foci quantification was performed with Image 
Xpress system microscopy and analysed with MetaMorph software (Molecular 
Devices, Berkshire, UK). 
 
2.9 SRB assay 
 
The cell survival was determined using the sulforhodamine B (SRB) colorimetric 
assay previously described (Skehan, 1990). The SRB dye binds proteins of the cell. It 
is an anionic aminoxanthene dye that forms an electrostatic complex with the basic 
amino acid residues of proteins under moderately acid conditions, which provides a 
sensitive linear response. Because the binding is stoichiometric, the quantity of dye 
dissolved from the stained and fixed cells is proportional to cell mass and 
representative of cell density. Therefore, the SRB assay detects the number of cells 
but not cell proliferation. Approximately 5000 cells per well seeded in 96-well plates 
were fixed with 100 µl of cold 40 % trichloroacetic acid for 1 h at 4 °C. After three 
washes with cold water, cells were stained with 0.4 % sulforhodamine B (that binds to 
protein basic amino acid residues) for 1 h at RT. Cells were then rinsed three times 
with 1 % acetic acid and left to dry overnight. The protein-bound dye was dissolved 
the next day in 10 mM Tris base solution for 30 min and measured at 495 nm using a 
Sunrise™ plate reader (Tecan Group Ltd). The results obtained were expressed as 
the mean of eight replicates relative to the results obtained for the vehicle control at 0 
h providing the percentage of cell survival.   
This assay is widely used for in vitro cytoxicity screening. This assay has been 
used for high-throughput drug screening at the National Cancer Institute. Studies 
undertaken by groups showed that results from the SRB assay correlates well with 
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the MTT assay (tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (Vichai and Kirtikara 2006). 
Controls: all SRB assays with siRNA condition were performed with a mock 
control. No difference has been found compared with the non-targeting siRNA, 
therefore the mock data have not been included for clarity purpose.   
2.10 CELL CYCLE ANALYSIS 
 
Cell cycle analysis was performed using propidium iodide (PI) staining alone. 
Cells were trypsinized, collected by centrifugation, and washed in 1X PBS  before 
fixing in 70 % ethanol. Fixed cells were washed twice in 90 % ethanol and then re-
suspended in 1X PBS containing propidium iodide (1 mg/ml) supplemented with 
RNase (20 units/ml) for 15 min at 4 °C. The single cell suspensions were analysed on 
a FACSCalibur flow cytometer (BD Biosciences Immunocytometry Systems, San 
Jose, CA) with CellQuest (BD Biosciences) acquisition software. For protein staining, 
cells were rinsed in PBS 1X before fixing in 70 % ethanol overnight at 4 °C. The fixed 
cells were then washed twice with 1X PBS and resuspended in 1X PBS containing 
0.5 % of BSA. After centrifugation, the pellet was resuspended in 100 µl 1X PBS 
containing 1 % BSA and an antibody against P-ATM (Ser1981) (1:800), P-H2AX 
(Ser139) (1:400) or FOXM1-C20 (1:400) and incubated for 2 h at RT. After 
centrigutation, pellets were washed in 100 µl 1X PBS  containing an anti-mouse or 
anti-rabbit Alexa 488 (green)-conjugated secondary antibody (1:400) (Invitrogen, 
Molecular Devices, UK) for 1 h at RT in the dark. After washing, pellets were 
counterstained with propidium iodide (1 mg/ml) supplemented with RNase (20 
units/ml) for 15 min at RT. The samples were analysed by flow cytometry as 
described above. The experiments were performed in triplicate. 
 
 
 
2.11 STATISTICAL ANALYSIS 
 
Statistical analyses were performed using GraphPad Prism v5.0. The statistical 
significance of differences between the means of two groups was evaluated by 
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paired Student’s t test and considered significant when n.s non significant, * P≤0.1,  
**P≤0.01 and *** P≤0.001.  
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 FOXM1 is a transcriptional target of ERalpha and has a 
critical role in breast cancer endocrine sensitivity and resistance 
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3.1 Introduction  
 
Breast cancer is the most common cancer in women in the UK. The forkhead 
box family member FOXM1 was previously reported elevated in breast cancer 
adenocarcinoma as well as carcinoma from other origins (Pilarsky, Wenzig et al. 
2004, Kalin, Wang et al. 2006, Kim, Ackerson et al. 2006, Yoshida, Wang et al. 
2007). FOXM1 is highly expressed in embryo and proliferating adult tissues, while its 
expression is low in quiescent cells (Korver, Roose et al. 1997). FOXM1 regulates 
the expression of cell cycle regulatory genes involved in the G1/S and G2/M phase 
transitions (Laoukili, Kooistra et al. 2005). A cDNA microarray study previously 
identified FOXM1 as one of the 344 ERα responsive genes in breast cancer cells 
(Cicatiello, Scafoglio et al. 2004). Moreover, a recent study in our laboratory showed 
a positive correlation between ERα and FOXM1 protein expression in breast cancer 
cells (Madureira, Varshochi et al. 2006).  
 
Oestrogens are the most important regulators of breast cancer growth and act 
through the oestrogen receptors, ERα and ERß. ERα activity induces breast cancer 
cell proliferation, while ERß is an anti-proliferative factor (Paruthiyil, Parmar et al. 
2004). Oestrogens are heavily implicated in breast cancer because of their role in 
stimulating breast cell division, their activity during the critical periods of breast 
growth and development, and their effect on other hormones that stimulate breast 
cell division. Although ERα oncogenic potential, its expression in breast cancer 
patients is a good prognostic. Anti-oestrogen or endocrine therapies are effective 
only in patients with ERα positive breast cancer. Clinically, tamoxifen has been the 
most commonly used endocrine agent, and is suitable for both pre- and post-
menopausal women. Tamoxifen is a selective ERα modulator that blocks the binding 
of oestrogen on ERα and induces the recruitment of co-repressors preventing ERα 
transcriptional activity.  
 
Treatment of breast cancer with anti-oestrogens results in G1 cell cycle arrest 
and in some cases, cell death (Lykkesfeldt, Larsen et al. 1986). However, about half 
of the patients who initially respond to endocrine therapy become resistant despite 
continued expression of ERα (Ali and Coombes 2002, Goss, Muss et al. 2008, 
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Yamashita 2008). Indeed, loss of ERα expression occurs in a minority of resistant 
breast cancer while various mechanisms of endocrine resistance in ERα positive 
breast cancer have been reported. ERα is regulated through transcriptional, post-
transcriptional and post-translational mechanisms, and deregulation of one of these 
processes can result in endocrine resistance (Musgrove and Sutherland 2009). 
Emerging data indicate that altered expression of several growth factors receptors 
and overexpression of ERα co-activators can constitutively phosphorylate and 
thereby activate ERα conferring breast cancer endocrine resistance.  
 
The previous observation in our laboratory that ERα positive breast cancer cells 
express higher levels of FOXM1 led to hypothesise that FOXM1 may be regulated by 
ERα. Based on the recent evidence linking FOXM1 with drug resistance, I 
investigated the regulation of FOXM1 by ERα and its ligands in MCF-7 cells, and 
FOXM1 potential role in breast cancer endocrine resistance. 
3.2 Results 
 
3.2.1 Transcriptional regulation of FOXM1 by ERα in 
endocrine sensitive breast cancer cells 
 
3.2.1.1 ERα ligands and ERα silencing modulate FOXM1 
expression 
 
To investigate whether FOXM1 is a target of ERα, the ERα positive MCF-7 
breast cancer cell line and ERα negative MDA-MB-231 breast cancer cell line were 
treated with ERα ligands: estradiol (E2), tamoxifen (OHT) and fulvestrant (ICI). The 
efficacy of these treatments was verified by pS2 protein expression,  a previously 
described oestrogen responsive gene (Soulez and Parker 2001). As expected, pS2 
protein expression increased with the addition of E2 and decreased upon both anti-
oestrogens OHT and ICI in MCF-7 cells (Fig. 3.1A). I further observed that E2 
enhanced FOXM1 protein and mRNA expression within 24 h and remained high until 
48 h in the ERα positive MCF-7 cells. By contrast, E2 did not change FOXM1 protein 
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and mRNA levels in the ERα negative MDA-MB-231 cells (Fig. 3.1B). The treatments 
with OHT and ICI reduced the expression of FOXM1 protein and mRNA in MCF-7 
cells 24 h and 48 h after treatment, while FOXM1 expression was not affected by 
these treatments in MDA-MB-231 cells (Fig. 3.1B). Notably, E2 treatment decreased 
ERα protein expression in the ERα positive MCF-7 cells. Indeed, it has been reported 
that E2 increases ERα turnover (Nawaz, Lonard et al. 1999, Wijayaratne and 
McDonnell 2001). Moreover, ICI caused ERα degradation in the ERα positive MCF-7 
cells (Long and Nephew 2006). These data have been confirmed in the ERα positive 
ZR-75-1 breast cancer cell line in our laboratory (data not shown; provided by 
Demetra Constantinidou). 
 
In addition, the ability of OHT and ICI to antagonize E2-regulated FOXM1 
upregulation was examined Figure 3.2. Therefore MCF-7 cells were stimulated by E2 
for 4 h and then treated with OHT or ICI from 0 h to 48 h. The result showed that the 
effects of OHT and ICI following E2 stimulation were similar to those observed under 
normal growth conditions (Fig. 3.2). The ERα targets, pS2 and cyclin D1, and 
FOXM1 targets, PLK and CDC25B, were induced by E2 and repressed by the 
addition of OHT and ICI. Notably, FOXM1 expression pattern varied between Figures 
3.1 and 3.2. Studies showed that if starvation is not perfect, some leakage might 
have occurred and cells slowly accumulate material leading to S phase initiation even 
during the period of incubation in low serum. Cells closer to initiation (later in S 
phase) can reach initiation mass sooner than cells earlier in the G1 phase. Cells later 
in the G1 phase at the time growth arrest are less likely to have a delayed cell 
division. Cells earlier in the cycle will not accrue enough leakage to initiate DNA 
synthesis and thus will exhibit a delayed cell division. FOXM1 expression pattern 
varies throughout the cell cycle. Therefore, it is possible that starvation was not 
reached Figure 3.2 leading to cells in different cell cycle phases with different FOXM1 
protein expression levels (Cooper 2003, Cooper 2003).  
 
In conclusion, the expression of FOXM1 protein and mRNA is upregulated by 
the ERα agonist and downregulated by ERα antagonists only in the ERα positive 
MCF-7 cells suggesting that ERα regulates FOXM1 expression. To provide further 
evidence of FOXM1 regulation by ERα, the effect of ERα silencing on FOXM1 protein 
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and mRNA levels was studied in MCF-7 cells. After 24 h transfection, ERα siRNA 
effectively silenced ERα at protein level and mRNA levels, and reduced the levels of 
FOXM1 protein and mRNA significantly (Fig. 3.3). In accordance with previous 
findings in the laboratory, FOXM1 siRNA also reduced ERα protein and mRNA levels 
(Madureira, Varshochi et al. 2006). Unfortunately, the quality of the western blot for 
this experiment is very poor and should be repeated. 
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Figure 3.1 Expression of FOXM1 and ERα in response to E2, tamoxifen and ICI 
treatments in breast cancer cell lines. MCF-7 (A) and MDA-MB-231 (B) cells were cultured 
in 5 % double-charcoal striped FCS and phenol red free medium for 24 h before being 
stimulated with 10-8 mol/L of E2. Breast cancer cells cultured in 10 % FCS and phenol red 
medium were also treated with 10-6 mol/L of OHT or 10-7 mol/L of ICI. At times indicated, cells 
were collected and analysed for FOXM1, ERα, pS2 and ß-tubulin expression by western 
blotting. FOXM1 mRNA levels of these cells were also analysed by RT-qPCR, and 
normalized with L19 RNA expression. All data shown represent the averages of data from 
three independent experiments, and the error bars show the standard deviations.  
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Figure 3.2 Induction of FOXM1 expression by E2 is antagonized by OHT and ICI in 
MCF-7 cells. MCF-7 cells were cultured in 5 % double-charcoal striped FCS and phenol red 
free medium for 24 h before stimulation with 10-8 mol/L of E2 (-4h). Four hours after E2 
stimulation, the MCF-7 cells were treated with 10-6 mol/L of OHT or 10-7 mol/L of ICI for the 
indicated times. Cells were collected and analysed for FOXM1, ERα, PLK, CDC25b, CYCLIN 
D1 and ß-tubulin protein expression using western blotting.  
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Figure 3.3 Effects of ERα silencing on the expression of FOXM1. MCF-7 cells were 
transiently transfected with ERα, FOXM1 or NS (non-specific) siRNA (100 nmol/L) with 
oligofectAMINE according to the manufacturer instructions. After 24 h transfection, cells were 
analysed for protein levels by western blot (A.) using specific antibodies as indicated and for 
mRNA levels of FOXM1 (B.) and ERα (C.) by RT-qPCR. All data shown represent the 
averages of three independent experiments, and the error bars show the standard 
deviations. Statistical analyses were done using Student’s t test. *, P≤0.1, **, P≤0.01 and ***, 
P≤0.001, significant and n.s, non significant.  
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3.2.1.2 FOXM1 promoter responds to ERα ligands 
 
The RT-qPCR data obtained in Figure 3.3 showed that FOXM1 is 
transcriptionally regulated by ERα. In order to elucidate whether FOXM1 is regulated 
at promoter level by ERα, Demetra Constantinidou and myself transiently co-
transfected an ERα expression vector with three different FOXM1 promoter 
constructs in a luciferase reporter vector (Fig. 3.4A), previously made by Demetra 
Constantinidou in our laboratory, in COS-1 cells. We observed a 2-fold increase of 
luciferase activity of the 2 kb full length FOXM1 (pGL3-Full-length) and 1.5-fold 
increase of the luciferase activity of the 1.3 kb Hind III truncation constructs (pGL3-
Hind III) 24 h after E2 treatment (Fig. 3.4B). The highest luciferase activity was 
obtained with the 300 pb Apa I truncation construct (pGL3-Apa I) that showed an 
enhancement of 2.5-fold upon 4 h E2 treatment, consistent with a previous study 
identifying a similar region of the FOXM1 promoter that responds to serum 
stimulation (Korver, Roose et al. 1997). As positive control, we performed this 
experiment with the pS2 promoter (pGL3-ERE) under the luciferase reporter gene 
and observed an increase of 5-fold of the luciferase activity following E2 treatment. 
The addition of OHT for 24 h following E2 treatment resulted in a repression of all 
luciferase reporter gene activities previously induced by E2 (Fig. 3.4B). 
 
These reporter assays were performed with the help of Demetra 
Constantinidou, who examined the proximal FOXM1 promoter sequence and 
identified potential ERα-responsive elements (EREs) by using the Transcription 
Element Search System (TESS website). These analyses revealed an ERE-like 
element located at -45 pb from the transcription start site that could explain the 
responsiveness to ERα ligands of the three FOXM1 promoters constructs used. 
Consequently, studies were focused on the characterization of the ERE-like element 
at -45 pb in the Apa I promoter fragment. By introducing mutations in both arms of 
the ERE-like palindrome of the Apa I truncation (Bourdeau, Deschenes et al. 2004) 
(Fig. S.D.7.1), Demetra Constantinidou observed by luciferase assay that the ERE3 
mutant (mERE3) lost the majority of the responsiveness to E2 (Fig. S.D.7.2).  
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Figure 3.4 ERα induces the transcriptional activity of the human minimal FOXM1 
construction gene. Effect treatment with E2 alone or in combination with OHT and transient 
expression of ERα on FOXM1 promoter activity. A. Schematic representation of the 2.4 kb 
full length, 1.4 kb Hind III and 0.3 kb Apa I FOXM1-luciferase reporter constructs previously 
made in the laboratory. B. COS-1 cells were cultured in 5 % double-charcoal striped FCS 
and phenol red free medium were transiently transfected with 20 ng of either the empty 
pGL3-basic, or FOXM1 truncations: pGL3-Full length, pGL3-Hind III, pGL3-ApaI, or the 
control pGL3-ERE (pS2) promoter and 0 ng or 10 ng of ERα expression vector in the 
presence or absence of 10-8 mol/L of E2 alone for 4 h or 10-8 mol/L of E2 for 4 h followed by 
10-6 mol/L of OHT for 24 h. Cells were treated 24 h after transfection and harvested for 
luciferase assay. All relative luciferase activity values were corrected by co-transfected 
Renilla activity. All data shown represent the averages of data from three independent 
experiments, and the error bars show the standard deviations.  
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3.2.1.3 ERα and HDAC2 bind on the ERE-like site of FOXM1 
promoter in vitro 
 
To investigate whether ERα binds to the previously characterized ERE-like site 
in vitro, a pull-down assay with biotin-labeled oligonucleotides was performed using 
ERα positive MCF-7 and ZR-75-1 breast cancer cell lines. Streptavidin agarose 
beads were used to bind the wild-type oestrogen response element biotin-
oligonucleotide (WT ERE-biotin) after incubation with nuclear protein extracts of 
breast cancer cells. Furthermore, a competition of the binding of the nuclear extract 
to the WT ERE biotin-oligonucleotide by addition of an excess of either wild-type (WT 
ERE-nonbiotin) or mutated (mut ERE3-nonbiotin) unlabelled-oligonucleotides was 
performed (Fig. 3.5). The binding of ERα to biotinylated oligonucleotides was 
analyzed by western blot and immunoblotted with an anti-ERα antibody. In Figure 
3.5, I observed that ERα binding was completely abolished by the addition of 
unlabelled WT ERE oligonucleotide (WT ERE-nonbiotin, lane 2), while it was only 
slightly decreased with unlabeled mERE3 oligonucleotides (mERE3-nonbiotin, lane 
3) under control vehicle condition in MCF-7 cells and ZR-75-1 cells. This result 
indicates that the WT ERE unlabeled-oligonucleotide has a higher affinity for ERα 
binding than mERE3. Moreover the effect of OHT, ICI and E2 on ERα binding on 
ERE sequence was verified in MCF-7 and ZR-75-1 cells (Fig. 3.5). The results show 
that ERα binding decreased in both cell lines upon ICI treatment (lane 12), whereas 
ERα binding seemed to be steady following OHT (lane 6) and E2 (lane 18) 
treatments. In agreement with previous studies and Figure 3.1, ICI decreased ERα 
protein level, while OHT stabilized it.  
 
Collectively, these results demonstrated that ERα binds specifically to the ERE-
like element found on FOXM1 promoter in vitro under E2 and OHT treatments. 
However, these data did not explain the differential mechanism of FOXM1 regulation 
by ERα upon OHT and E2, since ERα binds to the WT ERE sequence in both OHT 
and E2 conditions. To address this point, pull-down assays were performed in MCF-7 
cells and immunoblotted with HDAC2 antibody, a histone deacetylase specifically 
overexpressed in breast cancer cells (Fig. 3.5). Interestingly, HDAC2 binds only to 
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the WT ERE biotin-oligonucleotides (WT ERE-biotin, lane 4 and 6) upon OHT but not 
under E2 (lane 16 and18) conditions. This result suggests that OHT treatment 
induces ERα co-repressors binding including HDAC2 to repress FOXM1 expression.  
Surprisingly, HDAC2 was detected upon ICI treatment on the WT ERE biotin-
oligonucleotides (WT ERE-biotin, lane 10). This result raised two issues for this 
experiment: the lack of a control input and the lack of protein extract quantification 
after incubation with the streptavidin-beads. These controls could add a quantitative 
value to the experiment and determine whether HDAC2 binds ERE under ICI 
treatment.  
 
 
 
 
Figure 3.5 ERα binds directly to the ERE-like site on FOXM1 promoter in vitro.  MCF-7 
and ZR-75-1 cells were cultured in 5 % double-charcoal striped FCS and phenol red free 
medium for 24 h before being stimulated with 10-8 mol/L of E2 for 24 h. Cells cultured in 10 % 
FCS and phenol red medium were treated with 10-6 mol/L of OHT, 10-7 mol/L of ICI or control 
vehicle (control) for 24 h. Nuclear extracts from MCF-7 and ZR-75-1 cells were incubated 
with biotin-oligonucleotides representing region of the FOXM1 promoter containing the wild 
type ERE (WT ERE-biotin) in the absence or presence of molar excess of non-biotinylated 
ERE3 (mut ERE3-nonbiotin) or wild type ERE (WT ERE-nonbiotin) oligonucleotides. Proteins 
binding to the biotinylated oligonucleotides were pulled-down using streptavidine agarose 
beads and analysed by western blot using ERα antibody for ZR-75-1 cells, and with ERα and 
HDAC2 antibodies for MCF-7 cells. Nuclear extracts from MCF-7 cells were incubated with 
biotin-oligonucleotides representing region of the FOXM1 promoter containing the  wild type 
ERE or the mutated ERE3 site in the absence or presence of molar excess of non-
biotinylated ERE3 or wild type ERE oligonucleotides. Proteins binding to the biotinylated 
oligonucleotides were pulled-down using streptavidine agarose beads and analysed by 
western blot using HDAC2 antibody.  
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3.2.1.4 ERα binds specifically to FOXM1 promoter in vivo 
 
I further studied the in vivo binding of ERα on FOXM1 promoter in the MCF-7 
and ZR-75-1 cell lines after OHT or ICI treatments using a semi-quantitative 
chromatin immunoprecipitation (Fig. 3.6A). The ERα-bound DNA was amplified with 
the FOXM1 ERE site primers. In agreement with the pull-down studies, ERα 
occupied FOXM1 promoter in control vehicle conditions and its occupancy decreased 
clearly after ICI treatment and was not affected by OHT treatment. For negative 
controls, samples were IP with non-specific IgG antibodies and PCR was performed 
on a region where ERα is absent.  Semi-quantitative ChIP assays also showed an 
increase in the recruitment of HDAC1 and HDAC2 upon OHT treatment. Consistent 
with this finding, I showed a decrease of acetylated H3 and H4 on FOXM1 promoter, 
indicating that OHT treatment caused the recruitment of HDACs that confer 
transcriptional repression to the ERE region of FOXM1 promoter (Fig. 3.6B). 
Histones H3 and H4 are ubiquitously expressed and enriched on actively transcribed 
region. Therefore, this experiment should be repeated with appropriate negative 
controls including histone deacetylases such as HDACs or SIRTs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
 
 
 
 
Figure 3.6 Chromatin immunoprecipitation (ChIP) analysis of the human FOXM1 
promoter. A. MCF-7 and ZR-75-1 cells untreated or treated with 10-6 mol/L of OHT or 10-7 
mol/L of ICI for 24 h were used for ChIP assays using anti-IgG control, anti-ERα antibodies 
as indicated. B. MCF-7 untreated or treated with 10-6 mol/L of OHT for 24 h were used for 
ChIP assays using anti-IgG control and antibodies against acetylated H3 and H4, HDAC1 
and HDAC2 as described above. After crosslink reversal, the co-immunoprecipitated DNA 
was amplified by PCR using primers amplifying the FOXM1 ERE containing region (−184/+4) 
and a control region (−1157/−1257), and resolved on 2 % agarose gel. Representative data 
from three independent experiments are shown. 
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3.2.1.5 FOXM1 silencing is cytotoxic for MCF-7 cells 
independent of the E2 mitogenic effect 
 
Since the previous results showed FOXM1 as an ERα-responsive gene, I 
investigated the effects of FOXM1 knockdown on the survival of MCF-7 cells. 
Western blot analysis Figure 3.7A showed that FOXM1 was efficiently silenced by 
specific siRNA and that ERα expression was also decreased by FOXM1 siRNA. This 
is in line with previous findings in our laboratory that FOXM1 regulates ERα 
expression (Madureira, Varshochi et al. 2006). MCF-7 cells were oestrogen-starved 
for 48 h and then stimulated with E2 in the presence or absence of FOXM1 siRNA 
(Fig. 3.7). Notably, E2 treatment decreased ERα protein expression as already 
observed in Figure 3.1. The results of SRB assay showed that FOXM1 silencing 
induced the number of cells in the ERα positive MCF-7 cells following E2 or control 
vehicle (Fig. 3.7B). Taken together, the results indicate that FOXM1 has a role in the 
survival of ERα positive MCF-7 cells independent of E2. It would also be a good 
control to repeat this experiment with siRNA against ERα and FOXM1 combined to 
confirm that FOXM1 overcome the role of ERα in cell proliferation of MCF-7 cells. 
The effect of FOXM1 silencing on MCF-7 cell proliferation should be studied using 
different methods: vital staining or measure of DNA synthesis. Trypan blue selectively 
colour dead cells in blue, while the quantification of 3H-thymidine or 
bromodeoxyuridine incorporated into newly synthetized DNA indicate proliferation. 
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Figure 3.7 Effects of FOXM1 silencing on E2-induced proliferation of MCF-7 cells. 
MCF-7 cells were transiently transfected with non-specific (NS) and specific siRNA against 
FOXM1 (FOXM1) (100nmol/L) using oligofectAMINE according to the manufacturer 
instructions and, starved for 48 h and incubated with 10-8 mol/L of E2 for 24 h and analysed 
by western blotting with anti-FOXM1, ERα, β-tubulin (A.). Treatment with 10-8 mol/L of E2 for 
0, 24, 48 h was performed before cells were harvested for SRB assays (B.). Representative 
data from three independent experiments are shown. 
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3.2.2 Deregulation of FOXM1 in tamoxifen resistant breast 
cancer cells 
3.2.2.1 Deregulation of FOXM1 protein and mRNA 
expression in tamoxifen resistant cells 
 
Since the majority of the patients who develop resistance to hormonal therapy 
are ERα positive, a dysfunction of ERα could result in FOXM1 deregulation and 
endocrine resistance in breast cancer cells. To address this question, I studied 
FOXM1 expression in tamoxifen sensitive MCF-7 cells (MCF-7) and tamoxifen 
resistant MCF-7 cells (MCF-7TAMR4) after treatment with OHT. Consistent with 
Figure 3.1, OHT treatment caused a drastic reduction in FOXM1 protein and mRNA 
levels after 24 h until 72 h in MCF-7 cells, whereas no significant decrease was 
observed in MCF-7TAMR4 cells (Fig. 3.8A). Similar to FOXM1 expression pattern, 
FOXM1 target genes such as PLK, CDC25B, cyclin A and ERα showed a decrease 
in their protein expression in MCF-7 cells, but did not change in MCF-7TAMR4 cells, 
consistent with FOXM1 expression levels (Fig. 3.8A). 
Additionally, to elucidate whether FOXM1 is involved in tamoxifen resistance, 
our group developed a stable MCF-7 cell line overexpressing a constitutive active 
form of FOXM1, the N-terminal deleted FOXM1 form (ΔN-FOXM1) which was 
previously described (Park, Wang et al. 2008). The protein and mRNA expression of 
FOXM1 under a constitutively active promoter (CMV) in MCF-7 cells led to a high and 
constant FOXM1 and ΔN-FOXM1 protein expression, and constant FOXM1 mRNA 
expression even following 72 h OHT treatment (Fig. 3.8B). As in MCF-7TAMR4 cells, 
FOXM1 targets protein expressions are consistent with FOXM1 expression pattern 
and remained unchanged. Moreover, to confirm whether FOXM1 has a pivotal role in 
tamoxifen resistance, different clones of MCF-7 cells (Pool of all clones, Clone 1, 
Clone 3, Clone 4) stably transfected with the full length wild-type FOXM1 (MCF-7-
FOXM1) previously generated in the laboratory were used (Fig. 3.8C). Western blot 
analysis showed that the transfection of the full length FOXM1 abolished the 
downregulation of FOXM1 in clones 2 and 3, while FOXM1 was decreased in clone 1 
and pool following OHT. This suggests that FOXM1 might be regulated at post-
transcriptional levels by tamoxifen as FOXM1 expression is driven by CMV promoter 
in this experiment. Taken together, the full length FOXM1 overexpression partially 
100 
 
prevented the downregulation of FOXM1 targets including ERα, CDC25b, PLK and 
CYCLIN B1 in response to tamoxifen treatment (Fig. 3.8C).  
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Figure 3.8 Full length and partial FOXM1 overexpression reduced the downregulation 
of FOXM1 and its target genes following tamoxifen treatment. MCF-7, MCF-7TAMR4 and 
MCF-7 ∆N-FOXM1 cells were treated with 10-6 mol/L of OHT in a time course of 72 h. A. Cell 
lysates were prepared at the times indicated, and the expression of FOXM1, ERα, CDC25B, 
PLK, and β-tubulin were analysed by Western blotting. B. Cells were harvested and FOXM1 
mRNA levels were analysed by RT-qPCR, normalised with L19 housekeeping gene. C. Wild-
type MCF-7 and overexpressing-FOXM1 MCF-7 (pool of clones, clone 1, 2 and 3) cell 
lysates were prepared at the times indicated, and the expression of FOXM1, ERα, PLK, 
CDC25B, CYCLIN B1, CYCLIN D1 and β-tubulin were analyzed by Western blotting.  
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3.2.2.2 Reduced G1 cell cycle arrest in tamoxifen resistant 
cells after OHT 
 
I performed cell cycle analysis of the MCF-7, MCF-7TAMR4 and ΔN-FOXM1 
MCF-7 cells following treatment with OHT (Fig. 3.9A). The results showed that OHT 
caused predominantly a G1 cell cycle arrest in the parental MCF-7 cells, but had 
comparatively lower effects on the cell cycle distribution of the MCF-7TAMR4 and ΔN-
FOXM1 MCF-7 cells (Fig. 3.9B). The calculation of the percentage of increase 
relative to 0h in cells in G1 phase showed that OHT caused a G1 cell cycle arrest in 
MCF-7TAMR4  at a lower extend than in the wild-type MCF-7 cells, whereas OHT did 
not increase the number of cells in G1 phase in ΔN-FOXM1 MCF-7 cells (Fig.3.9B).  
The cell cycle profile of the MCF-7 cells stably transfected with the wild-type 
FOXM1 (MCF-7-FOXM1) demonstrated that these cells underwent a cell cycle arrest 
at G1, concomitant with FOXM1 downregulation, but at a lower extend compared 
with MCF-7 cells transfected with the empty vector (Fig. 3.10). Similar to the western 
blot, pool and clone 1 MCF-7 cells did not show a strong difference in the number of 
cells in G1 phase compared with the wild-type MCF-7 cells, while clones 2 and 3 
showed a lower increase in cells in G1 phase after 72h treatment. Collectively, these 
results indicate that FOXM1 has a role in mediating the G1 cell cycle arrest OHT-
induced, and that its overexpression reverses MCF-7 sensitivity to G1 cell cycle 
arrest OHT-induced. Furthermore it would be interesting to overexpress a 
transcriptionally dead FOXM1 to demonstrate that FOXM1 activity is required for the 
inhibition of the G1 cell cycle arrest OHT-induced. At this point, it would also have 
been interesting to compare the proliferation of MCF-7, MCF-7TAMR4 and ΔN-
FOXM1 MCF-7 cells following OHT. 
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Figure 3.9 Cell cycle regulation in wild-type (MCF-7), tamoxifen resistant (MCF-7TAMR4) 
and constitutively active ∆N-FOXM1 expressing MCF-7 cells in response to tamoxifen 
treatment. MCF-7, MCF-7 TAMR4 and MCF-7 ∆N-FOXM1 cells were treated with 10-6 mol/L 
of OHT in a time course of 72 h. A. Cell cycle phase distribution was analyzed by flow 
cytometry after propidium iodide staining. Percentage of cells in each phase of the cell cycle 
(sub-G1, G1, S, and G2/M) is indicated. Representative data from three independent 
experiments are shown. B. Percentage increase in cells in G1 phase relative to 0h. Statistical 
analyses were done using Student’s t test. *, P≤0.1, **, P≤0.01 and ***, P≤0.001, significant 
and n.s, non significant.  
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Figure 3.10 FOXM1 upregulation rescues OHT-induced cell growth arrest and decrease 
of endogenous FOXM1 in response to tamoxifen treatment. A. Wild-type MCF-7 and 
overexpressing-FOXM1 MCF-7 cells (pool of clones, clone1, 2 and 3) were fixed at 0, 24, 48, 
and 72 h after OHT treatment, and cell cycle phase distribution was analysed by flow 
cytometry after propidium iodide staining. Percentage of cells in each phase of the cell cycle 
(sub-G1, G1, S, and G2/M) is indicated. B. Percentage increase in cells in G1 phase relative 
to 0h. Statistical analyses were done using Student’s t test. *, P≤0.1, **, P≤0.01 and ***, 
P≤0.001, significant and n.s, non significant.  
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3.2.2.3 Combination of OHT and FOXM1 silencing has a 
cytostatic effect on MCF-7 tamoxifen resistant cells  
 
Previous results showed that the constitutively active form of FOXM1 and the 
full length FOXM1 reduced the G1 cell cycle arrest induced by OHT. I next tested 
whether FOXM1 silencing would affect the survival of tamoxifen resistant cells to 
OHT treatment. The downregulation of FOXM1 by specific siRNA was verified by 
western blot (Fig. 3.11A). In the non-specific siRNA condition, the expression of 
FOXM1 was enhanced during the time course due to the fact that FOXM1 is a 
proliferative factor (Fig. 3.11A). Oppositely, FOXM1 protein expression remained low 
until 72 h in cells transfected with specific FOXM1 siRNA (Fig. 3.11A). Interestingly, 
western blot analysis also showed a downregulation of ERα protein expression upon 
FOXM1 silencing indicating that ERα is still under FOXM1 regulation in these cells. 
Additionally, I performed the SRB assay and observed that FOXM1 silencing 
decreased the survival of tamoxifen resistant cells (Fig. 3.11B). The combination of 
FOXM1 siRNA and OHT treatment had a cytostatic effect on these cells after OHT 
treatment (Fig. 3.11B). A recent publication showed that Thiostrepton directly 
interacts with FOXM1 protein to reduce FOXM1 transcriptional activity (Hegde, 
Sanders et al. 2011). It would be interesting to compare the effect of FOXM1 
silencing to this inhibitor on the tamoxifen resistant cell proliferation and survival.  
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Figure 3.11 FOXM1 silencing rescues tamoxifen anti-growth effect in MCF-7TAMR4 
cells. MCF-7TAMR4 cells were transiently transfected with non-specific  or FOXM1 siRNA for 
24 h (100nmol/L) using oligofectAMINE according to the manufacturer instructions, and were 
harvested at different time after transfection and analysed by western blot using FOXM1, 
ERα and β-tubulin antibodies (A.) and harvested for SRB assays (B.). Statistical analyses 
were done using Student’s t test. *, P≤0.1, **, P≤0.01 and ***, P≤0.001, significant and n.s, 
non significant.  
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3.2.3 Potential mechanisms of tamoxifen resistance 
3.2.3.1 FOXM1 phosphorylation and transcriptional 
activation  
 
Western blot analysis Figure 3.12 showed that CYCLIN A, but not its catalytic 
partner CDK2, was downregulated after 24 h OHT treatment in MCF-7 cells and this 
decline in CYCLIN A level occurred in a slower kinetic in MCF-7TAMR4 and ΔN-
FOXM1 cells. Consistent with this, the CDK2 activity revealed by the phosphorylation 
of pRB on Threonine 821 decreased drastically in MCF-7 cells compared with MCF-
7TAMR4 and ΔN-FOXM1 cells.  Given that the complex CYCLIN A/CDK2 
phosphorylates FOXM1 and can activate its transcriptional activity (Wierstra and 
Alves 2006, Laoukili, Alvarez et al. 2008, Laoukili, Alvarez-Fernandez et al. 2008, 
Park, Wang et al. 2008), this finding suggests a potential mechanism by which 
FOXM1 can cause tamoxifen resistance in MCF-7TAMR4 and ΔN-FOXM1 cells.  
 
Western blot analysis also showed that the level of CYCLIN D1 and its 
associated activity revealed by the CDK4 phospho-pRb (Ser807/811) antibody were 
overexpressed in the ΔN-FOXM1 cells and maintained in the MCF-7TAMR4 cells. In 
addition, the stable MCF-7-FOXM1 cell line also showed an increase in the 
expression levels of CYCLIN D1, particularly in clones 2 and 3 (Figure 3.8). Given 
that the complex CYCLIN D1/CDK4 phosphorylates FOXM1 in multiple sites and can 
activate its transcriptional activity (Anders, Ke et al. 2011), this finding suggests 
another potential mechanism by which FOXM1 can cause tamoxifen resistance in 
MCF-7TAMR4 and ΔN-FOXM1 cells.  
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Figure 3.12 Constitutively active ∆N-FOXM1 expressing MCF-7 cells show the same 
protein expression pattern as MCF-7TAMR4 cells in response to tamoxifen treatment. 
MCF-7, MCF-7TAMR4 and MCF-7 ∆N-FOXM1 cells were treated with 10-6 mol/L of OHT in a 
time course of 72 h. Cell lysates were prepared at the times indicated, and the expression of 
CYCLIN A, CDK2, CYCLIN D1, CDK4, P-pRB(cdk2), P-pRB(cdk4), total pRB and β-tubulin 
were analysed by Western blotting.  
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3.2.3.2 ERα overexpression and silencing do not alter 
FOXM1 expression in tamoxifen resistant cells 
 
Western blot analysis showed that ERα overexpression in MDA-MB-231 ERα-
negative cells had no effect on FOXM1 protein expression (Fig. 3.13), while ERα-
agonist increased FOXM1 protein expression in MCF-7 ERα positive cells (Fig. 3.1). 
Similarly, ERα silencing did not affect FOXM1 protein expression in MCF-7 tamoxifen 
resistant cells, while ERα silencing decreased FOXM1 protein level in MCF-7 cells 
(Fig. 3.3). These data suggest that FOXM1 regulation is controlled by other mitogenic 
factors in ERα-negative and tamoxifen resistant cells. 
 
 
 
 
 
 
 
Figure 3.13 ERα ectopic expression and silencing in the tamoxifen resistant ERα-
negative MDA-MB-231 and ERα-positive MCF-7TAMR4 breast cancer cells. MDA-MB-231 
cells were transfected with increasing amounts of ERα. MCF-7TAMR4 cells were transiently 
transfected with non-specific siRNA and siRNA targeting ERα for 24 h (100nmol/L). The 
expression of FOXM1, ERα, CYCLIN D1, pS2 and β-tubulin was analysed by western 
blotting. 
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3.2.3.3 Protein deregulations in tamoxifen resistant cells 
 
ERα is inhibited by the binding of tamoxifen which induces the recruitment of 
co-repressors, preventing ERα conformational changes and transcriptional activity. 
Semi-quantitative ChIP assays Figure 3.6B showed that tamoxifen treatment of MCF-
7 cells induced the recruitment of HDACs (ERα co-repressor) decreasing the 
acetylation levels of histones 3 and 4 as observed for two ERα target genes, pS2 and 
C-MYC (Masiakowski, Breathnach et al. 1982, Carroll, Meyer et al. 2006). Thereby, it 
is possible that recruitment of ERα co-repressors and co-activators is deregulated in 
tamoxifen resistant cells leading to tamoxifen insensitivity. Protein analysis of AIB1 
(co-activator) showed a high expression level in tamoxifen resistant MCF-7 cells even 
following tamoxifen, while AIB1 expression level decreased in MCF-7 cells treated 
(Figure 3.14). 
 
 A recent study showed C-MYB as an ERα target gene and determined the role 
of C-MYB in the proliferation of ERα-positive breast cancer cells, but not in ERα-
negative cells (Drabsch, Hugo et al. 2007). While the role of C-MYB has been well 
studied in cell growth and transformation, little is known about B-MYB family member. 
Although a direct role of B-MYB in cancer has not been yet established, B-MYB is 
found amplified in breast, liver, ovarian carcinomas and cutaneous T-cells 
lymphomas (Forozan, Mahlamäki et al. 2000, Tanner, Grenman et al. 2000, 
Zondervan, Wink et al. 2000, Mao, Orchard et al. 2003). B-MYB expression is 
upregulated in metastasis compared to localised prostate tumours and its 
overexpression is associated with poor prognosis in breast cancer patients 
(Amatschek, Koenig et al. 2004). As FOXM1, B-MYB is a cell cycle-regulatory gene. 
Its expression is induced at G0/S and reached a maximum level in S phase (Lam, 
Bennett et al. 1995). A study showed that MYB mRNA and protein levels were not 
affected by FOXM1 silencing, whereas FOXM1 mRNA and protein levels were both 
reduced in a time-dependent manner after MYB silencing. These results suggest that 
MYB is a transcriptional activator of FOXM1 (Lefebvre, Rajbhandari et al. 2010). 
Therefore, altered B-MYB expression in breast cancer may affect FOXM1 expression 
and be involved in tamoxifen resistance. Preliminary data on tamoxifen resistant 
breast cancer cells confirmed that B-MYB is deregulated compared to wild-type MCF-
7 cells (Fig.3.14).  
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Figure 3.14 AIB-1 and B-myb expression pattern in tamoxifen sensitive and resistant 
MCF-7 cells. Both cell lines were treated with OHT over 72 h. The expression of AIB-1, B-
MYB and β-tubulin were analysed by western blotting. 
 
 
 
 
 
 
 
In addition to ERα, ERβ is an oestrogen receptor encoded by a distinct gene 
than oestrogen receptor alpha, but both bind with equal affinity oestrogens. ERα 
promotes the proliferation of breast epithelium and cancer cells, while ERβ has anti-
proliferative and pro-apoptotic effects. A recent study in our laboratory has shown 
FOXM1 has a target of ERβ1, but only in ERα positive breast cancer cells. MCF-7 
cells collected 24 hours after transfection with pcDNA3 as a control or pcDNA3-Flag-
ERβ1 were subjected to semi-quantitative ChIP analysis with the use of an ERα 
antibody and an anti-Flag antibody, which recognized the transfected Flag-tagged 
ERβ1. The ChIP assays showed that there was an increase in ERβ1 recruitment to 
the ERE region on FOXM1 promoter when ERβ1 is transfected. Concomitantly, 
occupancy of ERE region by ERα was drastically reduced in MCF-7 cells with ERβ1 
ectopic expression, indicating that ERβ1 expression caused the disassociation of 
ERα from ERE region of the FOXM1 promoter (Fig. 3.15). Given that ERβ1 is 
repressing FOXM1, it is possible that ERβ1 is downregulated in tamoxifen resistant 
cells leading to constant cell proliferation and tamoxifen resistance.  
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Figure 3.15 Chromatin immunoprecipitation of ERβ and ERα in MCF-7 cells. MCF-7 
cells were transfected with ERβ and harvested for ChIP assays using anti-IgG, anti-Flag 
(recognized transfected ERβ) and anti-ERα antibodies as indicated. After crosslink reversal, 
the co-immunoprecipitated DNA was amplified by PCR using primers amplifying the FOXM1 
ERE containing region (−184/+4) and resolved in 2% agarose gel.  
 
 
3.3 Discussion  
 
3.3.1 Regulation of ER and FOXM1 through a positive 
feedback loop in breast cancer cells 
 
 Colleagues in the laboratory previously studied FOXM1 mRNA expression and 
its relationship to ERα mRNA level in breast cancer biopsy samples (Millour, 
Constantinidou et al. 2010). After exclusion of the data with high levels of FOXM1 
expression (upper 25th percentile), a statistically significant correlation between ERα 
and FOXM1 mRNA expression was found. This is in agreement with a recent breast 
cancer patient microarray dataset analysis indicating that high levels of FOXM1 
mRNA expression (upper 25th percentile) are associated with poor prognosis in 
breast cancer (Martin, Patrick et al. 2008). The discordance between ERα and 
FOXM1 mRNA expression in patient samples with high FOXM1 expression probably 
indicates that in these subjects FOXM1 expression is deregulated, with the control of 
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FOXM1 transcription by ERα overridden by other mitogenic signals or genetic 
changes.  
 
A previous study in our laboratory also showed that the expression of ERα is 
regulated by FOXM1 in breast cancer cell lines (Madureira, Varshochi et al. 2006). In 
this report, I investigated the reciprocal regulation of FOXM1 expression by ERα. 
Using breast carcinoma cell lines, I showed that FOXM1 protein and mRNA 
expression are regulated by ER-ligands, including E2, OHT, and ICI (Fig. 3.1A). In 
addition, I also found that depletion of ERα by RNA interference in MCF-7 cells leads 
to the downregulation of FOXM1 expression (Fig. 3.3). Reporter gene assays 
demonstrated that ERα activates FOXM1 transcription through an ERE located at -45 
bp upstream of the transcriptional start site (Fig. 3.4) (Bourdeau, Deschenes et al. 
2004). The direct binding of ERα to the FOXM1 promoter was confirmed in vitro by 
DNA pull-down assays, and in vivo by semi-quantitative ChIP analysis (Fig. 3.5 and 
3.6). Silencing of FOXM1 by RNA interference had a cytostatic effect on tamoxifen 
resistant cells (Fig. 3.11). Conversely, ectopic expression of a constitutive active 
FOXM1 form can abrogate the G1 cell cycle arrest mediated by OHT (Fig. 3.9).  
3.3.2 Uncoupled ER and FOXM1 feedback loop regulation 
in tamoxifen resistant breast cancer cells 
 
The findings that tamoxifen represses FOXM1 expression in endocrine sensitive 
but not in resistant breast carcinoma cell lines, and that FOXM1 overexpression can 
abrogate G1 cell cycle arrest induced by tamoxifen, further suggested that 
deregulation of FOXM1 may contribute to anti-oestrogen insensitivity. FOXM1 mRNA 
levels are higher in tamoxifen resistant MCF-7 cells relative to wild-type MCF-7 cells, 
suggesting that the main mechanism of FOXM1 regulation is transcriptional in these 
cells (Fig. 3.8B). Moreover, the constitutive active FOXM1 form overexpressing cells, 
where FOXM1 is under CMV promoter, showed a decrease in FOXM1 protein 
expression following tamoxifen indicating a post-translational mechanism of 
regulation too (Fig. 3.8C). The observation that there was no significant changes in 
ERα or endogenous FOXM1 levels in the MCF-7 cells expressing the active FOXM1 
form highlighted an important positive feedback mechanism between ERα and 
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FOXM1, described here and previously (Madureira, Varshochi et al. 2006). This 
makes FOXM1 a particularly critical ERα target gene in breast cancer development 
and endocrine resistance, as the feedback loop will amplify the mitogenic action of 
oestrogens. Furthermore, it seems that this positive feedback transcriptional 
mechanism is uncoupled in ERα-negative breast cancer, as ERα overexpression did 
not induce FOXM1 expression (Fig. 3.13). In addition, the positive feedback 
transcriptional mechanism is also uncoupled in ERα-positive tamoxifen resistant 
breast cancer cells as ERα silencing did not affect FOXM1 expression while FOXM1 
silencing reduced ERα expression in tamoxifen resistant cells (Fig. 3.13). This finding 
suggests that FOXM1 is a strong transcription activator in tamoxifen resistant cells. 
 
3.3.3 Deregulated AIB1, an ERα co-factor, in tamoxifen 
resistant breast cancer cells 
 
Over the last years, it has become evident that ERα activation is not only 
dependent on the binding of ligands, but also depends on interaction between co-
factors and associated signaling pathways. Altered levels of ERα co-factors are 
observed in tamoxifen resistant patients. AIB1, an ERα co-activator, is found 
overexpressed in tamoxifen resistant breast cancer patients, and NCoR, an ERα co-
repressor, is reduced in tumours that acquired tamoxifen resistance (Lavinsky, 
Jepsen et al. 1998, Osborne, Bardou et al. 2003). AIB1 protein analysis showed high 
expression in tamoxifen resistant MCF-7 cells even following tamoxifen, while AIB1 
expression decreased in MCF-7 cells treated (Figure 3.14). Semi-quantitative ChIP 
assays demonstrated the mechanism by which tamoxifen represses FOXM1 
expression in MCF-7 cells. Tamoxifen treatment of MCF-7 cells induced the 
recruitment of HDACs decreasing the acetylation levels of histones 3 and 4 as 
observed for two ERα target genes, pS2 and C-MYC (Masiakowski, Breathnach et al. 
1982, Carroll, Meyer et al. 2006). Thereby, I speculate that recruitment of ERα co-
activators is deregulated in tamoxifen resistant cells, which might affect the regulation 
of FOXM1 by ERα. However, ERα silencing did not affect FOXM1 expression in the 
tamoxifen resistant cells, which indicates that FOXM1 regulation is controlled by 
other mitogenic factors. For instance, the cell cycle regulator CYCLIN D1 regulates 
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positively FOXM1 and its overexpression is associated with tamoxifen resistance 
(Butt, McNeil et al. 2005, Wierstra and Alves 2006).  
 
3.3.4 Deregulation of FOXM1 negative and positive 
regulators as potential mechanisms of tamoxifen 
resistance 
 
The expression pattern of CYCLIN D1 showed a strong increase in its protein 
expression in MCF-7 cells overexpressing the active form of FOXM1 compared to 
wild-type and tamoxifen resistant cells. It is known that CYCLIN D1/CDK4 
phosphorylates pRB releasing FOXM1 from pRB repression (Wierstra and Alves 
2006), but CYCLIN D1/CDK4 also phosphorylates FOXM1 in multiple sites (Anders, 
Ke et al. 2011). Therefore, it is likely that a positive feedback loop between FOXM1 
and CYCLIN D1 occurs in the FOXM1 overexpressing cells. Given the well-
documented role of cyclin D1 in endocrine resistance (Lundgren, Holm et al. 2008, 
Wang, Dean et al. 2008, Finn, Dering et al. 2009, Yamashita, Takahashi et al. 2009, 
Zwart, Rondaij et al. 2009) and G1/S transition (Fung and Poon 2005, Myatt and Lam 
2007, Tashiro, Tsuchiya et al. 2007), our data also support a role for FOXM1 in 
mediating breast cancer endocrine sensitivity and resistance at least in part through 
modulating CYCLIN D1 expression.  
 
In addition to ERα, ERβ is an oestrogen receptor encoded by a distinct gene 
than oestrogen receptor alpha, but both bind with equal affinity oestrogens. ERα 
promotes the proliferation of breast epithelium and cancer cells, while ERβ has anti-
proliferative and pro-apoptotic effects. ERβ is expressed in several variants in normal 
and malignant tissues, but Roger and colleagues reported a decrease in ERβ protein 
expression in pre-invasive mammary tumours compared to normal or benign lesions 
(Roger, Sahla et al. 2001). There is a conflicting data regarding the co-expression of 
both ERs and association with prognostic, endocrine responsiveness and survival. 
However, ERβ has been in general shown to be associated with favourable 
prognostic for endocrine therapy in breast cancer. A recent study in our laboratory 
has shown FOXM1 has a target of ERβ1, but only in ERα-positive breast cancer 
cells. Indeed, I showed by semi-quantitative ChIP that ERβ1 competes with ERα on 
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the ERE of FOXM1 promoter to repress FOXM1 transcription (Fig. 3.15). 
Consequently, ERβ1 downregulation in tamoxifen resistant cells could lead to 
inhibition of cell cycle arrest tamoxifen-induced.  
 
 
A recent study showed C-MYB as an ERα target gene and determined the role 
of C-MYB in the proliferation of ERα positive breast cancer cells, but not in ERα 
negative cells (Drabsch, Hugo et al. 2007). While the role of C-MYB has been well 
studied in cell growth and transformation, little is known about B-MYB family member. 
Although a direct role of B-MYB in cancer has not been yet established, B-MYB is 
found amplified in breast, liver, ovarian carcinomas and cutaneous T-cells 
lymphomas (Forozan, Mahlamäki et al. 2000, Tanner, Grenman et al. 2000, 
Zondervan, Wink et al. 2000, Mao, Orchard et al. 2003). B-MYB expression is 
upregulated in metastasis compared to localised prostate tumours and its 
overexpression is associated with poor prognosis in breast cancer patients 
(Amatschek, Koenig et al. 2004). As FOXM1, B-MYB is a cell cycle-regulatory gene. 
Its expression is induced at G0/S and reached a maximum level in S phase (Lam, 
Bennett et al. 1995). B-MYB activity is modulated by posttranslational modifications 
including phosphorylation during S phase by cyclin/cdk complexes (Sala, Kundu et al. 
1997). It has been shown to promote DNA replication and maintenance of genomic 
integrity by regulating the transcription of genes essential for G2/M phase 
progression (García and Frampton 2006, Tarasov, Tarasova et al. 2008). 
Furthermore, B-MYB overexpressing cells were significantly enriched in genes 
involved in G2/M progression (Thorner, Hoadley et al. 2009). Based on the 
similarities of B-MYB and FOXM1 target genes, a cross-talk between B-MYB and 
FOXM1 has been investigated. Recent evidence demonstrated that B-MYB and 
FOXM1 co-regulate one another in a positive feedback loop (Lefebvre, Rajbhandari 
et al. 2010, Lorvellec, Dumon et al. 2010). ChIP analysis revealed that B-MYB and 
FOXM1 co-ordinate the transcriptional regulation of genes involved in proliferation in 
germinal centres of B-cell (Lefebvre, Rajbhandari et al. 2010). Therefore, I suggest 
that altered B-MYB expression in breast cancer may affect FOXM1 expression and 
be involved in tamoxifen resistance. The first western blot analysis on tamoxifen 
resistant breast cancer confirmed that B-MYB is deregulated compared to wild-type 
MCF-7 cells (Fig. 3.14). In addition, B-MYB has recently been associated with 
117 
 
tamoxifen resistance in a high-throughput screening for tamoxifen resistance 
(Gonzalez-Malerva, Park et al. 2011). 
 
3.3.5 Conclusion 
 
In this study, I showed a differential regulation of FOXM1 in endocrine sensitive 
and resistant breast cancer cell lines. These findings also provided potential insights 
in the mechanism of anti-oestrogen action and endocrine resistance, and showed 
that FOXM1 deregulation may involve deregulated AIB1, CYCLIN D1, ERβ1 or B-
MYB proteins. Furthermore, this study raises a potential new strategy for the 
treatment of breast cancer endocrine resistant where FOXM1 is frequently 
overexpressed. Targeting FOXM1 with siRNA in this study had a cytostatic effect on 
tamoxifen resistant cells. Therefore, the inhibition of FOXM1 with small molecules, 
such as thiostrepton or siamycin A, in combination with tamoxifen might resensitise 
tamoxifen resistant cells to cell cycle arrest induced by tamoxifen as observed in this 
study.  
 
 
 
 
Figure 3.16 Potential pathways in endocrine therapy. Tamoxifen reduces ERα pathway 
and FOXM1 in endocrine sensitive cells leading to G1 cell cycle arrest. Whereas deregulated 
proteins including cyclin, proliferative factor, ER co-factor in tamoxifen resistant cells could 
prevent cell cycle arrest OHT-induced. 
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3.4 Future work  
 
This report shows that targeting FOXM1 in tamoxifen resistant breast cancer 
cells is an attractive strategy considering that FOXM1 is overexpressed in tamoxifen 
resistant breast cancer cells and that FOXM1 deregulation is involved in tamoxifen 
resistance. I raised several potential mechanisms of FOXM1 deregulation in this 
study that need to be clarified. Treatment with tamoxifen induces the release of ERα 
co-activators and the recruitment of ERα co-repressors. However, I observed a high 
and constant expression of AIB1 in tamoxifen resistant breast cancer cells. 
Consequently, investigating the recruitment, expression and regulation of co-
activators in tamoxifen resistant cells would reveal whether this process is 
deregulated and would provide new potential strategies to overcome resistance. For 
instance, histone deacetylase inhibitors are already in use as monotherapy or in 
combination with taxol and radiation for a wide range of cancers (Dowdy, Jiang et al. 
2006, Lane and Chabner 2009, Mueller, Yang et al. 2011). Furthermore, the 
electrophile disulfite benzamide DIBA has given promising results in mice models. 
DIBA switched tamoxifen agonist to antagonist activity by facilitating the dissociation 
of co-activators and the association of co-repressor on the promoter of ER-
responsive genes resulting in a decrease in xenograft tumor growth of tamoxifen 
resistant human cells in mice (Wang, Yang et al. 2006). This study also reveals a 
potential positive feedback loop between FOXM1 and CYCLIN D1. It was reported 
that CYCLIN D1 modulates the phosphorylation status of pRB leading to the release 
of FOXM1 by pRB (Gladden and Diehl 2003, Wierstra and Alves 2006). CYCLIN D1 
is a validated anti-cancer target with several compounds in clinical trials. Therefore, 
further investigations of FOXM1 regulation by CYCLIN D1 and reciprocal would give 
new opportunities for treating tamoxifen resistant breast cancer patients. Finally, the 
study of ERβ1 in our laboratory identified ERβ1 as a negative FOXM1 regulator that 
could be downregulated in tamoxifen resistant cells. ERβ1 was observed decreased 
in pre-invasive mammary tumour compared to normal or benign lesions, but so far 
altered expression of ERβ1 in tamoxifen resistance has not been investigated 
(Roger, Sahla et al. 2001). Thereby, the study of ERβ1 expression would provide 
further molecular mechanism of tamoxifen resistance and potential strategy to 
overcome tamoxifen resistance. B-MYB has been recently identified as a positive 
regulator of FOXM1, which co-ordinates with FOXM1 to regulate genes involved in 
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G2/M phase transition. Our preliminary data suggest that B-MYB is also 
overexpressed in tamoxifen resistant ERα positive breast cancer cells and might 
participate to FOXM1 deregulation via a feedback loop. Therefore, it would be 
interesting to investigate B-myb role and regulation in tamoxifen resistance. 
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CHAPTER 4 ATM and p53 regulate FOXM1 expression via E2F in 
breast cancer epirubicin treatment and resistance 
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4.1 Introduction 
 
Cytotoxic chemotherapy agents are the most commonly drugs used in cancers. 
Taxanes and anthracyclines are cytotoxic chemotherapy drugs that have been 
frequently used in the neo-adjuvant and adjuvant settings to reduce tumour size prior 
to surgery and eliminate left over cells to prevent recurrence (Martin, Villar et al. 
2003). These cytotoxic agents are used to treat patients with ER/PR/HER2 receptors 
in combination to anti-oestrogen or HER2-targeted therapies. Importantly, 
chemotherapy drugs are the only therapeutic option for triple receptor negative 
patients. Furthermore, cytotoxic chemotherapy agents are used to treat breast cancer 
patients that are resistant to endocrine and targeted therapies, and these agents are 
particularly important in the treatment of advanced or metastatic solid cancers 
(Alvarez 2010, Palmieri, Krell et al. 2010).  
 
Anthracyclines, including doxorubicin (also called Daunorubicin) and epirubicin, 
are a group of Streptomyces peucetius bacteria-derived antibiotics commonly used in 
cancer chemotherapy. These compounds have been shown to be effective for the 
treatment of a broad spectrum of cancers such as breast, lung, and ovary 
carcinomas as well as leukaemia (Lown 1993, Nielsen, Maare et al. 1996). Despite 
being some of the most effective and widely used anti-cancer drugs in the clinic, 
patients relapse because of the development of acquired drug resistance (Gonzalez-
Angulo, Morales-Vasquez et al. 2007, Broxterman, Gotink et al. 2009, Zelnak 2010). 
The exact mechanism of action of anthracyclines is still not completely clear, but 
likely to interfere with DNA replication and induce DNA intercalation triggering DNA 
damages (Gewirtz 1999, Rivera 2010). Resistance to these DNA targeting anti-
cancer drugs is a major clinical obstacle for patients that initially respond to the 
treatment. It involves multiple mechanisms including enhancement of DNA repair. 
Consistently, DNA repair gene network signature has been found to be associated 
with anthracycline response in triple negative metastatic breast cancer (Rodriguez, 
Makris et al. 2010). A better understanding of the molecular mechanisms of 
anthracycline action and resistance is required for the development of novel 
strategies for the treatment of advanced or metastatic breast cancer and for 
overcoming resistance. 
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FOXM1 is required for normal G1/S and G2/M cell cycle phase transitions. 
Besides its involvement in cell cycle transitions, FOXM1 has a multifaceted role in 
biological processes. Notably, FOXM1 has been recently linked to DNA damage 
repair (Tan, Raychaudhuri et al. 2007, Kwok, Peck et al. 2010). In addition, FOXM1 
dysregulation has been shown to be involved in the development of cisplatin 
resistance in breast cancer (Kwok, Peck et al. 2010). Accordingly, FOXM1 
overexpression has been shown to confer resistance to the humanized anti-HER2 
monoclonal antibody (trastuzumab) and microtubule-stabilizing drug (paclitaxel) 
(Carr, Park et al. 2010). Moreover, chapter 3 of this thesis shows that FOXM1 is a 
transcriptional target of ER  and play key role in breast cancer endocrine therapy 
resistance (Millour, Constantinidou et al. 2010). In this chapter, I investigated the 
expression and regulation of FOXM1 in epirubicin sensitive and resistant MCF-7 
breast carcinoma cell lines and its involvement in epirubicin resistance. 
 
4.2 Transcriptional regulation of FOXM1 by p53 in 
epirubicin sensitive MCF-7 cells 
 
4.2.1 Activation of p53 transcriptionally represses FOXM1  
 
The recent observation that p53 represses FOXM1 expression following 
daunorubicin treatment led to predict that epirubicin also activates p53 to repress 
FOXM1 expression in breast cancer cells (Barsotti and Prives 2009). To assess the 
role and mechanism by which p53 mediates the epirubicin response in breast cancer 
cells, I first examined the expression of FOXM1 in p53 positive MCF-7 and p53 
negative MDA-MB-453 breast cancer cell lines. Western blot analysis of MCF-7 cells 
revealed that epirubicin treatment strongly induced the expression of the p53 protein 
and its target the cyclin-dependent kinase inhibitor p21Cip1 from 16 h post-treatment, 
and decreased FOXM1 protein level significantly from 24 h post-treatment (Fig. 4.1). 
Unsurprisingly, p53 and the inhibitor p21Cip1 were undetectable in MDA-MB-453 cell 
line before and after treatment. Consistently, RT-qPCR analysis revealed no 
significant decrease in FOXM1 transcript level in MDA-MB-453 cells, while epirubicin 
induced a drastic reduction of FOXM1 mRNA level in MCF-7 cells. Contrary to 
FOXM1 mRNA level, FOXM1 protein levels varied throughout the treatment. 
However, the variation in FOXM1protein levels can be attributed to multiple levels of 
regulation and a shorter division time in these cell rather than treatment related. 
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Indeed, FOXM1 protein level varies throughout the cell cycle as well as cyclin A and 
B1 (Fig. 4.1) and is subject to post-translational modifications including 
phosphorylations. Collectively, these results show that FOXM1 is downregulated at 
mRNA and protein levels in response to epirubicin in the p53 positive MCF-7 cells, 
while FOXM1 expression remained relatively constant in the p53 negative MDA-MB-
453 cells, suggesting that activated p53 plays a role in FOXM1 regulation. 
 
To further confirm that p53 is responsible for the downregulation of FOXM1 
expression in MCF-7 cells following epirubicin treatment, MCF-7 cells were 
transiently transfected with non-specific (NS siRNA) or p53-targeting siRNA (p53 
siRNA), treated with epirubicin and FOXM1 expression examined. Western blot and 
RT-qPCR analysis showed that silencing of p53 attenuated FOXM1 downregulation 
at both protein and mRNA levels in response to epirubicin (Fig. 4.2A and 4.2C). The 
inability of p53 depletion to completely abolish the downregulation of FOXM1 also 
suggested that p53 might not be the sole regulator of FOXM1 expression in response 
to epirubicin (Fig. 4.2A). A previous study showed that p53 represses FOXM1 
expression via pRB following daunorubicin treatment (Barsotti and Prives 2009). 
Thereby, one mechanism by which p53 can repress FOXM1 expression is through its 
ability to induce p21Cip1, which can in turn repress cyclin-CDK-mediated pRB 
hyperphosphorylation, resulting in the repression of E2F transcriptional activity 
(Giacinti and Giordano 2006). Surprisingly, although p53 knock-down abrogated the 
induction of p21Cip1 and the downregulation of FOXM1 by epirubicin, silencing of 
p21Cip1 had little effect on the epirubicin-induced FOXM1 downregulation, suggesting 
that epirubicin can also repress FOXM1 expression via p21Cip1-independent 
mechanisms (Fig. 4.2B and 4.2D). To further investigate the role of p53 and p21Cip1 
in regulating FOXM1 expression in response to epirubicin, wild-type (wt), p53-
deficient (p53-/-), and p21-deficient (p21Cip1-/-) mouse embryo fibroblasts (MEFs) were 
subjected to epirubicin treatment and the expression of FOXM1 investigated (Fig. 
4.3). Treatment of the wt and p21Cip1-/- MEFs with epirubicin resulted in a reduction of 
FOXM1 mRNA expression within 16 h, further confirming that p21Cip1 is not essential 
for the repression of FOXM1 expression by epirubucin (Fig. 4.3). In contrast, 
epirubicin did not cause a downregulation of FOXM1 mRNA expression in the p53-
deficient MEFs (Fig. 4.3). Together these data support the idea that epirubicin 
represses FOXM1 expression at the transcriptional level through p53. 
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Figure 4.1 Expression of FOXM1 in response to epirubicin treatment in breast cancer 
cell lines. MCF-7 and MDA-MB-453 cells cultured in 10 % FCS and phenol red DMEM 
medium were treated with 1 µmol/L of epirubicin. At times indicated, cells were collected and 
analysed for FOXM1, CYCLIN A, p53, p21Cip1, CYCLIN B1 and β-tubulin expression by 
western blotting. FOXM1 mRNA levels of these cells were also analysed by RT-qPCR, and 
normalized with L19 RNA expression. All data shown represent the averages of data from 
three independent experiments, and the error bars show the standard deviations. Statistical 
analyses were done using Student’s t test. *, P≤0.1, **, P≤0.01 and ***, P≤0.001, significant 
and n.s, non significant.  
 
 
 
 
 
 
 
125 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Activation of p53 in MCF-7 cells represses FOXM1 expression. MCF-7 cells 
cultured in 10 % FCS and phenol red DMEM medium were either transfected with non-
specific siRNA (NS siRNA), siRNA smart pool against p53 (p53 siRNA) (A. and C.), or siRNA 
smart pool against p21Cip1 (p21Cip1 siRNA) (B. and D.) (100 nmol/L). Twenty-four hours after 
transfection, MCF-7 cells were treated with 1 µmol/L of epirubicin and harvested for western 
blot and analysed using RT-qPCR at 0, 24 and 48 h. The protein expression levels were 
determined for FOXM1, p53, p21Cip1 and β-tubulin and the mRNA level was determined for 
FOXM1 and normalized with L19 RNA expression. Columns, means derived from three 
independent experiments; bars, SD. Statistical analyses were done using Student’s t test. *, 
P≤0.1, **, P≤0.01 and ***, P≤0.001, significant and n.s, non significant.  
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Figure 4.3 FOXM1 repression by p53 in a p21-independent manner. Wild-type, p53-/- and 
p21Cip1-/- MEF cells cultured in 10 % FCS and phenol red DMEM medium were treated with 1 
µmol/L of epirubicin for 0, 16, 24 and 48 h, and RT-qPCR was performed to determine 
FOXM1 mRNA transcript levels and normalize with L19 RNA expression. Columns, means 
derived from three independent experiments; bars, SD. Statistical analyses were done using 
Student’s t test. *, P≤0.1 and ** P≤0.01, significant.  
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4.2.2 p53 can regulate FOXM1 through an E2F site in its 
promoter 
 
The pRB/E2F transcription factors are principal regulators of the cell cycle and 
function downstream of the p53 canonical pathway (Giacinti and Giordano 2006). To 
assess whether the E2F transcription factors are involved in the p53-dependent 
FOXM1 repression, we analysed the expression pattern of E2F1, a well-
characterized E2F-responsive gene product as well as a subunit of the E2F 
transcription factor dimers (DeGregori and Johnson 2006). The other E2F family 
members are expressed in different tissues and contexts (Kusek, Greene et al. 
2000). Treatment of MCF-7 cells with epirubicin markedly reduced E2F1 mRNA 
levels within 16 h, whereas E2F1 transcript level increased in response to epirubicin 
in the p53 negative MDA-MB-453 cells (Fig. 4.4A). Furthermore, the close correlation 
between the mRNA expression pattern of E2F1 and FOXM1 in MCF-7 cells suggests 
that p53 is likely to downregulate FOXM1 expression through the repression of E2F 
activity. 
 
To provide further evidence that epirubicin represses FOXM1 expression 
through inhibition of E2F activity, MCF-7 cells were treated with epirubicin for 0 and 
24 h, followed by ChIP analyses of E2F1 and its negative regulator pRB on FOXM1 
promoter (Fig. 4.4B). Our semi-quantitative ChIP assay showed that the in vivo 
occupancy of the proximal FOXM1 promoter by E2F1 decreased and pRB increased 
after epirubicin treatment, indicating that epirubicin causes the depletion of the 
transactivator E2F and the accumulation of the transcriptionally repressive pRB 
protein on FOXM1 promoter (Fig. 4.4B). Although, this experiment indicated a 
decreased in E1F and an increased in pRB occupancies on FOXM1 promoter, a 
ChIP assay using a quantitative PCR method would provide the exact quantification 
of the recruitment of these proteins.  
 
We next analysed the involvement of the putative E2F-binding sites in FOXM1 
promoter in FOXM1 repression upon epirubicin treatment. To this end, MCF-7 cells 
were transiently transfected with a luciferase reporter (pGL3) driven by either a 2.4 
kbp (Full Length), a 1.4 kbp (HindIII), or a 296 bp (ApaI) FOXM1 promoter, and the 
promoter activity was assayed at 0, 24 and 48 h after epirubicin treatment (Fig. 4.5). 
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The activity of all three FOXM1 promoter constructs was markedly reduced following 
exposure to 1 µmol/L epirubicin, consistent with the fact that the putative E2F-binding 
sites (site 1: -58 bp and site 2: -24 bp) locate inside all three FOXM1 promoter 
constructs (Fig. 4.5). We next examined whether p53 exerts its repression on FOXM1 
promoter activity through these putative E2F-binding sites. To this end, we co-
transfected into MCF-7 cells increasing amounts of pcDNA3-Flag-p53 together with 
either the wild-type ApaI FOXM1 promoter reporter (WT) or the ApaI FOXM1 
promoter lacking one (E2Fmut1 or E2Fmut2) or both (E2Fmut1/2) putative E2F-
binding sites. The results showed that p53 caused a drastic reduction (12.7 fold) in 
E2Fmut1 luciferase activity, comparable to that observed for WT (11.5 fold) (Fig. 
4.6A). By contrast, the repression by p53 was considerably reduced in both the 
E2Fmut2 and the E2Fmut1/2, suggesting that the second putative E2F-binding site 
(site 2) mediates the repression of FOXM1 promoter by p53. Next, activity of the wild-
type ApaI (WT) as well as mutated pGL3-ApaI constructs (E2Fmut1, E2Fmut2, and 
E2Fmut1/2) was examined by co-transfection assays in MCF-7 cells with different 
amounts of pCMV-E2F1 expression vector. The results showed that the E2Fmut1 
construct showed similar responsiveness to E2F1 as the WT (Fig. 4.6B). In contrast, 
both the E2Fmut2 and the E2Fmut1/2 mutants lost the majority of their 
responsiveness to E2F1 transfection. Together these co-transfection results provide 
strong evidence that the E2F-binding element located at −24 bp confers the 
responsiveness to p53 and E2F1. Taken together, these results indicate that 
epirubicin can induce p53 to repress FOXM1 through modulating E2F activity on 
FOXM1 promoter. 
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Figure 4.4 E2F1 is decreased in response to epirubicin in MCF-7 cells. A. MCF-7 and 
MDA-MB-453 cells cultured in 10 % FCS and phenol red DMEM medium were treated with 1 
µmol/L of epirubicin for 0, 16, 24 and 48 h and RT-qPCR was performed to determine E2F1 
transcript levels and normalize with L19 RNA expression. Columns, means derived from 
three independent experiments; bars, SD. Statistical analyses were done using Student’s t 
test. *, P≤0.1 and ** P≤0.01, significant. B. MCF-7 cells untreated or treated with 1 µmol/L of 
epirubicin for 24 h were used for ChIP assays using IgG negative control, anti-E2F1 and anti-
pRB antibodies as indicated. After crosslink reversal, the co-immunoprecipitated DNA was 
amplified by PCR using primers amplifying the FOXM1 E2F-binding sites containing region (-
184/+4 bp) and a control region (-1157/-1257 bp), and resolved in 1 % agarose gel.  
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Figure 4.5 FOXM1 promoter activity in response to epirubicin. Schematic representation 
of the full length, HindIII and ApaI FOXM1-luciferase reporter constructs and the E2F-binding 
sites 1 (-58 bp) and 2 (-24 bp). MCF-7 cells were transiently transfected with 20 ng of either 
the empty pGL3-basic, pGL3-Full length, pGL3-HindIII or the pGL3-ApaI, and cells were 
treated with 1 µmol/L of epirubicin. Cells were, as described in material and methods, 
harvested at 0, 24 and 48 h after treatment and assayed for luciferase activity. All relative 
luciferase activity values are corrected for co-transfected Renilla activity. The fold of 
repression were calculated between 0 h and 48 h of epirubicin treatment. Columns, means 
derived from three independent experiments; bars, SD.  
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Figure 4.6 Modulation of FOXM1 promoter by p53 and E2F1 via E2F binding site. MCF-
7 cells cultured in 10 % FCS and phenol red DMEM medium were transiently transfected 
with 20 ng of either the wild-type (WT), E2F-binding site 1 mutated (E2Fmut1), E2F-binding 
site 2 mutated (E2Fmut2), or E2F-binding site 1 and 2 mutated (E2Fmut1/2) pGL3-ApaI 
constructs together with increasing amounts (0, 10 and 30 ng) of pcDNA3-Flag-p53 (A.) and 
pCMV-E2F1 (B.). Cells were harvested after 24 h transfection and assayed for luciferase 
activity as described in Material and Methods. All relative luciferase activity values are 
corrected for co-transfected Renilla activity. The fold of repression and activation were 
calculated and indicated between 0 h and 48 h of epirubicin treatment. Columns, means 
derived from three independent experiments; bars, SD. Statistical analyses were done using 
Student’s t test. **, P≤0.01 and ***, P≤0.001, significant and n.s, non significant.  
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4.3 Differential mechanism of FOXM1 regulation in 
epirubicin resistant MCF-7 cells 
 
4.3.1 Deregulation of FOXM1 protein and mRNA levels in 
epirubicin resistant cells 
 
The involvement of FOXM1 in DNA damage response and chemotherapy drug 
resistance led us to hypothesise that FOXM1 has a role in anthracycline sensitivity as 
well as resistance in breast cancer. In order to test this conjecture, an epirubicin 
resistant breast cell line MCF-7EPIR was used for this study. MCF-7EPIR cell line was 
established by a former PhD student by chronic exposure of the parental drug 
sensitive MCF-7 to stepwise increases in epirubicin concentration until a 
concentration of resistance up to 10 µmol/L. I confirmed by SRB assays that MCF-
7EPIR cells displayed strong resistance to cell death epirubicin-induced compared to 
the parental MCF-7 cells (Fig. 4.7A). I next examined the effect of epirubicin on the 
cell viability of MCF-7 and MCF-7EPIR cells at 1 µmol/L, a concentration generally 
used in cancer therapy. The SRB assay revealed that survival of MCF-7 cells was 
significantly inhibited following epirubicin treatment, while survival of MCF-7EPIR cells 
was relatively unaffected in the presence of epirubicin (Fig. 4.7B). There was also a 
significant difference in the survival rate between the epirubicin-treated MCF-7 and 
MCF-7EPIR cells at both 24 h and 48 h. Cell cycle analysis showed that epirubicin 
exposure (1 µmol/L) induced an accumulation of MCF-7 cells at G2/M and sub-G1 
phases, indicative of G2/M phase transition delay and cell death, whereas no 
significant changes in cell cycle profile are observed for MCF-7EPIR cells (Fig. 4.7C).  
 
Subsequent western blot analysis revealed no significant changes in the levels 
of FOXM1 and FOXM1 protein targets, CYCLIN B1 and PLK, following 48 h 
treatment with epirubicin (1 µmol/L) in MCF-7EPIR cells in contrast to the 
downregulation observed in MCF-7 cells Figure 4.1 (Fig. 4.8A). Consistently, RT-
qPCR analysis revealed no significant decrease in FOXM1 transcript level in MCF-
7EPIR cells (Fig. 4.8B). Importantly, p53 and p21Cip1 protein levels were undetectable 
in MCF-7EPIR cells by western blot analysis (Fig. 4.8A), the band detected in the p53 
lane being an unspecific band. Although p53 mRNA levels are not relevant for its 
functional activity, we further investigated whether MCF-7EPIR cells could have lost 
p53 mRNA expression. RT-qPCR analysis further showed that p53 transcript level is 
reduced by 3.5 fold in MCF-7EPIR cells compared to MCF-7 cells (Fig. 4.8C). 
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Collectively, these results show that FOXM1 expression is deregulated in epirubicin 
resistant MCF-7 cells likely due to the lost of repression by p53, suggesting that 
FOXM1 has a role in epirubicin sensitivity and resistance. 
 
4.3.2 Increased DNA repair in epirubicin resistant cells 
 
Next, I sought to determine the molecular mechanism that confers epirubicin 
resistance to MCF-7EPIR cells. It has been previously shown that FOXM1 expression 
is associated with cisplatin-induced DNA damage response and drug resistance 
(Kwok, Myatt et al. 2008). I therefore examined the formation of DNA damage foci by 
P-H2AX staining in MCF-7 and MCF-7EPIR cells following epirubicin treatment, 
including some enlargement of cells showed by the white arrows and represented in 
the white window. The results showed an increase in the mean number of P-H2AX 
foci/cell over time after epirubicin treatment in MCF-7 cells, while the level of P-H2AX 
foci/cell remained relatively constant in MCF-7EPIR cells, suggesting higher DNA 
repair activities in these cells (Fig. 4.9). This result was also confirmed in a recent 
study (Monteiro, Khongkow et al. 2012). To investigate this further, we evaluated the 
expression level of the DNA repair protein ATM in MCF-7 and MCF-7EPIR cells. 
Western blot and RT-qPCR analysis demonstrated that the levels of ATM protein and 
mRNA are strongly upregulated in MCF-7EPIR cells compared to MCF-7 cells (Fig. 
4.10A), thus suggesting a role of ATM in mediating an increase in DNA repair activity 
in resistant cells. The ATR mRNA expression level was investigated and showed an 
significantly elevated ATR mRNA level in MCF-7 cells compared with MCF-7EPIR 
cells. This finding might suggest a difference in the activation of DNA repair proteins 
between these two cell lines (Fig. 4.10B).  
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Figure 4.7 Characterisation of epirubicin resistant MCF-7EPIR cells. A. MCF-7 and MCF-
7EPIR cells cultured in 10 % FCS and phenol red DMEM medium were treated with 
increasing concentrations of epirubicin for 24 h. Number of cells was measured using SRB 
assay as described in Material and Methods. B. MCF-7 and MCF-7EPIR cells cultured in 10 
% FCS and phenol red DMEM medium were treated with 1 µmol/L of epirubicin for 0, 16, 24 
and 48 h and SRB assay was performed. Statistical analyses were realized using Student t-
test for untreated versus treated. C. MCF-7 and MCF-7EPIR cells cultured in 10 % FCS and 
phenol red DMEM medium were treated with 1 µmol/L of epirubicin for 0, 16, 24 and 48 h 
and cells were stained with propidium iodide and analysed FACS analysis carried out. 
Percentage of cells in each phase (sub-G1, G1, S, G2/M) is indicated. Representative data 
from three independent experiments are shown.  
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Figure 4.8 Inverse correlation between FOXM1 and p53 expression in MCF-7 and MCF-
7EPIR cell lines. A. and B. MCF-7EPIR cells cultured in 10 % FCS and phenol red DMEM 
medium were treated with 1 µmol/L of epirubicin for 0, 16, 24 and 48 h. At indicated time, 
cells were collected and analysed by western blotting to determine the protein expression 
levels of FOXM1, CYCLIN B1, PLK, p53, p21Cip1 and β-tubulin (A.), and by RT-qPCR (B.) to 
determine FOXM1 mRNA transcript levels. Columns, means derived from three independent 
experiments; bars, SD. C. MCF-7 and MCF-7EPIR cells cultured in 10 % FCS and phenol red 
DMEM medium were harvested to determine p53 mRNA transcript level by RT-qPCR. 
Columns, means derived from three independent experiments; bars, SD. Statistical analyses 
were done using Student’s t test. **, P≤0.01 and ***, P≤0.001, significant and n.s, non 
significant.  
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Figure 4.9 Epirubicin resistant MCF-7EPIR cells show a reduction of DNA damage in 
response to epirubicin treatment. A. MCF-7 and MCF-7EPIR cells treated with 1 µmol/L of 
epirubicin for 0, 0.5, 1.5 and 5 h were stained with P-H2AX antibody and DAPI. Images were 
visualized and scored by ImageXpress (Molecular Devices). The results are the average of 
three independent experiments. Mean ± SD. Statistical analyses were performed using 
Students’s test.  **, P ≤ 0.01 significant; n.s non significant. B. MCF-7 and MCF-7EPIR cells 
treated with 1 µmol/L of epirubicin were stained with P-H2AX antibody (green) and DAPI 
(red). Images visualized by confocal microscopy. Images: magnification: x 20; insets x 80.  
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Figure 4.10 Increased expression of ATM in epirubicin resistant MCF-7EPIR cells. MCF-
7 and MCF-7EPIR cells cultured in 10 % FCS and phenol red DMEM medium were analysed 
for FOXM1, ATM and and β-tubulin by western blotting (A.). Cells were harvested to 
determine ATM (B.) and ATR (C.) mRNA levels using RT-qPCR. Columns, means derived 
from three independent experiments; bars, SD. Statistical analyses were done using 
Student’s t test. **, P≤0.01 and ***, P≤0.001, significant and n.s, non significant.  
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4.3.3 ATM is involved in FOXM1 regulation and epirubicin 
resistance 
 
 
To determine whether the ATM signalling pathway is involved in FOXM1 
regulation in response to epirubicin, we treated MCF-7 and MCF-7EPIR cells with 
epirubicin in the absence or presence of Ku-55933, a known ATM inhibitor (Fig. 
4.11).  Western blot analysis demonstrated that epirubicin induced a shift of FOXM1 
protein at a lower size in MCF-7 cells as already shown previously, while it did not 
affect FOXM1 protein level and/or size in MCF-7EPIR cells (Fig. 4.11). However, the 
combination of epirubicin with Ku-55933 repressed E2F1 and FOXM1 protein 
expression in MCF-7 and MCF-7EPIR cells, indicating that Ku-55933 re-sensitised 
the resistant MCF-7EPIR cells to FOXM1 downregulation epirubicin-induced (Fig. 
4.11). These results suggest that the ATM DNA damage response is involved in 
FOXM1 regulation in MCF-7EPIR cells independent of p53 status. However, it has 
been shown that Ku-55933 alone has no effect on cell cycle while Ku-55933 
combined with etoposide induces a G2 arrest (Hickson et al. 2004). Taking into 
account that FOXM1 expression is reduced when cell cycle is stopped, FOXM1 
downregulation Figure 4.11 might be the consequence of Ku-55933 combined with 
epirubicin treatment. 
 
Consequently, ATM expression and activity were investigated in MCF-7 and 
MCF-7EPIR cells by western blot analysis (Fig. 4.12A). Treatment with epirubicin 
activated ATM phosphorylation (on serine 1981) and also induced ATM expression in 
MCF-7EPIR within 24 h, while this induction was not detectable in MCF-7 cells (Fig. 
4.12A). Phosphorylation of ATM downstream target CHK2 was strongly enhanced in 
MCF-7EPIR cells and to a much lesser extent in MCF-7 cells. In addition, treatment 
with epirubicin strongly activated p53 reflected by the phosphorylation of p53 on 
serine 15. In contrast, phosphorylated p53 on serine 15 was undetectable in MCF-
7EPIR cells, demonstrating that p53 is not active in these cells. 
 
To determine whether ATM is a key player of FOXM1 regulation, I silenced 
ATM expression using siRNA strategy (ATM siRNA) in both MCF-7 and MCF-7EPIR 
cells, and studied FOXM1 expression in response to epirubicin (Fig. 4.12B). Western 
blot analysis showed that ATM knock-down had little effect on FOXM1 and E2F1 
expression in MCF-7 cells. While the expression level of FOXM1 remained constant 
139 
 
in MCF-7EPIR cells transfected with non-specific siRNA (NS siRNA) upon epirubicin 
treatment, epirubicin caused a decrease in FOXM1 protein expression in MCF-7EPIR 
cells when ATM is silenced (Fig. 4.12B). Furthermore, E2F1 protein decreased in 
MCF-7EPIR cells following ATM knock-down and epirubicin treatment, which 
correlates with FOXM1 protein expression.  These findings confirmed a differential 
mechanism of regulation by ATM between MCF-7 and MCF-7EPIR cells. These 
findings also suggest that the lack of active p53 and the induction of ATM in MCF-
7EPIR cells are responsible for FOXM1 expression in response to epirubicin.  
 
As ATM is a protein kinase that phosphorylates proteins including p53, mdm2, 
h2ax, chk2 following DNA damage, I performed a time course with MCF-7 and MCF-
7EPIR cells treated with epirubicin (Zhou and Elledge 2000). I showed that FOXM1 
protein level (higher band) increased in MCF-7EPIR cells, while FOXM1 is 
downregulated in MCF-7 cells (Fig. 4.13A). Furthermore, I immunoprecipitated 
FOXM1 proteins and probed with anti-MPM2, an antibody recognising 
phosphorylated proteins, to investigate FOXM1 phosphorylation status in MCF-7 and 
MCF-7EPIR cells epirubicin-treated.  Immunoblotting with MPM2 antibody showed a 
decrease in phosphorylation of immunoprecipitated FOXM1 in MCF-7 cells, while 
FOXM1 phosphorylation remained high in MCF-7EPIR cells following epirubicin (Fig. 
4.13B). In addition, it has previously been shown that FOXM1 protein is 
phosphorylated by CHK2 after DNA damage. Given that CHK2 functions directly 
downstream of ATM in DNA damage response, it is predicted that the induction of 
FOXM1 expression by ATM may occur through post-translational mechanisms (Tan, 
Raychaudhuri et al. 2007). In contrast to Tan et al. study, silencing of both checkpoint 
kinases (CHK1 and CHK2) did not affect FOXM1 protein expression in untreated and 
treated MCF-7EPIR cells (Fig. 4.13C). Notably, the loading of CHK1 siRNA protein 
samples was lower than non-specific and CHK2 siRNA, but FOXM1 levels still 
remained steady in these samples over the time course. 
 
To further investigate FOXM1 regulation by ATM, I used the siRNA strategy to 
reduce ATM expression (ATM siRNA) and investigated FOXM1 mRNA transcript 
levels in MCF-7EPIR cells treated with epirubicin. ATM silencing significantly reduced 
ATM mRNA levels as well as FOXM1 mRNA levels in MCF-7EPIR cells treated with 
epirubicin, suggesting that ATM regulates FOXM1 at transcriptional level (Fig. 
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4.14A). Given that E2F1 protein expression followed FOXM1 protein expression 
pattern when ATM is silenced, I analysed E2F1 mRNA levels in MCF-7EPIR cells 
treated with epirubicin and performed ChIP assay. The results showed that E2F1 
mRNA expression and E2F1 occupancy of FOXM1 promoter remained steady in 
MCF-7EPIR cells treated with epirubicin (Fig. 4.14B and 4.14C).  
These data suggested that ATM regulates FOXM1 transcriptionally via E2F1 
and that FOXM1 might also be regulated by phosphorylations in MCF-7EPIR cells. 
Given the role of ATM in DNA repair and the fact that ATM regulates FOXM1 in 
epirubicin resistant cells, it is likely that FOXM1 has a role in epirubicin resistance. In 
addition, the role of FOXM1 in epirubicin sensitivity and resistance is further 
supported by the observations that overexpression of FOXM1 in MCF-7 cells can 
decrease the sensitivity to epirubicin (supplementary data realised by Julia K. Langer 
Fig. S.D.7.3) and that FOXM1 knock-down in MCF-7EPIR cells did mimic the 
cytotoxic effects of epirubicin on MCF-7 cells (Fig. 4.15). However, the preliminary 
SRB result did not show that ATM silencing has an effect on the survival of the 
epirubicin resistant cells compared to FOXM1 silencing (Fig. 4.15). These results 
could indicate that FOXM1 is regulated by multiple pathways including ATM, but 
remains the main regulator in epirubicin resistance. 
 
Although the SRB assay showed that FOXM1 silencing reduced the survival of 
the epirubicin resistance cells, a clonogenic or colony formation assay would be a 
better method to test the effect of FOXM1 inhibition on epirubicin sensitivity and 
resistance. Clonogenic assay is the method of choice to determine cell reproductive 
death after treatment. Only a fraction of seeded cells retains the capacity to produce 
colonies (Franken, Rodermond et al. 2006). Testing FOXM1 silencing in epirubicin 
resistant cells using this assay would tell us whether FOXM1 is a key player for 
epirubicin resistance. 
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Figure 4.11 ATM inhibition and epirubicin downregulate FOXM1 in MCF-7EPIR cells. 
MCF-7 and MCF-7EPIR cells were treated with 1 µmol/L of epirubicin alone or in combination 
with 10 µmol/L of Ku-55933 for 24 h and the protein expression levels of FOXM1, P-CHK2, 
CHK2, E2F1 and β-tubulin were analysed by western blot analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
142 
 
 
 
 
 
 
Figure 4.12 ATM is involved in FOXM1 regulation in epirubicin resistant MCF-7EPIR 
cells. A. MCF-7 and MCF-7EPIR were treated with 1 µmol/L of epirubicin and the protein 
expression levels of P-ATM, ATM, P-CHK2, CHK2, P-p53 (ser15) and β-tubulin were 
analysed by western blot analysis. B. MCF-7 and MCF-7EPIR cells were either transfected 
with non-specific (NS) siRNA (100 nmol/L) or siRNA smart pool against ATM (100 nmol/L). 
Twenty-four hours after transfection, cells were treated with 1 µmol/L of epirubicin and 
harvested for western blot at 0, 24 and 48 h. The protein expression levels were determined 
for FOXM1, ATM, E2F1, cleaved PARP and β-tubulin.  
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Figure 4.13 Phosphorylation of FOXM1 in MCF-7EPIR cells. A. MCF-7 and MCF-7EPIR 
cells cultured in 10 % FCS and phenol red medium were treated with 1 µmol/L of epirubicin 
in a time course of 48 h. Cell lysates were prepared at indicated times, and the expression of 
FOXM1 and β-tubulin was analysed by western blotting. B. MCF-7 and MCF-7EPIR cells 
cultured in 10 % FCS and phenol red medium were treated with 1 µmol/L of epirubicin for 24 
h. Cell lysates were subjected to immunoprecipitation using anti-FOXM1 antibody and 
immunoblotted with anti-MPM2 and FOXM1 antibodies. C. MCF-7EPIR cells were either 
transfected with non-specific (NS) siRNA, CHK1- or CHK2-targeting siRNA (100 nmol/L) and 
treated with 1 μmol/L of epirubicin for 0, 24 and 48 h.  The protein levels were analysed by 
western blotting using anti-FOXM1, anti-PLK, anti-CHK1, anti-CHK2 and anti-β-tubulin 
antibodies.  
 
 
144 
 
 
 
 
Figure 4.14 E2F1 occupancy on FOXM1 promoter remains steady in MCF-7EPIR cells. 
A. Cells were transfected with non-specific and FOXM1-targeting siRNA (100 nmol/L) and 
were treated with 1 μmol/L of epirubicin for 48 h and harvested for determination of FOXM1 
and ATM mRNA levels by RT-qPCR analysis. Statistical analyses were performed using 
Students’s test.  **, P ≤ 0.01 significant; n.s non significant. B. MCF-7EPIR cells were treated 
with 1 µmol/L of epirubicin for 0, 16, 24 and 48 h and RT-qPCR was performed to determine 
E2F1 transcript levels. Columns, means derived from three independent experiments; bars, 
SD. C. After cross-link reversal, the co-immunoprecipitated DNA was amplified by PCR using 
primers amplifying the FOXM1 E2F1-biding sites containing region (-184/+4) and a control 
region (-1157/-1257), and resolved on 2 % agarose gel (left panel). Quantification by RT-
qPCR gave similar results (right panel).   
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Figure 4.15 Silencing of FOXM1 combined with epirubicin treatment increases cell 
death in MCF-7EPIR cells. A. MCF-7EPIR cells were either transfected with non-specific 
(NS) siRNA or FOXM1-targeting siRNA (100nmol/L) and treated with 1μmol/L of epirubicin 
for 72 h.  Cells were harvested for western blot analysis to validate the silencing efficiency 
using anti-FOXM1 and anti-β-tubulin antibodies. B. The transfected MCF-7EPIR cells treated 
with 1μmol/L of epirubicin were collected for SRB assay at 0, 24, 48, 72 h. C. The transfected 
MCF-7EPIR cells treated with 1μmol/L of epirubicin were also collected for FACS analysis 
carried out after propidium iodide staining. Cell death was analysed using flow cytometry. 
The percentages of cells in sub-G1 were calculated. Columns, means derived from three 
independent experiments; bars, SD. D. MCF-7EPIR cells were either transfected with non-
specific (NS) siRNA or ATM-targeting siRNA (100nmol/L) and treated with 1μmol/L of 
epirubicin for 72 h.  The transfected MCF-7EPIR cells treated with 1 μmol/L of epirubicin were 
collected for SRB assay at 0, 24, 48 h. Experiment performed once in triplicates. 
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4.4 Discussion 
 
4.4.1 FOXM1 is a crucial target of p53  
 
FOXM1 has been found to be frequently upregulated in a large variety of human 
cancers (Wang, Kiyokawa et al. 2002, Kalinichenko, Major et al. 2004, Kalin, Wang et 
al. 2006, Kim, Ackerson et al. 2006, Liu, Dai et al. 2006, Laoukili, Stahl et al. 2007, 
Wang, Banerjee et al. 2007). In addition, emerging evidence revealed that FOXM1 
also has a role in cancer drug resistance. Studies demonstrated that FOXM1 level is 
an important determinant of sensitivity to breast cancer chemotherapy drugs, such as 
trastuzumab, gefitinib, lapatinib, paclitaxel and cisplatin (Kwok, Peck et al. 2010). 
Consistent with these findings, this study established that FOXM1 is a crucial cellular 
target of the anthracycline epirubicin in breast cancer cells. FOXM1 expression is 
downregulated by epirubicin in the sensitive MCF-7 cells, but not in the resistant 
MCF-7EPIR cells. Moreover, FOXM1 protein levels are higher in the epirubicin 
resistant MCF-7EPIR cells relative to the sensitive MCF-7 cells. Taken together, 
these data suggest that FOXM1 also has a role in epirubicin resistance. In 
agreement, a recent study revealed that the anthracycline daunorubicin can repress 
FOXM1 expression through the sequential activation of p53, p21Cip1 and RB family of 
proteins (Barsotti and Prives 2009). Using p53-/- and wt MEFs, we established that 
FOXM1 expression is negatively regulated by p53 (Fig. 4.3). However, epirubicin can 
effectively repress FOXM1 expression in the p21Cip1-/- MEFs (Fig. 4.3). This finding 
indicates that p53 can repress E2F activity and FOXM1 expression independent of 
the cyclin-dependent kinase inhibitor p21Cip1, despite previous studies showing that 
the activation of pRB by the anthracycline daunorubicin is mediated at least partially 
through p21Cip1 (Barsotti and Prives 2009). Based on the fact that E2F1 gene is an 
E2F-regulated gene, its expression reflects the cellular E2F activity. Transient 
reporter assays indicate that the effects of epirubicin, its cellular targets p53 and 
E2F1 are mediated through a proximal E2F-binding site within FOXM1 promoter (Fig. 
4.6). In agreement, a recent study revealed that a great majority of genes repressed 
by p53 and p73 contains E2F-binding sites, suggesting that p53 proteins repress 
gene expression through inhibiting E2F activity (Scian, Carchman et al. 2008). The 
direct binding of pRB and E2F1 on FOXM1 promoter was confirmed in vivo by ChIP 
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analysis. ChIP assays also revealed that upon epirubicin treatment pRB level 
increased and E2F1 level decreased within FOXM1 promoter region containing the 
E2F-binding site (Fig. 4.4). Collectively, these findings indicate that epirubicin can 
repress FOXM1 expression through induction of p53, which in turn represses E2F 
activity through activating pRB and downregulating E2F1 expression.  
 
4.4.2 p53 status is not a determinant of epirubicin response 
 
Many chemotherapy agents in the treatment of cancer cause DNA damage that 
is sensed by the tumour suppressor protein p53, triggering DNA repair and inducing 
apoptosis (Liu and Kulesz-Martin 2001). In case of mutation or deletion of p53 gene, 
the efficiency of chemotherapy agents is compromised (Aas, Børresen et al. 1996, 
Reles, Wen et al. 2001). Mutations of p53 occur in more than half of all tumours and 
have been linked to drug resistance (Hollstein, Sidransky et al. 1991). Despite that 
the loss or mutation of p53 is associated with resistance to chemotherapy in many 
cancers including breast cancer (Aas, Børresen et al. 1996), this study shows 
evidence that DNA damage-sensing kinase ATM has also a role in regulating FOXM1 
expression and epirubicin resistance, independent of p53. For instance, epirubicin 
fails to activate p53 in MCF-7EPIR cells, but reduces FOXM1 protein expression in 
combination with ATM inhibitor treatment (Fig. 4.11). Similarly, the combination of 
epirubicin with ATM silencing completely abrogated FOXM1 protein expression (Fig. 
4.12). Furthermore, U2OS cells treated with epirubicin activates p53 but only reduces 
FOXM1 levels in combination with caffeine (an ATM inhibitor) (Millour, de Olano et al. 
2011). Taken together, this study shows that p53 is not the major component of 
epirubicin resistance. The role of p53 in drug sensitivity occurs through the activation 
of cell cycle arrest and apoptosis genes transcription. Based on its role, the 
transfection of p53 in MCF-7EPIR was tested, but p53 was not sufficient to restore 
epirubicin sensitivity (data not shown). Similarly, ectopic expression of p53 in lung 
cancer cell lines failed to alter the sensitivity of the cell line to the chemotherapeutic 
agents adriamycin, taxol and carboplatin (Breen, Heenan et al. 2007).  
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4.4.3 FOXM1 is a target of ATM 
 
Based on the fact that ATM controls DNA repair through protein 
phosphorylation leading to the activation of gene transcription, we analysed the 
regulation of FOXM1 by ATM.  Downregulation of ATM using siRNA significantly 
reduced FOXM1 mRNA levels, indicating that ATM regulates FOXM1 at 
transcriptional level (Fig. 4.14A). Consistently, ample evidence has demonstrated 
that ATM regulates E2F1 expression in response to DNA damage, although the 
mechanism involved is not completely understood (Blattner, Sparks et al. 1999, 
Carcagno, Ogara et al. 2009). For example, genotoxic stress has been reported to 
upregulate E2F1 expression at transcriptional level through the activation of ATM 
(Carcagno, Ogara et al. 2009). On the contrary, a previous study also showed that 
E2F1 expression is upregulated in response to DNA damage because of an increase 
in protein stability indicating a post-translational regulation mechanism (Blattner, 
Sparks et al. 1999). Current evidence indicates that E2F1 expression can be involved 
in proliferation and tumorigenesis as well as apoptosis and tumour suppression 
(Kusek, Greene et al. 2000, Polager and Ginsberg 2009). However, in the context of 
cancer chemotherapy, the current observations evidently suggest that E2F1 is linked 
to cell survival through promoting FOXM1 expression. In a previous microarray study, 
E2F1-3 proteins have been shown to promote the expression of genes involved in 
DNA replication, DNA repair and mitosis, and interestingly some of these E2F-
regulated genes identified, such as CYCLIN B1, are also transcriptional target of 
FOXM1 (Polager, Kalma et al. 2002, Ren, Cam et al. 2002, Russo, Magro et al. 
2006). Consistently, a number of recent studies have demonstrated that E2F1 
expression is induced by a variety of DNA damaging agents and genotoxic 
chemotherapeutic drugs and mirrors that of p53. Based upon our current findings that 
ATM induces E2F activity and FOXM1 expression in response to DNA damage and 
that E2F can promote FOXM1 transcription, this study proposes that ATM enhances 
E2F1 expression and activates E2F-dependent FOXM1 expression at transcriptional 
level in response to DNA damaging agents, such as epirubicin. 
 
In addition, western blotting and immunoprecipitation experiments (Figure 4.13) 
in MCF-7 and MCF-7EPIR cells suggested that FOXM1 phosphorylation is enhanced 
by epirubicin in MCF-7EPIR cells. Taken together, our findings showed FOXM1 
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involvement in DNA damage response pathway and for the first time a relationship 
between FOXM1 and ATM. Numerous studies have shown that ATM regulates by 
phosphorylation numerous genes involved in cell cycle checkpoints, apoptosis and 
DNA repair. For instance, ATM phosphorylates the checkpoint kinase 2 (CHK2) on 
threonine 68 in response to DNA damage. When activated, CHK2 inhibits CDC25C 
phosphatase preventing entry into mitosis and allowing repair of the DNA. In addition, 
it has previously been shown that FOXM1 protein is phosphorylated by CHK2 on 
serine 361 in response to DNA damage. This phosphorylation event has also been 
proposed to increase the stability of the FOXM1 protein to promote expression of 
DNA repair genes (Tan, Raychaudhuri et al. 2007). Given that CHK2 functions 
directly downstream of ATM in DNA damage response, it is predicted that the 
induction of FOXM1 expression by ATM may therefore also occur through post-
translational mechanisms in response to DNA damage (Tan, Raychaudhuri et al. 
2007). In contrast, silencing experiments showed that neither CHK2 nor CHK1 is 
involved in FOXM1 regulation in MCF-7EPIR cells (Figure 4.13C). Given that FOXM1 
is stabilised after epirubicin in MCF-7EPIR cells and that ATM knock-down completely 
abolished FOXM1 expression, we hypothesised that ATM could directly 
phosphorylate FOXM1. To investigate this hypothesise, I performed in vitro 
radioactive-labelled kinase assay using ATM, FOXM1 and CHK2 (positive control) 
recombinant proteins. While CHK2 protein did phosphorylate FOXM1 as already 
published (Tan, Raychaudhuri et al. 2007), I did not observe any phosphorylation 
events when ATM was added to FOXM1 protein (data not shown).  
 
4.4.4 FOXM1 involvement in DNA repair and cell survival 
 
Increased ATM expression in MCF-7EPIR cells indicates that ATM may promote 
DNA repair to counteract the DNA damage-induced cell death triggered by genotoxic 
chemotherapy drugs. Consistent with this, the sustained levels of foci in the MCF-
7EPIR cells after epirubicin are significantly reduced when compared with the drug 
sensitive MCF-7 cells, as revealed by the P-H2AX staining (Fig.4.9). Moreover, this 
idea is further supported by our finding that depletion of ATM activity (by siRNA or 
Ku-55933 inhibitor) abolished the accumulation of FOXM1. Consequently, we 
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showed that FOXM1 silencing reduced cell survival (Fig. 4.15), and could sensitise 
the resistant MCF-7-EPIR cells to epirubicin sensitivity. Conversely, FOXM1 
overexpression delays apoptosis induced by epirubicin (Fig. S.D.7.3) and by cisplatin 
in MCF-7 cells as well as increased DNA repair (Kwok, Peck et al. 2010). Taken 
together, this study shows FOXM1 involvement in ATM DNA damage response. 
 
4.4.5 Conclusion 
 
In summary, our data suggest that the genotoxic chemotherapy agent, 
epirubicin, triggers the accumulation and activation of p53 and ATM, and it is the 
antagonistic signals of activated ATM and p53 that converge on E2F to control 
FOXM1 expression, DNA damage repair and cell survival. Specifically, p53 represses 
while ATM enhances E2F activity, FOXM1 expression, cell survival in response to 
epirubicin. In consequence, the development of epirubicin resistance can be due to 
the loss of p53 function and an increase in ATM expression and activity. The finding 
that ATM as well as p53 modulates FOXM1 expression may have important 
implications for the diagnosis and treatment of drug resistant cancers, particularly 
those lacking functional p53. For example, ATM and FOXM1 inhibitors can be 
important cancer therapeutics as they can cause cell death independent of p53 
status. ATM and FOXM1 inhibitors can also be used in combination with conventional 
genotoxic therapeutic agents to enhance drug efficacy and overcome resistance. 
Furthermore, p53, ATM and FOXM1 could be useful biomarkers for the prediction of 
epirubicin sensitivity in cancer patients.  
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Figure 4.16 Antagonistic pathways in epirubicin treatment. Epirubicin triggers the 
accumulation and activation of p53 and ATM. It is antagonistic signals of activated ATM and 
p53 that converge on E2F directly or indirectly to control FOXM1 expression and might 
regulate DNA damage repair and cell survival.  
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4.5 Future work 
 
Based on our results showing that epirubicin resistant MCF-7EPIR cells have 
lost p53 activity and that DNA damage agents act through p53, the identification of 
new therapeutic agents is needed in combination with DNA agents to resensitise 
cells to cytotoxic drugs. DNA damage induces a cascade of protein kinases that 
repair DNA breaks through the regulation of DNA repair proteins. Emerging 
evidences show FOXM1 involvement in DNA repair response (Tan, Raychaudhuri et 
al. 2007, Kwok, Peck et al. 2010). It was first reported that CHK2 phosphorylates 
FOXM1 leading to its phosphorylation and regulation of DNA repair genes, XRCC1 
and BRCA2 (Tan, Raychaudhuri et al. 2007). In our study, we showed a different 
mechanism of FOXM1 regulation in which ATM regulates FOXM1 at transcriptional 
level. Some evidence suggests that ATM also regulates FOXM1 at post-translational 
level, but our attempts to perform in vitro kinase assay failed. It would be beneficial to 
verify whether ATM can regulate FOXM1 phosphorylation and investigate the 
phosphorylation site involved. An alternative would be that FOXM1 is phosphorylated 
by another DNA damage kinase. Furthermore, investigation of the detailed role of 
FOXM1 in DNA repair would clarify what is FOXM1 primary role in the epirubicin 
resistant cells.  
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CHAPTER 5 FOXM1 regulates ATM phosphorylation and DNA 
damage response via transcriptional activation of NBS1 
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5.1 Introduction 
 
Breast cancer is the most cancer in women and one of the most prevalent 
causes of death in women due to cancer relapse and metastasis to other organs 
(Jemal, Siegel et al. 2009). Cytotoxic chemotherapeutic drugs are largely used in the 
treatment of many cancers from different origins and to reduce the chance of 
metastasis (Martin, Villar et al. 2003, Smith and Chua 2006). Chemotherapy agents 
encompass alkylating agents, anti-metabolite, topoisomerase inhibitors, 
anthracyclines and anti-mitotic agents (Hortobagyi 1995, Rodler, Korde et al. 2010, 
Rodríguez-Lescure 2010). Each class of drug act differently, but all lead to DNA 
damages. Among cytotoxic chemotherapies, anthracyclines are anti-cancer 
antibiotics widely used and effective for the treatment of breast, lung, ovarian and 
leukaemia cancers (Lown 1993). Anthracyclines mechanism of action is thought to 
interfere with enzymes involved in DNA replication, but is also likely to be involved in 
DNA intercalation and DNA damage (Euhus 2011). ATM is a key factor activated 
following DNA damage that induces phosphorylation of its downstream target histone 
H2AX, leading to the recruitment of DNA repair proteins to the sites of damage 
(Fernandez-Capetillo, Chen et al. 2002, Celeste, Fernandez-Capetillo et al. 2003). 
Although ATM signalling pathway and downstream targets are known, further 
elucidations are necessary to understand all mechanisms activating ATM and DNA 
repair. It has been reported that changes in chromatin structure induced by the 
MRE11/RAD50/NBS1 (MRN) complex was essential for ATM auto-phosphorylation 
and activation (Lee and Paull 2004, Lee and Paull 2005).  
 
The mammalian FOXM1 transcription factor belongs to the forkhead box 
superfamily and plays a critical role in cell proliferation, as it is required for G1/S and 
G2/M cell cycle transitions (Laoukili, Kooistra et al. 2005, Wierstra and Alves 2007). 
Besides its role in cell growth, FOXM1 also regulates organogenesis, angiogenesis, 
metastasis and DNA damage repair (Dai, Kang et al. 2007, Tan, Raychaudhuri et al. 
2007, Raychaudhuri and Park 2011). Consistent with its roles, FOXM1 is found 
elevated in a broad spectrum of carcinomas (Kalinichenko, Major et al. 2004, 
Pilarsky, Wenzig et al. 2004, Chandran, Ma et al. 2007, Zeng, Wang et al. 2009). In 
addition to its involvement in tumorigenesis, FOXM1 dysregulation was implicated in 
tamoxifen resistant breast cancer cells through abrogation of tamoxifen anti-
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proliferative effect (Millour, Constantinidou et al. 2010). Furthermore, FOXM1 
dysregulation has been shown to play a role in the development of cisplatin and 
epirubicin resistance in breast cancer (Kwok, Peck et al. 2010, Millour, 
Constantinidou et al. 2010, Millour, de Olano et al. 2011). The role of FOXM1 in 
resistance to DNA damage agents is thought to be due to enhanced DNA repair. 
However, FOXM1 involvement in DNA damage signalling pathway has not been 
explored. In this report, the role of FOXM1 in ATM DNA damage response in 
epirubicin resistance was studied. 
 
5.2 FOXM1 is involved in single and double stranded DNA 
repair in epirubicin resistant breast cancer cells 
 
The previous study chapter 4 and published work from our laboratory showed 
FOXM1 involvement in resistance to DNA damage agents including epirubicin and 
cisplatin. The study chapter 4 showed that epirubicin enhances P-H2AX DNA 
damage foci in epirubicin sensitive breast cancer cells, while P-H2AX foci are 
sustained and low in epirubicin resistant breast cancer cells. This study suggests a 
higher DNA repair system in the epirubicin resistant cell line (Millour, de Olano et al. 
2011). To investigate single stranded DNA repair mechanism of epirubicin resistant 
MCF-7EPIR cells, the host-cell reactivation assay (HCR) was used. The plasmid 
harbouring firefly luciferase was damaged by a nicking endonuclease on a single 
strand of the DNA and repaired by the cellular DNA repair machinery. Only fully 
repaired plasmid transcribed correctly generate active firefly luciferase (Fig. 5.1) 
(Matijasevic, Precopio et al. 2001). According to differences in transfection 
efficiencies, the luciferase data were not normalised to the undamaged control 
plasmid, but normalised to Renilla and compared to the time 0 h (from the same 
transfection mix). Additionally, all controls with undamaged plasmid were performed 
(data not shown). The firefly luciferase activity of the damaged plasmid was 
recovered by 1174-fold 72 h post-transfection in epirubicin resistant MCF-7EPIR cells, 
while luciferase activity was only recovered by 5.2-fold 72 h after transfection in 
epirubicin sensitive MCF-7 cells (Fig. 5.1A). This result indicates that MCF-7EPIR 
cells have an enhanced mechanism of repair for single strand damage than MCF-7 
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cells. FOXM1 was examined for its role in DNA repair in MCF-7EPIR cells using the 
HCR assay. The firefly luciferase activity of the damaged plasmid transfected 
combined with the non-specific siRNA (NS siRNA) in MCF-7EPIR cells was recovered 
by 24.5-fold after 48 h transfection, which matches the result obtained Figure 5.1A 
(Fig. 5.1B). In contrast, FOXM1 silencing (FOXM1 siRNA) completely abrogated the 
luciferase recovery, suggesting that FOXM1 plays an important role in DNA repair in 
MCF-7EPIR cells (Fig. 5.1B. Notably, these results remain preliminary and manual. It 
has also been reported that dysregulated FOXM1 is involved in cisplatin and 
epirubicin resistance and it is thought to be due to enhanced DNA repair 
mechanisms. Our lab has recently investigated FOXM1´s role in double stranded 
DNA repair using HeLa cell lines harbouring an integrated direct repeat green 
fluorescent protein reporter for HR or NHEJ. These experiments showed that FOXM1 
depletion reduced the HR DSB repair, but had no significant effects on NHEJ repair 
(Monteiro, Khongkow et al. 2012). 
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Figure 5.1 FOXM1 depletion alters single stranded DNA repair in MCF-7EPI
R 
cells. A. 
MCF-7EPI
R
 and MCF-7 cells were transiently co-transfected with damaged firefly luciferase 
and undamaged renilla luciferase plasmids. After 24 h transfection, luciferase activities were 
assayed at 0, 48 and 72 h and the ratios firefly/renilla were calculated. Folds increase 
relative to 0 h are shown. B. MCF-7EPI
R
 cells were either transfected with non-specific (NS) 
siRNA or FOXM1-targeting siRNA (100 nmol/L). Twenty-four hours after transfection, cells 
were co-transfected with damaged firefly luciferase and undamaged renilla luciferase 
plasmids, and luciferase activities were assayed at 0, 24 and 48 h and the ratios firefly/renilla 
were calculated. Folds increase relative to 0 h are shown. Columns, means derived from 
three independent experiments; bars, SD.   
 
 
 
158 
 
5.3 Enhanced recruitment of FOXM1 and P-H2AX in MCF-
7EPI
R
 cells following DNA breaks 
 
As MCF-7EPIR cells have high DNA repair in response to epirubicin (Fig. 4.9 
and 4.10), the recruitment of DNA repair proteins at double strand breaks (DSB) sites 
was investigated. For this purpose, the eukaryotic homing endonuclease I-Ppol, 
which has a 15 base pair recognition sequence to cleave endogenous DNA sites in 
the human genome, was used to cleave specifically one site on the chromosome 1 
on an intron of the DAB1 gene. Expression of the I-Ppol leads to a cleavage of the I-
Ppol target sites (DAB1 gene), generating DSBs (equivalent to 0.8 Gy irradiation) and 
activating ATM-dependent signalling pathway (Berkovich, Monnat et al. 2007). 
Although it is inaccurate to compare DNA damage epirubicin-induced with DNA 
damage I-Ppol-induced because of the difference in DNA damage levels, the 
generation of DSBs by I-Ppol transfection was confirmed in MCF-7 and MCF-7EPIR 
cells using the expression level of P-H2AX (Fig. 5.2). Western blotting of I-Ppol would 
have also been a good control in this case. The P-H2AX and FOXM1 were 
immunoprecipitated and the DNA sequence bound to these proteins was amplified 
using DAB1 primers and normalised with -actin housekeeping gene. DNA breaks 
induced by I-Ppol transfection induced a strong enhancement in the recruitment of P-
H2AX and FOXM1 proteins on the sites of DNA breaks in MCF-7EPIR cells relative to 
MCF-7 cells and to the respective IgG negative control (Fig. 5.2). These results 
suggest that the recruitment of DNA repair proteins to the DSB sites is enhanced in 
MCF-7EPIR cells compared to MCF-7 cells epirubicin sensitive. In addition, these 
data might indicate that FOXM1 may be necessary either for H2AX phosphorylation 
or for the recruitment of P-H2AX at the DSBs. Impaired H2AX phosphorylation or 
recruitment would affect DNA repair proteins recruitment.  
 
However, these results remain preliminary and imprecise. Indeed, Michael 
Kastan et al. improved this system by adding a mutant oestrogen receptor hormone-
binding domain to I-Ppol to create a fusion protein that localized to the nucleus in 
response to 4-hydroxytamoxifen (4-OHT). Addition of 4-OHT to cells infected with an 
oestrogen receptor-I-Ppol retrovirus results in a time-dependent cleavage of I-Ppol 
site (Berkovich, Monnat et al. 2007). In Figure 5.2, the kinetic of transfection is likely 
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to be very different as MCF-7 cells are much easier and quicker to transfect than 
MCF-7EPIR cells. Therefore, the level of H2AX recruitment in MCF-7 cells might be 
low because the transfection is rapid in these cells and 24 hrs after transfection the 
damages have already been repaired. Western blotting of I-Ppol in a time course 
could also provide us with extra information about the kinetic of transfection. 
However, the difference between the level of P-H2AX in the western blot and ChIP 
experiments for MCF-7 cells is striking. H2AX recruitment on DSB might not be on 
the amplified site. H2AX protein recruitment might also be low because these MCF-7 
cells have a low level of DNA damage repair pathway activation. Indeed, in Figure 
4.12 MCF-7 cells showed a very low level or no phospho-ATM after epirubicin 
treatment. The experiment has been repeated several times using western blot with 
high sensitivity detection methods, but the expression of phospho-ATM remained 
undetectable. 
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Figure 5.2 Increased in the recruitment of FOXM1 and repair factors at DNA breaks in 
MCF-7EPI
R 
cells. A. MCF-7 and MCF-7EPIR cells were transfected with with 3 μg of empty 
vector or vector encoding for I-Ppol and harvested for western blot analysis 48 h post-
transfection. The protein expression levels were determined for P-H2AX and β-tubulin. B. 
Transient expression of the I-Ppol for 24 h leads to a cleavage of the I-Ppol target sites and 
generation of DSBs. After cross link reversal of epirubicin-treated MCF-7 and MCF-7EPI
R
 
cells, the H2AXpSer139 and FOXM1 were immunoprecipitated and the DNA sequences 
bound to these proteins were amplified using DAB1 primers. Input DNA was used to 
normalise the amplified DNA. Columns, means derived from three independent experiments; 
bars, SD.  Statistical analyses were done using Student’s t test. **, P≤0.01 and ***, P≤0.001, 
significant and n.s, non significant.  
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5.4 FOXM1 is required for the activation of ATM, H2AX and 
CHK2 DNA repair proteins 
Since the HCR assay showed that FOXM1 is essential to repair DNA in MCF-
7EPIR cells and might be necessary for H2AX phosphorylation, the effect of FOXM1 
silencing was examined on the phosphorylation of DNA repair proteins. For this 
purpose, MCF-7EPIR cells were transiently transfected with non-specific siRNA and 
FOXM1-targeting siRNA and examined for their ability to phosphorylate ATM and its 
targets when treated with 1 μmol/L of epirubicin. Western blot analysis confirmed that 
FOXM1 was effectively silenced at least over 48 h after treatment (Fig. 5.3A). The 
use of phosphospecific antibodies showed an increase in the phosphorylation of 
ATM, H2AX and CHK2 following epirubicin exposure in the non-specific siRNA 
condition (Fig. 5.3A). In contrast, the phosphorylation of ATM was completely 
abrogated, and phosphorylations of H2AX and CHK2 were reduced in treated MCF-
7EPIR cells when FOXM1 was silenced (Fig. 5.3A). To further confirm the reduction 
in ATM phosphorylation, the percentage of P-ATM positive cells were assessed by 
staining using flow cytometry in MCF-7EPIR cells treated with non-specific and 
FOXM1-targeting siRNA. After 48 h treatment with 1 μmol/L of epirubicin, the 
percentage of P-ATM positive cells increased compared to untreated condition in the 
non-specific siRNA condition, while it decreased in cells treated with siRNA targeting 
FOXM1, independent of epirubicin treatment (Fig. 5.3B). The validation of FOXM1 
silencing was also confirmed by staining using flow cytometry, and for each antibody 
an IgG secondary antibody negative control was performed (Fig. 5.3B). Notably, 
FOXM1 enhancement at protein level Figure 5.3A was not observed using flow 
cytometry indicating that total FOXM1 protein expression remained the same and 
that FOXM1 induction observed by western blotting could be due to an increase in its 
phosphorylation levels. The reduction in H2AX phosphorylation observed Figure 5.3A 
was confirmed by immunofluorescence staining in MCF-7EPIR cells treated with non-
specific and FOXM1-targeting siRNA in absence and presence of epirubicin at 1 
μmol/L for 24 h (Fig. 5.4). Although our previous study chapter 4 showed low levels 
of P-H2AX foci in epirubicin resistant cells compared to MCF-7 cells, the foci were 
present and sustained over the treatment (Millour, de Olano et al. 2011). In this 
study, the quantification of P-H2AX foci in MCF-7EPIR cells showed a decrease of 
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foci in cells treated with siRNA targeting FOXM1 compared to non-specific siRNA 
condition at 24 h epirubicin treatment (Fig. 5.4B). This result is in opposition to results 
from a recent study using the same cell lines (Monteiro, Khongkow et al. 2012). 
However, these results were confirmed in a human fibroblast cell line (Fig. 5.5). 
FOXM1 silencing in human fibroblast cells also abrogated ATM, H2AX and Chk2 
phosphorylations, and by consequent their activation (Fig. 5.5 and 5.6). Figure 5.5 
the use of the siRNA targeting ATM should be used to confirm the specificity of the 
phosphor-ATM antibody and total Chk2 and H2AX antibodies should be used Figure 
5.6 as control. Taken together, these data show that FOXM1 silencing reduced 
phosphorylation events following DNA damage response in MCF-7EPIR cells and 
suggest that it may reduce recruitment of these proteins at the DSBs sites.  
 
 
Figure 5.3 FOXM1 silencing reduces ATM phosphorylation on serine 1981 in MCF-
7EPI
R 
cells. A. MCF-7EPI
R
 cells were either transfected with non-specific (NS) siRNA or 
FOXM1-targeting siRNA (100 nmol/L). Twenty-four hours after transfection, MCF-7EPI
R
 cells 
were treated with 1 µmol/L of epirubicin and harvested for western blot analysis at 0, 24 and 
48 h. The protein expression levels were determined for FOXM1, ATMpSer1981, ATM, 
H2AXpSer139, H2AX, Chk2pThr68, Chk2 and β-tubulin. B. MCF-7EPI
R
 cells transfected with 
siRNA NS and siRNA FOXM1 untreated and treated with 1 µmol/L of epirubicin 48 h were 
assessed by staining with an antibody against ATMpSer1981, or FOXM1, or an isotype IgG 
(negative control), followed by an Alexa 488-conjuguated secondary antibody. The 
percentage of cells ATMpSer1981 or FOXM1 positive were determined by flow cytometry. 
Columns, means derived from three independent experiments; bars, SD. Statistical analyses 
163 
 
were done using Student’s t test. **, P≤0.01 and ***, P≤0.001, significant and n.s, non 
significant.  
 
 
 
 
 
 
Figure 5.4 FOXM1 silencing decreases H2AX phosphorylation on serine 139 in MCF-
7EPI
R 
cells. A. MCF-7EPI
R
 cells were either transfected with non-specific (NS) siRNA or 
FOXM1-targeting siRNA (100 nmol/L). Twenty-four hours after transfection, MCF-7EPI
R
 cells 
were treated with 1 µmol/L of epirubicin for 24 h and stained with H2AXpSer139 antibody 
(green) and DAPI (red). Images visualized by confocal microscopy. Images: magnification: x 
20; insets x 80. B. The results were quantified using Image J and were the average of three 
independent experiments. Columns, means derived from three independent experiments; 
bars, SD. Statistical analyses were done using Student’s t test. **, P≤0.01 and ***, P≤0.001, 
significant and n.s, non significant.  
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Figure 5.5 FOXM1 silencing in human fibroblast cells abrogates ATM phosphorylation. 
Human fibroblast (48BRhtert) cells were either transfected with non-specific (NS) siRNA or 
FOXM1-targeting siRNA (100 nmol/L). Twenty-four hours after transfection, cells were 
treated with 1µmol/L of epirubicin and harvested for western blot analysis at 0, 24 and 48 h. 
The protein expression levels were determined for FOXM1, ATMpSer1981, ATM, FOXM1 
and β-tubulin.  
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Figure 5.6 FOXM1 silencing in human fibroblast cells decreases Chk2 and H2AX 
phosphorylation. Human fibroblast (48BRhtert) cells were cultured, treated with 1 μmol/L of 
epirubicin for 48 h and stained with Chk2pThr68 and H2AXpSer139 antibodies (red) and 
DAPI (blue). Images visualized by confocal microscopy. Images: magnification: x 20; insets x 
80.  
  
 
 
166 
 
5.5 FOXM1 is required for ATM auto-phosphorylation upon 
epirubicin  
 
It has been reported that ATM is regulated by the members of E2F family either 
at post-translational level or at promoter level (Berkovich and Ginsberg 2003, Hong, 
Paulson et al. 2008). To elucidate the mechanism by which FOXM1 regulates ATM, 
ATM mRNA level was examined in MCF-7EPIR cells when FOXM1 was silenced in 
combination with 1 μmol/L of epirubicin. RT-qPCR analysis showed that FOXM1 
silencing did not affect ATM mRNA levels compared to the non-specific siRNA 
condition in MCF-7EPIR cells (Fig. 5.7A). Furthermore, western blot analysis of wild-
type (wt) and FOXM1 knock-out (Foxm1-/-) MEFs cells treated with 1 μmol/L 
epirubicin showed a reduction in P-ATM level, while ATM mRNA levels remained 
steady in Foxm1-/- cells (Fig. 5.7B and C). Taken these results together, the reduction 
of FOXM1 levels by transient knock-down or genomic knock-out decreased the level 
of ATM phosphorylation, but did not affect its mRNA levels. The reverse was showed 
with FOXM1 overexpression in wt MEFs that increased ATM phosphorylation as well 
as ΔN-FOXM1 overexpression (Fig. 5.7D). Collectively, these data indicate that 
FOXM1 plays a role in regulating ATM auto-phosphorylation on serine 1981.  
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Figure 5.7 FOXM1 does not regulate ATM transcriptionally. A. MCF-7EPI
R
 cells were 
either transfected with non-specific (NS) siRNA or FOXM1-targeting siRNA (100 nmol/L). 
Twenty-four hours after transfection, MCF-7EPI
R
 cells were treated with 1 µmol/L of 
epirubicin and harvested for RT-qPCR analysis at 0 and 24 h. ATM mRNA levels were 
determined and normalised to L19 gene. MEFs wild-type (WT) and knock-out for FOXM1 
(Foxm1-/-) were treated with 1 µmol/L of epirubicin and harvested at indicated times for 
western blot (B.) and RT-qPCR analyses (C.). The protein expression of ATMpSer1981, 
ATM, FOMX1 and β-tubulin and the ATM mRNA were determined. Columns, means derived 
from three independent experiments; bars, SD. D. Wild-type MEFs were transiently 
transfected with empty vector and vectors encoding for FOXM1 and ΔN-FOXM1 and 
harvested after 24 h for western blot analysis. The protein expression of ATMpSer1981, 
ATM, FOXM1 and β-tubulin were examined.  
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5.6 Transcriptional regulation of NBS1 by FOXM1 
 
It has been reported that ATM is recruited and fully activated at the DSB sites 
by the MRN complex (Lee and Paull 2004, Lee and Paull 2005). The modulation of 
ATM phosphorylation via the regulation of the MRN complex through FOXM1 was 
investigated in MCF-7EPIR cells. To investigate whether FOXM1 regulates members 
of the MRN complex, the effect of FOXM1 silencing was examined on MRE11, 
RAD50 and NBS1 mRNA levels in MCF-7EPIR cells. RT-qPCR data revealed that 
FOXM1 knock-down reduced significantly NBS1 mRNA, but has no effect on MRE11 
and RAD50 mRNA levels in MCF-7EPIR cells (Fig. 5.8A). This finding was confirmed 
in the human fibroblast cell line (Fig. 5.8B). Indeed, FOXM1 silencing significantly 
reduced NBS1 mRNA levels, but not MRE11 or RAD50 mRNA levels. This study was 
extended to breast cancer cell lines including MDA-MB-231, ZR-75-1 and MCF-7 
cells. Each of these cell lines showed a significant reduction of NBS1 mRNA after 
FOXM1 silencing, indicating NBS1 as a potential transcriptional target of FOXM1 
(Fig. 5.8C). Transient reporter assay was performed to study whether FOXM1 
regulates NBS1 at promoter level. Full length FOXM1 did not affect significantly 
NBS1 promoter activity (data not shown), but ectopic expression of the active 
FOXM1 form, ∆N-FOXM1, induced a significant increase in the luciferase activity of 
NBS1 promoter (WT FHK-luc) in MCF-7 cells in a dose-dependent manner (Fig. 
5.9B). The study of NBS1 promoter revealed a forkhead binding site located at -78 pb 
from the transcription start explaining the responsiveness of NBS1 promoter to 
FOXM1 active form (Fig. 5.9A). Directed mutagenesis of the forkhead site (mFHK-
luc) abrogated the transcriptional induction of NBS1 promoter by ∆N-FOXM1 
expression vector compared to the wild-type promoter WT FHK-luc (Fig. 5.9B). 
Chromatin immunoprecipitation assays showed that FOXM1 binds NBS1 promoter 
after ectopic expression of FOXM1 in MCF-7 cells and after epirubicin treatment in 
MCF-7EPIR cells (Fig. 5.9C). These results suggest that FOXM1 could affect ATM 
auto-phosphorylation via the transcriptional regulation of NBS1. 
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Figure 5.8 FOXM1 silencing significantly decreases NBS1 mRNA levels. A. MCF-7EPI
R
 
cells, B. Human fibroblast cells, and C. MDA-MB-231, ZR-75-1 and MCF-7 cells were 
transiently transfected with non-targeting siRNA and siRNA against FOXM1, and harvested 
for RT-qPCR analysis. The mRNA levels of FOXM1, NBS1, MRE11 and RAD50 were 
examined. Columns, means derived from three independent experiments; bars, SD. 
Statistical analyses were done using Student’s t test. *, P≤0.1 **, P≤0.01 and ***, P≤0.001, 
significant.  
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Figure 5.9 FOXM1 binds directly to NBS1 promoter through the Forkhead binding site 
(FHK). A. Schematic representaiton  of NBS1 luciferase promoter construction pXL2-Nbs1, 
wild-type Forkhead (WT FHK) and mutant Forkhead (mFHK) binding sites performed using 
site directed mutagenesis. B. HEK293T cells were cultured in 10% FCS DMEM medium and 
transiently transfected with pXL2-Nbs1 and increasing amount of deltaN-FOXM1 
constructions (0 and 10 ng) and assessed for luciferase assay. All relative luciferase activity 
values are corrected for co-transfected Renilla activity. Columns, means derived from three 
independent experiments; bars, SD. Statistical analyses were done using Student’s t test. **, 
P≤0.01 and ***, P≤0.001, significant and n.s, non significant. C. Chromatin 
immunoprecipitation  (ChIP)  analysis of NBS1 promoter. MCF-7 cells were transfected with 
pcDNA3 ( - ) or pcDNA3/FOXM1 ( + ) and MCF-7EPI
R
 cells were treated with epirubicin. 
These cells were used for ChIP assay using anti-IgG and anti-FOXM1 antibodies as  
indicated.  After cross-linkinf reversal, the co-immunoprecipitated DNA was amplified by PCR 
using primers for NBS1 FHK containing region ( -119 to -1 pb ) and a control region ( -281 to 
-128 pb ) and runned in 1% agarose gel.  
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5.7 NBS1 mediates ATM activation upon epirubicin 
 
Since this study indicates that FOXM1 regulates NBS1 transcriptionally and 
affects the phosphorylation of ATM, I hypothesised that FOXM1 regulates 
transcriptionally NBS1, which in turn regulates the auto-phosphorylation of ATM at 
the DNA break sites. To demonstrate that NBS1 is required for ATM activation, we 
used the wt and Nbs1-/- MEFs cells transfected with empty control vector and vector 
encoding for NBS1. The full activation of ATM is only observed in MEFs cells treated 
with epirubicin and transfected with NBS1, but not in MEFs cells lacking NBS1 (Fig. 
5.10). Taken together, these data indicate that ATM activation requires NBS1 and 
epirubicin treatment. This finding suggests that FOXM1 may acts upstream of ATM 
and NBS1 and could control ATM auto-phosphorylation through NBS1.  
 
To determine whether FOXM1 can activate ATM auto-phosphorylation, western 
blot analysis could be performed on Foxm1-/- cells transfected with empty vector or a 
plasmid encoding for NBS1 to circumvent the lack of FOXM1 and activate ATM.  
 
 
 
Figure 5.10 NBS1 is required for ATM activation upon epirubicin. NBS-LBI cells were 
either transfected with 3 μg of empty vector or vector encoding for NBS1 and treated with 1 
µmol/L of epirubicin 24 h and harvested for western blot analysis at 0, 24 and 48 h. The 
protein expression levels were determined for ATMpSer1981, ATM, FOXM1, Chk2, NBS1 
and β-tubulin.  
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5.8 Discussion 
 
Chemotherapeutic drugs generate double strand breaks by free radical attack of 
deoxyribose, inhibition of re-ligation of DNA strand broken by topoisomerase II or 
DNA replication. DNA DSBs are the most deleterious form of DNA damage because 
they do not leave an intact complementary strand to be used as a template for DNA 
repair and they induce DNA damage signalling pathway leading to cell cycle arrest, 
apoptosis or repair. Deregulation in DNA damage signalling pathway can favour DNA 
repair and inhibit apoptosis to contribute to chemotherapeutic drug resistance. Cells 
rely on two major DNA DSBs repair pathways: homologous recombination (HR) and 
non-homologous end-joining (NHEJ). HR requires a homologous template, sister 
chromatid, and allows repair of DSBs in S and G2 phases of the cell cycle (San 
Filippo, Sung et al. 2008, Moynahan and Jasin 2010). In contrast, NHEJ can operate 
throughout the cell cycle without the need for DNA template.  
 
5.8.1 FOXM1 is involved in ATM and its downstream 
substrates phosphorylations 
 
In response to DSBs, DNA damage signalling pathway delays the cell cycle 
before and during DNA replication (G1/S and intra-S checkpoints) and before cell 
division (G2/M checkpoints) to prevent duplication and segregation of damaged DNA. 
DNA damage signalling cascades are complex events that require various proteins 
whose function can be categorised as DNA damage sensors, transducers, mediators 
and effectors. DNA damage signalling pathway involves two key serine/threonine 
kinases: ATM (ataxia telangiectasia mutated) and ATR (ATM and rad3-related).  The 
MRE11/RAD50/NBS1 sensor complex detects DSBs and contributes to the 
recruitment and activation of the ATM transducer. Mediator proteins, such as MDC1 
(mediator of DNA damage checkpoint), 53BP1 (p53-binding protein 1) and BRCA1, 
help activate effector kinases CHK1 and CHK2, which spread the signal throughout 
the nucleus (Lavin, Delia et al. 2006). In this study, FOXM1 silencing abrogates ATM 
phosphorylation in MCF-7EPIR and fibroblast cells, which is required for 
phosphorylation events of the DNA damage cascade (Fig. 5.3A and 5.5). Similarly, 
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the level of P-ATM positive cells was reduced when cells were transfected with 
FOXM1-targeting siRNA (Fig. 5.3B). FOXM1 silencing also reduces phosphorylation 
of CHK2 and P-H2AX in MCF-7EPIR cells (Fig. 5.3A) and human fibroblasts (Fig. 
5.6), which inhibits activation of transcription factors, cell cycle and apoptosis 
regulators and repair proteins (Matsuoka, Rotman et al. 2000, Bartek and Lukas 
2003, Iliakis, Wang et al. 2003). Although these results have been confirmed in 
different cell lines, it is in contradiction with results recently published. In this study I 
suggest that FOXM1 inhibition reduces P-H2AX and the activation of the DNA repair 
pathway, while the recent study shows that FOXM1 depletion increases P-H2AX and 
DNA damage. H2AX is a histone protein that is rapidly phosphorylated by ATM in 
response to DNA damage. Activated H2AX forms foci around the DSBs and helps to 
recruit the proteins responsible for DNA repair. In this study, I hoped to show that 
FOXM1 silencing reduced phosphorylations and recruitment of DNA repair proteins 
at the DSBs.  
 
The mechanism of ATM regulation by FOXM1 was investigated by western blot 
and RT-qPCR. The results revealed that FOXM1 silencing inhibits ATM auto-
phosphorylation, but does not affect total ATM protein and mRNA levels (Fig. 5.7). A 
recent study demonstrates that FOXO3A interacts with ATM to promote its auto-
phosphorylation on serine 1981 (Tsai, Chung et al. 2008). However, ATM and 
FOXM1 direct interaction was not found (data not shown), suggesting that FOXM1 
activates ATM auto-phosphorylation indirectly.  
 
5.8.2 FOXM1 regulates NBS1  
 
The role of the MRN complex in ATM activation has clearly been shown through 
analysis of ATM-dependent phosphorylation events in cells with MRN deficiencies 
(Uziel, Lerenthal et al. 2003). MRN complex stimulates ATM activation that induces 
p53, CHK2 and H2AX in vitro phosphorylations using recombinant proteins. The 
association between ATM and MRN is mediated through multiple protein-protein 
interactions, one between ATM and NBS1, and the other between ATM and 
MRE11/RAD50 (Lee and Paull 2004, You, Chahwan et al. 2005). As FOXM1 is a 
transcription factor, the transcriptional regulation of the MRN protein complex by 
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FOXM1 was investigated. RNA interference experiments demonstrated that FOXM1 
knock-down significantly decreased NBS1 mRNA in different human breast cancer 
cell lines and fibroblasts (Fig. 5.8). Furthermore, ectopic expression of the active form 
of FOXM1 induced NBS1 promoter activity, while mutation of the forkhead binding 
site abrogated NBS1 promoter activity induction following addition of FOXM1 active 
form (Fig. 5.9). Chromatin immunoprecipitation assays showed that FOXM1 directly 
binds NBS1 promoter following FOXM1 overexpression and DNA damage treatment 
(Fig. 5.9C). Similarly, NBS1 is a target of a transcription factor involved in cell growth 
control, C-MYC (Chiang, Teng et al. 2003). C-MYC function was known in promoting 
cell proliferation in normal and neoplastic cells, until its function was linked to the 
regulation of DNA DSB repair pathway. 
 
5.8.3 NBS1 activates ATM auto-phosphorylation 
 
Even though wild-type ATM is present, only reconstitution of MRN complex 
restores ATM auto-phosphorylation and phosphorylation of downstream substrates in 
MRN deficient cells (Uziel, Lerenthal et al. 2003, Lee and Paull 2004). In this study, 
rescue experiments in Nbs1-/- fibroblast cells also showed that the combination of 
epirubicin treatment with NBS1 fully induces ATM auto-phosphorylation (Fig. 5.10). 
Given that our promoter assay showed that FOXM1 regulates NBS1, the results 
could suggest that FOXM1 activates ATM through NBS1 transcription (Fig. 5.11). 
Similarly, NBS1 is required for E2F1 to induce p53 phosphorylation. In fibroblasts 
lacking NBS1, p53 and CHK2 phosphorylations were impaired, while E2F1 induced 
p53 and CHK2 phosphorylations in wild-type cells (Powers, Hong et al. 2004). 
 
5.8.4 FOXM1 function in DNA repair 
 
The role of FOXM1 in DNA repair was first showed in osteosarcoma cells with 
the direct regulation of XRCC1 and BRCA2, genes involved in DNA repair (Tan, 
Raychaudhuri et al. 2007). In this study, I showed that FOXM1 regulates NSB1, a 
sensor of DNA damage. A study found NBS1 as a downstream target of C-MYC 
proliferation factor and showed the role of C-MYC in DNA repair for the first time 
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(Chiang, Teng et al. 2003). This study is also the first evidence of FOXM1 function in 
ATM activation and ATM-mediated DNA damage phosphorylation cascade. DNA 
damage signalling pathway activates DNA damage sensors, transducers, mediators 
and effectors required for cell cycle arrest, apoptosis and DNA repair. Cells were co-
transfected with pre-damaged single strand DNA template and undamaged Renilla. 
The level of repair of damaged template was significantly enhanced in MCF7-EPIR 
cells relative to MCF-7 cells, whereas DNA repair was prevented in MCF7-EPIR cells 
treated with siRNA FOXM1 relative to non-specific siRNA (Fig. 5.1). These results 
indicate that FOXM1 is involved in HR. Furthermore, a recent study demonstrated the 
role of FOXM1 in HR, but not in NHEJ (Monteiro, Khongkow et al. 2012). 
 
A growing body of evidence indicate the importance of chromatin organisation 
in the DNA damage response, with the most prominent modifications being the 
phosphorylation of histone H2AX at the site of DNA breaks. As H2AX is associated 
with chromatin at DNA break sites and plays a key role in recruiting DNA repair 
proteins to nuclear foci, the recruitment of FOXM1 to DNA break sites was assessed 
by chromatin immunoprecipitation upon local induction of DNA damage by specific 
endonucleases. The generation of sequence-specific DSBs by I-Ppol endonuclease 
(Monnat, Hackmann et al. 1999, Berkovich, Monnat et al. 2008) was verified by 
H2AX phosphorylation (Fig. 5.2A). Transient transfection of I-Ppol in MCF-7EPIR cells 
increased the recruitment of phosphorylated-H2AX at DNA breaks sites (Fig. 5.2B). 
Importantly, DSBs enhance FOXM1 recruitment at DNA breaks in MCF-7EPIR cells 
(Fig. 5.2B). In contrast, P-H2AX and FOXM1 recruitments at DNA breaks is not 
increased following I-Ppol transfection in MCF-7 cells (Fig. 5.2A). This result is in 
opposition with the result published by Berkovich et al. in which P-H2AX was 
recruited on DSBs in MCF-7 cells after 16 hrs transfection with I-Ppol (Berkovich, 
Monnat et al. 2007). Our MC-7 cell lines showed a low level of DNA repair as 
observed Figure 5.1A. Hence, this experiment should be repeated with low passage 
MCF-7 cell lines. This study did show a higher level of FOXM1 recruitment at DNA 
breaks I-Ppol-induced as well as P-H2AX in MCF-7EPIR cells compared to MCF-7 
cells (Fig. 5.2). H2AX interacts with MDC1, 53BP1, NBS1, RAD51 and BRCA1 at 
DNA break sites, but because FOXM1 silencing decreased H2AX phosphorylation, 
FOXM1 might affect protein assembly of sensors, mediators and effectors.   
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5.8.5 Conclusion 
 
This study shows that FOXM1 activates the transcription of NBS1, member of 
the MRN sensor complex, inducing ATM auto-phosphorylation (on serine 1981) and 
the phosphorylation of ATM downstream targets including H2AX and CHK2 in MCF-
7EPIR cells (Fig. 5.3 and 5.4) and in human fibroblasts (Fig. 5.5 and 5.6). These 
results also showed that FOXM1 is required for the DNA damage phosphorylation 
events, suggesting that FOXM1 might affect DNA repair mechanisms in MCF-7EPIR 
cells. FOXM1 silencing completely abrogated the elevated DNA repair mechanism in 
MCF-7EPIR cells (Fig. 5.1B). The examination of protein recruitment at DNA breaks 
shows that FOXM1 is recruited after DNA breaks in MCF-7EPIR cells and might have 
a role in protein assembly ATM-mediated (Fig. 5.2). Together these results indicate 
that FOXM1 is required for DNA damage signalling and DNA repair, and involved in 
protein assembly at DSB breaks. This study showed differences in DNA damage 
signalling induction, DNA repair factor recruitment and DNA repair between breast 
cancer cell sensitive and resistant to epirubicin (Fig. 5.11). Taken together, this study 
unravels that FOXM1 has a crucial role in promoting DNA repair response in MCF-
7EPIR cells and suggests that targeting FOXM1 could potentially resensitise 
epirubicin-resistant cells to DNA damage and cell death. 
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Figure 5.11 Differential pathways upon epirubicin in sensitive and resistant MCF-7 
cells. In epirubicin sensitive MCF-7 cells, epirubicin activates p53 which downregulates E2F 
to repress FOXM1 expression and arrest the cell cycle. In epirubicin resistant MCF-7 cells, 
epirubicin activates ATM which in turn activates its downstream targets H2AX, CHK2 and 
E2F involved in DNA repair. E2F positively activates FOXM1 expression, which regulates 
NBS1 at promoter level. NBS1 is required to activate ATM auto-phosphorylation, which 
creates a feedback loop, controlling DNA damage repair and survival. 
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5.9 Future work 
 
This report shows that targeting FOXM1 in epirubicin resistant breast cancer 
cells is an attractive strategy considering that FOXM1 is overexpressed in these cells 
and that FOXM1 inhibition results in DNA repair defect in these cells. Epirubicin 
resistant breast cancer cells have a high capacity to repair DNA, while FOXM1 
silencing reduces ATM and its downstream targets activation. A previous study 
showed that FOXM1 regulates XRCC1 and BRCA2 DNA repair genes, consistent 
with FOXM1 inhibition resulting in defective DNA repair (Tan, Raychaudhuri et al. 
2007).  XRCC1 is important for two types of DNA repair, HR and NHEJ, while several 
lines of evidence indicate that BRCA genes are only critical for DSB repair by HR. In 
addition, this study showed that FOXM1 regulates NBS1 that is involved in both DSB 
repair mechanisms. Furthermore, a recent study showed that FOXm1 is involved in 
HR, but not in NHEJ (Monteiro, Khongkow et al. 2012). HR is particularly important 
during S and G2 phases, while NHEJ is dominant during G0, G1 and early S phases. 
It would be interesting to investigate whether a chemotherapeutic agent targeting G2 
phase would be more effective than an agent arresting cells in G1 phase.  
 
Recent work suggests that BRCA1 regulates the activity of MRN complex. 
Since FOXM1 regulates BRCA2 and a member of MRN complex, it could be possible 
that FOXM1 also regulates BRCA1. BRCA1 has been implicated in the transcription 
of several genes in response to DNA damage, such as p21Cip1 and GADD45 
(Venkitaraman 2001). This could be another link between FOXM1 and DNA repair. 
 
Protein assembly at sites of damage is important for the DNA damage 
response cascade and DNA repair. It would be interested to investigate deeper 
whether FOXM1 affects protein assembly. 
 
Previous studies showed that reduced FOXM1 expression significantly 
diminished DNA replication and mitosis in tumour cells. The current study suggests 
that inhibition of FOXM levels lead to defective DNA repair. Thereby, it would 
beneficial to study FOXM1 inhibitor, thiostrepton, and investigate whether it inhibits of 
ATM activation, reduces NBS1 levels as well as abolishes DNA repair and induces 
cell cycle arrest and cell death. 
179 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 FINAL DISCUSSION 
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Breast cancer is the most common cancer in the UK. Patients are treated 
according to their receptor status. ER/PR positive receptors breast cancer patients 
are treated with hormonal therapy and tamoxifen is the main agent given. However, 
30% of patients that initially respond to tamoxifen become resistant. Hormone 
receptor (HR) negative breast cancer patients only respond to chemotherapy. A wide 
range of chemotherapeutic agents is used for solid tumours, but these agents are not 
specific to types of cancer. Based on the fact that there is no biomarker for HR 
negative patients, treatment administrated are not specific to these breast cancers. In 
addition to the lack of specificity, patients treated with chemotherapeutic agents 
become resistant. Therefore, this information raises the urgent need to identify new 
targets involved in hormonal and chemotherapy drugs resistance, and to develop 
targeted agents.  
FOXM1 is a master transcription factor involved in the regulation of cell 
proliferation, cell survival, angiogenesis and metastasis. FOXM1 is a proliferation 
specific factor largely expressed in developing embryos and observed at very low 
levels in adults. The upregulation of FOXM1 has been widely observed in several 
types of cancer, including breast cancer. The last past years, studies showed FOXM1 
as an attractive target for anti-cancer drugs due to its specific expression in actively 
proliferating cells, especially cancer cells, and its role in cell cycle proteins regulation. 
Recent evidences raise FOXM1 as a novel target for prevention of drug resistance.   
In this thesis, I have documented FOXM1 involvement in anti-estrogen 
resistance. A recent study demonstrated elevated FOXM1 mRNA and protein levels 
in cisplatin resistant breast cancer compared to cisplatin sensitive. I hypothesized 
that FOXM1 could have an important role conferring tamoxifen resistance through the 
upregulation of cell cycle target genes. In addition, FOXM1 has been recently linked 
with DNA repair mechanism through the regulation of BRCA2 and XRCC1 (Tan, 
Raychaudhuri et al. 2007). Therefore, I suggested that FOXM1 could also be 
involved in epirubicin resistance through the upregulation of DNA repair target genes.  
If FOXM1 were found important in conferring both hormone receptor positive 
and negative drug resistances, FOXM1 inhibitors could be used to circumvent any 
types of breast cancer resistance. Indeed, I have detailed the mechanism of FOXM1 
transcriptional regulation by ERα in tamoxifen sensitive breast cancer cells. Taken 
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together with a recent study, FOXM1 is regulated in a positive feedback loop with 
ERα that can be used to stop and perhaps kill breast cancer cells with the ERα 
antagonist, tamoxifen. I also unravelled that FOXM1 mRNA is elevated in tamoxifen 
resistant cells related to tamoxifen sensitive cells, suggesting that FOXM1 is 
regulated at transcriptional level in tamoxifen resistant cells. My data indicate that 
FOXM1 is the major proliferation factor in tamoxifen resistant cells and that tamoxifen 
has no effect on the viability of these cells. I suggest that the lack of response to 
tamoxifen is likely to be due to deregulation of the ER-FOXM1 feedback loop and 
upregulation of the cyclin D1-FOXM1 loop.  Furthermore, my studies showed that 
targeting FOXM1 in these cells can resensitise tamoxifen resistant cells to G1 growth 
arrest tamoxifen-induced. Indeed, FOXM1 regulates a large range of cell cycle 
regulators but this study hints that the targeting of FOXM1 results in a significant cell 
growth inhibition.  
Pursuing the study, I found that FOXM1 is also upregulated in epirubicin 
resistant cells compared to epirubicin sensitive breast cancer cells. I unravelled a 
differential regulation of FOXM1 in sensitive and resistant cells. While FOXM1 is 
transcriptionally repressed by p53 via E2F1 in epirubicin sensitive cells, p53 is lost 
and FOXM1 is regulated by ATM through E2F1 in epirubicin resistant cells. A recent 
study has shown that FOXM1 phosphorylation and stabilization after DNA damage 
through the checkpoint kinase CHK2 promotes the transcriptional expression of DNA 
repair proteins, BRCA2 and XRCC1 (Anzick, Kononen et al. 1997, Tan, 
Raychaudhuri et al. 2007). This report identified NBS1 as a novel DNA repair FOXM1 
target gene. In addition, this study showed that FOXM1 is a crucial component of the 
DNA damage response by activating ATM indirectly. In response to DNA damage, 
the MRE11/RAD50/NBS1 complex regulates the activation of ATM kinase. Here I 
showed that FOXM1 is required to regulate a member of the MRE11/RAD50/NBS1 
complex, which is likely to promote ATM activation. ATM is the key activator of the 
double and single strand DNA repair pathways. Therefore, FOXM1 involvement in 
DNA repair was investigated and showed that FOXM1 knock-down completely 
abrogated DNA repair. FOXM1 is well-described to be required for cell survival but 
this study showed that FOXM1 is also essential for DNA repair and that targeting 
FOXM1 lead to DNA repair default and can induce cell death. 
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Drug resistance raises significant clinical challenges. The mechanisms by 
which cells acquire drug resistance are multiple. In the present study we have 
demonstrated for the first time that FOXM1 possesses a crucial role in tamoxifen and 
epirubicin resistance in breast cancer cells through enhancing cell proliferation and 
DNA-damage repair pathways. Several observations suggest that FOXM1 
expression is an important determinant of tamoxifen and epirubicin sensitivity and 
resistance. Following drug treatment, FOXM1 was downregulated in the sensitive 
MCF-7 cells while the resistant MCF-7 cells showed an up-regulation of both FOXM1 
mRNA and protein expression levels. Moreover, expression of the constitutively 
active ΔN-FOXM1 was sufficient to confer resistance to the cell cycle arrest OHT- 
and epirubicin-induced whereas the depletion of FOXM1 through siRNA knockdown 
reversed this effect.  
These observations may have implications in the development of a treatment 
for tamoxifen and epirubicin resistant patients, suggesting it would be more efficient 
to target a key oncogene such as FOXM1, rather than targeting a proliferative gene 
or DNA repair machinery, where potential compensatory mechanisms could occur. 
So far, the FOXM1 inhibitor, Thiostrepton, has only been approved by the FDA 
for the treatment of topical bacterial infection in cats and dogs. However, 
Thiostrepton has now been largely tested in different fibroblast, breast, colon; lung 
cancer cells (Bhat, Zipfel et al. 2008, Gartel 2008, Bhat, Halasi et al. 2009). Studies 
reveal that Thiostrepton inhibits FOXM1 expression, but not the expression of other 
members of the Forkhead box family. In addition, Thiostrepton inhibits the growth and 
induces apoptosis in human cancer cell lines of different origin (Bhat, Halasi et al. 
2009). The anti-cancer properties of Thiostrepton in breast cancer were not only 
investigated in vitro, but also in xenograft mouse models of breast cancer in vivo. The 
encapsulation of Thiostrepton enhanced its solubility and accumulation into tumour 
sites. Micelle-thiostrepton nanoparticules reduces tumour growth rate with the 
suppression of FOXM1 protein and induction of cell death (Wang and Gartel 2011) .  
Moreover, the inhibition of FOXM1 and co-treatment with anti-proliferative or 
DNA-damaging agents may be hypothesized to enhance therapeutic response. 
FOXM1 inactivation has already been tested for overcoming cisplatin resistance in 
breast cancer cells. SRB proliferative assays indicated that combination of cisplatin 
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and Thiostrepton showed synergistic effect on cell death rate in cells resistant to 
cisplatin, and that inhibition of FOXM1 is able to circumvent cisplatin resistance in 
breast cancer cells (Kwok, Myatt et al. 2008). The combination of Thiostrepton and 
Bortezomib (proteasome inhibitor) was also investigated and showed a similar 
synergistic effect on the induction of apoptosis in different cancer cells (Pandit and 
Gartel 2011). 
The mechanisms by which FOXM1 activity and expression are upregulated in 
tamoxifen and epirubicin resistant cells require further investigation. However this 
study and recent publications suggest a positive feedback loop between FOXM1 with 
cyclin D1 and B-myb in tamoxifen resistant cells and with ATM in epirubicin resistant 
cells. These observations may also have implications in the development of new co-
treatments. Cyclin D1 overexpression has been found in many cancer and correlate 
with the lack of response to tamoxifen in breast cancer. A study showed that 
inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell 
carcinoma cells is associated with increased cisplatin chemosensitivity (Zhou, Zhang 
et al. 2009). DNA repair pathways can enable tumour cells to survive DNA damage 
that is induced by chemotherapeutic treatments; therefore, inhibitors of specific DNA 
repair pathways might be efficient when used in combination with DNA-damaging 
chemotherapeutic drugs. The combination of ATM inhibitor with IR and doxorubicin 
has been tested and showed a significant increase in the sensitivity of lung cancer 
cells to the cytotoxic effect of these treatments (Shaheen, Znojek et al. 2011). 
Patients with defect in one repair pathway could potentially be treated with the 
inhibitor of the other pathway and benefit from maximum treatment outcome with 
minimal toxicity. This thesis and a recent study suggest that FOXM1 plays a key role 
in homologous recombination (Monteiro, Khongkow et al. 2012). Therefore, targeting 
a critical protein in non-homologous end joining such as DNA-PK in combination with 
FOXM1 inhibitor might abrogate any possible repair and increase the sensitivity of 
resistant breast cancer cells to chemotherapies.  
 The novel thiazole antibiotic Thiostrepton is a potential pre-clinical candidate 
that should be further studied in co-treatment with key inhibitors for overcoming 
breast cancer drug resistance. 
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Figure 6.1 Thiostrepton as a potential candidate to overcome endocrine and 
chemotherapy resistance in breast cancer. Tamoxifen treatment (OHT) inhibits FOXM1 
expression via ERα and FOXM1 functions in OHT-sensitive breast cancer cells, while OHT 
induces a range of key proteins regulated in a feedback loop with FOXM1 allowing cell 
survival and drug resistance in OHT-insensitive breast cancer cells. Epirubicin treatment 
represses FOXM1 expression via p53 upregulation in epirubicin sensitive cells, while FOXM1 
is regulated in a positive feedback loop with ATM preventing DNA damage accumulation and 
cell death. The use of Thiostrepton in combination with these treatments could break the 
positive feedback loop regulating FOXM1 and its targets, and overcome Tamoxifen and 
Epirubicin resistance. 
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Figure S.D.7.1. Schematic representation of the Apa I FOXM1 construct, showing the 
wild-type ERE, and three mutants ERE (mERE) sequences (mutant analysed by 
Demetra Constantinidou). 
  
 
 
 
 
 
 
 
 
Figure S.D.7.2. ERα induces the transcriptional activity of the human FOXM1 gene 
through an ERE proximal to the transcription start site (experiment performed by 
Demetra Constantinidou).  COS-1 cells were transfected with pGL3-F Length, pGL3-ApaI) 
or pGL3-ERE promoter constructs, together with increasing amounts (0, 0.1, 1, 10, and 20 
ng) of ERα expression vector. 
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Figure S.D.7.3 Ectopic expression of FOXM1 reduces MCF-7 cells sensitivity to cell 
death (Experiment performed by Julia K. Langer). MCF-7 cells wild-type, stably 
transfected with pcDNA3 or with FOXM1 were treated with 1μmol/L of epirubicin for 0, 4, 8, 
16 24 and 48 h. At indicated times, cells were harvested for western blot analysis to 
determine the protein expression of FOXM1, cleaved PARP, indicator of apoptosis, and β-
tubulin.  
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